VCAR compositions and methods of use

By designing chimeric antigen receptors (CARs) that contain antigen recognition regions and costimulatory domains, the problem of lack of specific antigen recognition in the prior art is solved, and efficient activation and accurate recognition of immune cells are achieved.

CN118878697APending Publication Date: 2024-11-01POSEIDA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410671512.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-12-21
Filing Date
2018-12-20
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

There is a lack of effective methods in the prior art to guide immune cells to recognize antigens in a specific manner without using traditional antibody sequences.

Method used

A chimeric antigen receptor (CAR) has been developed, which contains an antigen recognition region, a transmembrane domain and a costimulatory domain, which uses a single domain antibody such as VHH or VH, which can specifically bind to the antigen. And activate immune cells through costimulatory signals.

Benefits of technology

The specific recognition and activation of antigens by immune cells is achieved, the efficiency and accuracy of the immune response are improved, and a method to replace traditional antibody sequences is provided to guide the function of immune cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118878697A_ABST
    Figure CN118878697A_ABST
Patent Text Reader

Abstract

The present invention relates to VCAR compositions and methods of use. Disclosed are VHH chimeric antigen receptors (VCARs), VCAR transposons encoding the VCARs of the present disclosure, cells modified to express the VCARs of the present disclosure, and methods of making and using the same in adoptive cell therapy.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of Chinese patent application 201880087741.4 “VCAR compositions and methods of use” filed on December 20, 2018. Related Applications This application claims the benefit of provisional application USSN 62 / 608,571, filed December 20, 2017, and provisional application USSN 62 / 608,894, filed December 21, 2017, the contents of each of which are incorporated herein by reference in their entirety. Technical Field The present disclosure relates to molecular biology, and more particularly, to chimeric antigen receptors, and to transposons comprising one or more VCARs, and methods of making and using the same. Incorporation by Reference into the Sequence Listing The contents of the file named "CPCH2461204D.xml" created on May 27, 2024 and with a size of 650k are incorporated herein by reference in its entirety. Background Art There is a long-felt but unmet need in the art for methods to direct the specificity of immune cells without the use of traditional antibody sequences or fragments thereof. The present disclosure provides superior chimeric antigen receptors. Summary of the invention The present disclosure provides a chimeric antigen receptor (CAR), comprising: (a) an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one single domain antibody; (b) a transmembrane domain, and (c) an intracellular domain comprising at least one co-stimulatory domain. In some embodiments, a single domain antibody comprises a human or humanized sequence. In some embodiments, a single domain antibody comprises a non-naturally occurring sequence. In some embodiments, a single domain antibody comprises a recombinant or chimeric sequence. In some embodiments, a single domain antibody comprises a VHH or a sequence encoding a VHH. In some embodiments, a single domain antibody comprises a VH or a sequence encoding a VH. In some embodiments, a single domain antibody comprises a VH of the present disclosure or a sequence encoding a VH of the present disclosure. The present disclosure provides a chimeric antigen receptor (CAR), comprising: (a) an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VHH; (b) a transmembrane domain, and (c) an intracellular domain comprising at least one costimulatory domain. As used throughout the disclosure, a CAR comprising VHH is referred to as VCAR. In certain embodiments, the antigen recognition region may include two VHHs to produce a bispecific or tandem VCAR. In certain embodiments, the antigen recognition region may include three VHHs to produce a trispecific VCAR. In certain embodiments of the VCAR of the present disclosure, the extracellular domain may further include a signal peptide. Alternatively or additionally, in certain embodiments, the extracellular domain may further include a hinge between an antigen recognition region and a transmembrane domain. In certain embodiments, the extracellular domain may further include a signal peptide. Alternatively or additionally, in certain embodiments, the extracellular domain may further include a hinge between an antigen recognition region and a transmembrane domain. In certain embodiments of the VCARs of the present disclosure, the VHH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvagiigsggstyyadsvkgrfsisrdnskntldlqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrp eacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgq nqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-A; SEQ ID NO:362) In certain embodiments of the VCARs of the present disclosure, the VHH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpggsltlscaasgftfsnyamnwvrqapgkglewvsgiigsgattyyadsvkgrftisrdnskntlnlqmnslraedtaiyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrp eacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgq nqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-B; SEQ ID NO:364) In certain embodiments of the VCARs of the present disclosure, the VHH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpgeslrlscaasgftfsnyamnwvrqapgkglewvsgivggggtsyyadsvrgrftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrp eacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgq nqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-C; SEQ ID NO:366) In certain embodiments of the VCARs of the present disclosure, the VHH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpggslrlscaasgftfsnyamtwirqapgkglewvsgitgdggstfyadsvkgrftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrp eacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgq nqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-D; SEQ ID NO:368) or VHH comprises or consists of the following nucleic acid sequence: atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgccctgaagttcagctgcttgaatctggcggaggcctggttcaacctggcggatctctgagactgagctgtgccgccagcggcttcaccttcagcaattacgccatgacctggatcagacaggcccctggcaaaggcctggaatgggtgtccggaattacaggcgacggcggcagcaccttttacgccgattctgtgaagggcagattcaccatcagccgggacaacagcaagaacaccctgtacctgcagatgaacagcctgagagccgaggacaccgccgtgtactactgcgtgaaggactggaacaccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctccaacaccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagaggactggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacacaggaggaggacggctgctcttgtaggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga(VH-D;SEQ ID NO:369)。 In certain embodiments of the VCARs of the present disclosure, the VHH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglaqpggslrlscaasgftfssyamnwirqapgkglewvsgisgsggstyyadsvkgrftisrdnskntvylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrp eacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgq nqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-E; SEQ ID NO:370) Or the VHH comprises the following nucleic acid sequence or consists of the following nucleic acid sequence: atggcactgcctgtgacagccctgctgctgcctctggccctgctgctgcacgcagcacggcccgaggtgcagctgctggagtccggaggaggcctggcccagcctggcggcagcctgaggctgtcctgcgccgcctctggcttcacctttagctcctacgccatgaactggatcagacaggcccctggcaagggcctggagtgggtgtccggcatctccggctctggaggctctacatactatgccgacagcgtgaagggccggttcaccatcagcagagataactccaagaataccgtgtacctccagatgaactctctgcgggccgaggacaccgccgtgtactattgcgtgaaggattggaataccacaatgatcacagagaggggccagggcaccctggtgacagtgtctagcaccacaacccctgcccccagacctcccacacccgcccctaccatcgcgagtcagccactgtccctgcggcctgaggcctgccggcccgccgccggcggagcagtgcacacacggggcctggactttgcctgtgacatctacatatgggcaccactggcaggaacctgcggcgtgctgctgctgagcctggtcatcaccctgtactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacacaggaggaggacggctgctcttgtaggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga (VH-E; SEQ ID NO:371). In certain embodiments of the VCAR of the present disclosure, the VHH comprises the following amino acid sequence or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpgrslrlscaasgftftnyamnwvrqapgkglewvsgisggggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-F; SEQ ID NO:372) The present disclosure provides a chimeric antigen receptor (CAR), comprising: (a) an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH; (b) a transmembrane domain, and (c) an intracellular domain comprising at least one costimulatory domain. As used throughout the disclosure, a CAR comprising VH is referred to as VCAR. In certain embodiments, the antigen recognition region may include two VHs to produce a bispecific or tandem VCAR. In certain embodiments, the antigen recognition region may include three VHs to produce a trispecific VCAR. In certain embodiments, the extracellular domain may further include a signal peptide. Alternatively or additionally, in certain embodiments, the extracellular domain may further include a hinge between the antigen recognition region and the transmembrane domain. In certain embodiments, the extracellular domain may further include a signal peptide. Alternatively or additionally, in certain embodiments, the extracellular domain may further include a hinge between the antigen recognition region and the transmembrane domain. In certain embodiments of the VCAR of the present disclosure, including those comprising an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH, the VH comprises a human sequence or a humanized sequence. In certain embodiments of the VCARs of the present disclosure, including those comprising an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH, the VH comprising a non-naturally occurring sequence. In certain embodiments of the VCARs of the present disclosure, including those comprising an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH, the VH is not naturally occurring. In certain embodiments of the VCARs of the present disclosure, including those comprising an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH, the VH comprises a recombinant or chimeric sequence. In certain embodiments of the VCARs of the present disclosure, including those comprising an extracellular domain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH, the VH is generated by an in vitro procedure of affinity selection and recombination. In certain embodiments of the VCARs of the present disclosure, VH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvagiigsggstyyadsvkgrfsisrdnskntldlqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpea crpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnq lynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-A; SEQID NO:362) In certain embodiments of the VCARs of the present disclosure, VH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpggsltlscaasgftfsnyamnwvrqapgkglewvsgiigsgattyyadsvkgrftisrdnskntlnlqmnslraedtaiyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpea crpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnq lynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-B; SEQID NO:364) Or VH comprises the following nucleic acid sequence or consists of the following nucleic acid sequence: atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgccctgaagttcagctgcttgaatctggcggaggcctggttcaacctggcggatctctgacactgagctgtgccgccagcggcttcaccttcagcaactacgccatgaactgggtccgacaggcccctggcaaaggccttgaatgggtgtccggcatcattggctctggcgccaccacctactacgccgattctgtgaagggcagattcaccatcagccgggacaacagcaagaacaccctgaacctgcagatgaacagcctgagagccgaggacaccgccatctactactgcgtgaaggactggaacaccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctccaacaccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagaggactggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacacaggaggaggacggctgctcttgtaggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga(VH-B;SEQ ID NO:365)。 In certain embodiments of the VCARs of the present disclosure, VH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpgeslrlscaasgftfsnyamnwvrqapgkglewvsgivggggtsyyadsvrgrftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpea crpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnq lynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-C; SEQID NO:366) Or VH comprises the following nucleic acid sequence or consists of the following nucleic acid sequence: atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgccctgaagttcagctgcttgaatctggcggaggcctggttcagcctggcgaatctctgagactgagctgtgccgccagcggcttcaccttcagcaactacgccatgaactgggtccgacaggcccctggcaaaggccttgaatgggtgtccggaatcgttggcggcggaggcacaagctactacgccgattctgtgcggggcagattcaccatcagccgggacaacagcaagaacaccctgtacctgcagatgaacagcctgagagccgaggacaccgccgtgtactactgcgtgaaggactggaacaccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctccaacaccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagaggactggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacacaggaggaggacggctgctcttgtaggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaaggacaagatggccgaggcctattctgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga (VH-C; SEQ ID NO: 367). In certain embodiments of the VCARs of the present disclosure, VH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpggslrlscaasgftfsnyamtwirqapgkglewvsgitgdggstfyadsvkgrftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpea crpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnq lynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-D; SEQID NO:368) In certain embodiments of the VCARs of the present disclosure, VH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglaqpggslrlscaasgftfssyamnwirqapgkglewvsgisgsggstyyadsvkgrftisrdnskntvylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpea crpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnq lynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-E; SEQID NO:370) In certain embodiments of the VCARs of the present disclosure, VH comprises or consists of the following amino acid sequence: malpvtalllplalllhaarpevqllesggglvqpgrslrlscaasgftftnyamnwvrqapgkglewvsgisggggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpea crpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnq lynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (VH-F; SEQID NO:372) or VH comprises or consists of the following nucleic acid sequence: atggcactgcctgtgacagccctgctgctgcctctggccctgctgctgctgcacgcagcacggcccgaggtgcagctgctggagtctggaggaggcctggtgcagcccggccggtccctgagactgtcttgcgccgccagcggcttcacctttacaaactacgccatgaattgggtgcggcaggcccctggcaagggcctggagtgggtgtctggcatcagcggaggaggaggcagcacctactatgcagactccgtgaagggcaggttcaccatctcccgcgataactctaagaatacactgtacctccagatgaacagcctgagggcagaggacaccgccgtgtactattgcgtgaaggattggaataccacaatgatcacagagaggggacagggcaccctggtgaccgtgagcagcaccacaacccctgcccccagacctcccacacccgcccctaccatcgcgagtcagccactgtccctgcggcctgaggcctgccggcccgccgccggcggagcagtgcacacacggggcctggactttgcctgtgacatctacatatgggcaccactggcaggaacctgcggcgtgctgctgctgagcctggtcatcaccctgtactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacacaggaggaggacggctgctcttgtaggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga(VH-F;SEQ ID NO:373)。 In certain embodiments of the VCAR of the present disclosure, VCAR comprises a single domain antibody, VHH, VH or a combination thereof. In some embodiments, a single domain antibody, VHH or VH comprises a recombinant sequence and / or a chimeric sequence or is composed of a recombinant sequence and / or a chimeric sequence. In some embodiments, a single domain antibody, VHH or VH comprises a human sequence and / or a humanized sequence or is composed of a human sequence and / or a humanized sequence. In certain embodiments of the VCAR of the present disclosure, the VCAR comprises a single domain antibody. In some embodiments, the single domain antibody is a VHH or a VH antibody. In some embodiments, the VH antibody is a UniDab antibody. In some embodiments, the VH antibody is not a fragment of a naturally occurring monoclonal antibody. In certain embodiments of the VCAR of the present disclosure, the signal peptide may comprise a sequence encoding a human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR signal peptide. In certain embodiments of the VCAR of the present disclosure, the signal peptide may comprise a sequence encoding a human CD8α signal peptide. The human CD8α signal peptide may comprise an amino acid sequence containing MALPVTALLLPLALLLHAARP (SEQ ID NO: 374). The human 8α signal peptide may comprise an amino acid sequence containing MALPVTALLLPLALLLHAARP (SEQ ID NO: 374) or a sequence having at least 70%, 80%, 90%, 95% or 99% identity with an amino acid sequence containing MALPVTALLLPLALLLHAARP (SEQ ID NO: 374). The human CD8α signal peptide may be comprised of a sequence comprising The nucleic acid sequence of atggcactgccagtcaccgccctgctgctgcctctggctctgctgctgcacgcagctagacca (SEQ ID NO: 375) encodes. In certain embodiments of the VCAR of the present disclosure, the transmembrane domain may include a sequence encoding a human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR transmembrane domain. In certain embodiments of the VCAR of the present disclosure, the transmembrane domain may include a sequence encoding a human CD8α transmembrane domain. The CD8α transmembrane domain may include an amino acid sequence containing IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 376) or a sequence containing The amino acid sequence of IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 376) has at least 70%, 80%, 90%, 95% or 99% identity. The CD8α transmembrane domain can be composed of The nucleic acid sequence of atctacatttgggcaccactggccgggacctgtggagtgctgctgctgagcctggtcatcacactgtactgc (SEQ ID NO: 377) encodes. In certain embodiments of the VCAR of the present disclosure, the intracellular domain may comprise the human CD3 zeta intracellular domain. In certain embodiments of the VCAR of the present disclosure, at least one costimulatory domain may include human 4-1BB, CD28, CD40, ICOS, MyD88, OX-40 intracellular segment, or any combination thereof. In certain embodiments of the VCAR of the present disclosure, at least one costimulatory domain may include CD28 and / or 4-1BB costimulatory domain. The CD3ζ costimulatory domain may include a CD3ζ costimulatory domain containing RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG The amino acid sequence of GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 378) or a residue containing RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG The amino acid sequence of GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 378) has at least 70%, 80%, 90%, 95% or 99% identity. The CD3ζ costimulatory domain can be composed of cgcgtgaagtttagtcgatcagcagatgccccagcttacaaacagggacagaaccagctgtataacgagct gaatctgggccgccgagaggaatatgacgtgctggataagcggagaggacgcgaccccgaaatgggag gcaagcccaggcgcaaaaaccctcaggaaggcctgtataacgagctgcagaaggacaaaatggcagaa The 4-1BB costimulatory domain may comprise an amino acid sequence comprising KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 380) or a nucleic acid sequence comprising The amino acid sequence of KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 380) has at least 70%, 80%, 90%, 95% or 99% identity. The 4-1BB costimulatory domain can be composed of aagagaggcaggaagaaactgctgtatattttcaaacagcccttcatgcgccccgtgcagactacccagga ggaagacgggtgctcctgtcgattccctgaggaagaggaaggcgggtgtgagctg (SEQ ID NO: 381) nucleic acid sequence encoding. The 4-1BB costimulatory domain can be located between the transmembrane domain and the CD28 costimulatory domain. In certain embodiments of the VCAR of the present disclosure, the hinge may include a sequence derived from human CD8α, IgG4 and / or CD4 sequences. In certain embodiments of the VCAR of the present disclosure, the hinge may include a sequence derived from human CD8α sequences. The hinge may include a human CD8α amino acid sequence containing TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 382) or an amino acid sequence containing TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO: 382) having at least 70%, 80%, 90%, 95% or 99% identity. The human CD8 alpha hinge amino acid sequence can be encoded by a nucleic acid sequence comprising actaccacaccagcacctagaccaccaactccagctccaaccatcgcgagtcagcccctgagtctgagacc tgaggcctgcaggccagctgcaggaggagctgtgcacaccaggggcctggacttcgcctgcgac (SEQ ID NO: 383). The VHH and / or VCAR of the present disclosure may bind to an antigen with at least one affinity selected from: less than or equal to 10 -9 M, less than or equal to 10 -10 M, less than or equal to 10 -11 M, less than or equal to 10 -12 M, less than or equal to 10 -13 M, less than or equal to 10 -14 M and less than or equal to 10 -15 M of K D K can be determined by surface plasmon resonance D . The present disclosure provides anti-BCMA VCARs. The present disclosure provides compositions comprising a VCAR of the present disclosure and at least one pharmaceutically acceptable carrier. The present disclosure provides a transposon comprising a VCAR of the present disclosure. The transposon of the present disclosure may include a selection gene for identifying, enriching and / or isolating cells expressing the transposon. Exemplary selection genes encode any gene product (e.g., transcript, protein, enzyme) necessary for cell viability and survival. Exemplary selection genes encode any gene product (e.g., transcript, protein, enzyme) necessary for conferring resistance to drug attack, and in the absence of the gene product encoded by the selection gene, the cell is sensitive to the drug attack (or it may be fatal to the cell). Exemplary selection genes encode any gene product (e.g., transcript, protein, enzyme) necessary for viability and / or survival in a cell culture medium lacking one or more nutrients, and the one or more nutrients are necessary for cell viability and / or survival in the absence of the selection gene. Exemplary selection genes include, but are not limited to, neo (confers resistance to neomycin), DHFR (encodes dihydrofolate reductase and confers resistance to methotrexate), TYMS (encodes thymidylate synthase), MGMT (encodes O(6)-methylguanine-DNA methyltransferase), multidrug resistance gene (MDR1), ALDH1 (encodes aldehyde dehydrogenase family 1, member A1), FRANCF, RAD51C (encodes RAD51 paralog C), GCS (encodes glucosylceramide synthase), and NKX2.2 (encodes NK2 homeobox 2). The transposon of the present disclosure may include an inducible pro-apoptotic polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a pro-apoptotic polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the non-human sequence includes a restriction site. In certain embodiments, the ligand binding region can be a multimeric ligand binding region. The inducible pro-apoptotic polypeptide of the present disclosure may also be referred to as an "iC9 safety switch". In certain embodiments, the transposon of the present disclosure may include an inducible caspase polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a caspase polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the transposon of the present disclosure may include an inducible caspase polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a caspase polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the transposon of the present disclosure may comprise an inducible caspase polypeptide comprising (a) a ligand binding region, (b) a linker, and (c) a truncated caspase 9 polypeptide, wherein the inducible pro-apoptotic polypeptide does not comprise a non-human sequence. In certain embodiments of the inducible pro-apoptotic polypeptide, inducible caspase polypeptide, or truncated caspase 9 polypeptide of the present disclosure, the ligand binding region may comprise a FK506 binding protein 12 (FKBP12) polypeptide. In certain embodiments, the amino acid sequence of the ligand binding region comprising the FK506 binding protein 12 (FKBP12) polypeptide may comprise a modification at position 36 of the sequence. The modification may be a substitution of valine (V) for phenylalanine (F) at position 36 (F36V). In certain embodiments, the FKBP12 polypeptide is comprised of a polypeptide comprising GVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO: 384) is encoded by the amino acid sequence. In certain embodiments, the FKBP12 polypeptide is composed of GGGGTCCAGGTCGAGACTATTTCACCAGGGGATGGGCGAACATTTCCAAAAAGGGGCCAGACTTGCGTCGTGCATTACACCGGGATGCTGGAGGACGGGAAGAAAGTGGACAGCTCCAGGGATCGCAACAAGCCCTTCAAGTTCATGCTGGGAAAGCAGGAA GTGATCCGAGGATGGGAGGAAGGCGTGGCACAGATGTCAGTCGGCCAGCGGGCCAAACTGACCATTAGCCCTGACTACGCTTATGGAGCAACAGGCCACCCAGGGATCATTCCCCCTCATGCCACCCTGGTCTTCGATGTGGAACTGCTGAAGCTGGAG(SEQ ID NO:385) nucleic acid sequence encoding. In certain embodiments, inducers specific for a ligand binding region include AP20187 and / or AP1903, both of which are synthetic drugs, wherein the ligand binding region may include a FK506 binding protein 12 (FKBP12) polypeptide having a valine (V) substitution for phenylalanine (F) at position 36 (F36V). In certain embodiments of the inducible pro-apoptotic polypeptide, inducible caspase polypeptide or truncated caspase 9 polypeptide of the present disclosure, the linker region is encoded by an amino acid comprising GGGGS (SEQ ID NO: 386) or a nucleic acid sequence comprising GGAGGAGGAGGATCC (SEQ ID NO: 387). In certain embodiments, the nucleic acid sequence encoding the linker does not comprise a restriction site. In certain embodiments of the truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain arginine (R) at position 87 of the sequence. Alternatively or additionally, in certain embodiments of the inducible pro-apoptotic polypeptides, inducible caspase polypeptides or truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain alanine (A) at position 282 of the sequence. In certain embodiments of the inducible pro-apoptotic polypeptides, inducible caspase polypeptides or truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain alanine (A) at position 282 of the sequence. GFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRTGSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGALDCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSLGGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGL the amino acid sequence of RTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTS (SEQ ID NO:388) or comprising TTGGGGACGTGGGGGCCCTGGAGTCTCTGCGAGGAAATGCCGATC TGGCTTACATCCTGAGCATGGAACCCTGCGGCCACTGTCTGATCA TTAACAATGTGAACTTCTGCAGAGAAAGCGGACTGCGAACACGG ACTGGCTCCAATATTGACTGTGAGAAGCTGCGGAGAAGGTTCTCT AGTCTGCACTTTATGGTCGAAGTGAAAGGGGATCTGACCGCCAAG AAAATGGTGCTGGCCCTGCTGGAGCTGGCTCAGCAGGACCATGGA GCTCTGGATTGCTGCGTGGTCGTGATCCTGTCCCACGGGTGCCAG GCTTCTCATCTGCAGTTCCCCGGAGCAGTGTACGGAACAGACGGC TGTCCTGTCAGCGTGGAGAAGATCGTCAACATCTTCAACGGCACT TCTTGCCCTAGTCTGGGGGGAAAGCCAAAACTGTTCTTTATCCAG GCCTGTGGCGGGGAACAGAAAGATCACGGCTTCGAGGTGGCCAG CACCAGCCCTGAGGACGAATCACCAGGGAGCAACCCTGAACCAG ATGCAACTCCATTCCAGGAGGGACTGAGGACCTTTGACCAGCTGG ATGCTATCTCAAGCCTGCCCACTCCTAGTGACATTTTCGTGTCTTA CAGTACCTTCCCAGGCTTTGTCTCATGGCGCGATCCCAAGTCAGG GAGCTGGTACGTGGAGACACTGGACGACATCTTTGAACAGTGGGC CCATTCAGAGGACCTGCAGAGCCTGCTGCTGCGAGTGGCAAACGC Encoded by the nucleic acid sequence of TGTCTCTGTGAAGGGCATCTACAAACAGATGCCCGGGTGCTTCAATTTTCTGAGAAAGAAACTGTTCTTTAAGACTTCC (SEQ ID NO:389). The transposon of the present disclosure may comprise at least one self-cleaving peptide, which is located, for example, between one or more VHHs or VCARs of the present disclosure and the selection gene of the present disclosure. The transposon of the present disclosure may comprise at least one self-cleaving peptide, which is located, for example, between one or more VHHs or VCARs of the present disclosure and the inducible pro-apoptotic polypeptide of the present disclosure. The transposon of the present disclosure may comprise at least two self-cleaving peptides, i.e., a first self-cleaving peptide located, for example, upstream or immediately upstream of the inducible pro-apoptotic polypeptide of the present disclosure, and a second first self-cleaving peptide located, for example, downstream or immediately upstream of the inducible pro-apoptotic polypeptide of the present disclosure. At least one self-cleaving peptide may include, for example, a T2A peptide, a GSG-T2A peptide, an E2A peptide, a GSG-E2A peptide, a F2A peptide, a GSG-F2A peptide, a P2A peptide, or a GSG-P2A peptide. The T2A peptide may include an amino acid sequence containing EGRGSLLTCGDVEENPGP (SEQ ID NO: 392) or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity to an amino acid sequence containing EGRGSLLTCGDVEENPGP (SEQ ID NO: 392). The GSG-T2A peptide may include an amino acid sequence containing GSGEGRGSLLTCGDVEENPGP (SEQID NO: 393) or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity to an amino acid sequence containing GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 393). The GSG-T2A peptide may comprise a nucleic acid sequence comprising ggatctggagagggaaggggaagcctgctgacctgtggagacgtggaggaaaacccaggacca (SEQ ID NO: 394). The E2A peptide may comprise an amino acid sequence comprising QCTNYALLKLAGDVESNPGP (SEQ ID NO: 395), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity to an amino acid sequence comprising QCTNYALLKLAGDVESNPGP (SEQ ID NO: 395). The GSG-E2A peptide may comprise an amino acid sequence comprising GSGQCTNYALLKLAGDVESNPGP (SEQ ID NO: 396), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity to an amino acid sequence comprising GSGQCTNYALLKLAGDVESNPGP (SEQ ID NO: 396). The F2A peptide may comprise an amino acid sequence comprising VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 397), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-F2A peptide may comprise an amino acid sequence comprising GSGVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 398), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto.The P2A peptide may comprise an amino acid sequence comprising ATNFSLLKQAGDVEENPGP (SEQ ID NO: 399), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-P2A peptide may comprise an amino acid sequence comprising GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 400), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The transposon of the present disclosure may comprise a first and a second self-cleaving peptide, i.e., a first self-cleaving peptide located, for example, upstream of one or more VHHs or VCARs of the present disclosure, and a second self-cleaving peptide located, for example, downstream of one or more VHHs or VCARs of the present disclosure. The first and / or second self-cleaving peptide may comprise, for example, a T2A peptide, a GSG-T2A peptide, an E2A peptide, a GSG-E2A peptide, a F2A peptide, a GSG-F2A peptide, a P2A peptide, or a GSG-P2A peptide. The T2A peptide may comprise an amino acid sequence containing EGRGSLLTCGDVEENPGP (SEQ ID NO: 392) or a sequence having at least 70%, 80%, 90%, 95% or 99% identity to an amino acid sequence containing EGRGSLLTCGDVEENPGP (SEQ ID NO: 392). The GSG-T2A peptide may comprise an amino acid sequence comprising GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 393), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-T2A peptide may comprise a nucleic acid sequence comprising ggatctggagagggaaggggaagcctgctgacctgtggagacgtggaggaaaacccaggacca (SEQ ID NO: 394). The E2A peptide may comprise an amino acid sequence comprising QCTNYALLKLAGDVESNPGP (SEQ ID NO: 395), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-E2A peptide may comprise an amino acid sequence comprising GSGQCTNYALLKLAGDVESNPGP (SEQ ID NO: 396), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The F2A peptide may comprise an amino acid sequence comprising VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 397), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto.The GSG-F2A peptide may comprise an amino acid sequence comprising GSGVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 398), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The P2A peptide may comprise an amino acid sequence comprising ATNFSLLKQAGDVEENPGP (SEQ ID NO: 399), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-P2A peptide can comprise an amino acid sequence comprising GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 400), or a sequence at least 70%, 80%, 90%, 95%, or 99% identical to an amino acid sequence comprising GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 400). The present disclosure provides a composition comprising a transposon of the present disclosure. In certain embodiments, the composition may further comprise a plasmid comprising a sequence encoding a transposase. The sequence encoding the transposase may be an mRNA sequence. The transposon of the present disclosure may comprise a piggyBac transposon. In certain embodiments of this method, the transposon is a plasmid DNA transposon having a sequence encoding a chimeric antigen receptor, wherein the sequence encoding the chimeric antigen receptor is flanked by two cis-regulatory insulator elements. In certain embodiments, the transposon is a piggyBac transposon. The transposase of the present disclosure may comprise a piggyBac transposase or a compatible enzyme. In certain embodiments, and especially in those embodiments in which the transposon is a piggyBac transposon, the transposase is a piggyBac or super piggyBac (Super piggyBac, SPB) transposase. In certain embodiments, and especially in those embodiments in which the transposase is a super piggyBac (SPB) transposase, the sequence encoding the transposase is an mRNA sequence. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac (PB) transposase. The piggyBac (PB) transposase may comprise or consist of an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween to the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at one or more of positions 30, 165, 282, or 538 of the following sequence: In certain embodiments, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at two or more positions 30, 165, 282, or 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at three or more positions 30, 165, 282, or 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at each of the following positions 30, 165, 282, and 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the amino acid substitution at position 30 of the sequence of SEQ ID NO: 4 is a substitution of valine (V) for isoleucine (I). In certain embodiments, the amino acid substitution at position 165 of the sequence of SEQ ID NO: 4 is a substitution of serine (S) for glycine (G). In certain embodiments, the amino acid substitution at position 282 of the sequence of SEQ ID NO: 4 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 538 of the sequence of SEQ ID NO: 4 is a substitution of lysine (K) for asparagine (N). In certain embodiments of the methods of the present disclosure, the transposase is a super piggyBac (SPB) transposase. In certain embodiments, the super piggyBac (SPB) transposase of the present disclosure may comprise or consist of an amino acid sequence of the sequence of SEQ ID NO: 4, wherein the amino acid substitution at position 30 is a substitution of valine (V) for isoleucine (I), the amino acid substitution at position 165 is a substitution of serine (S) for glycine (G), the amino acid substitution at position 282 is a substitution of valine (V) for methionine (M), and the amino acid substitution at position 538 is a substitution of lysine (K) for asparagine (N). In certain embodiments, the super piggyBac (SPB) transposase may comprise or consist of an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween with the following sequence: The present disclosure provides a vector comprising a VCAR of the present disclosure. In certain embodiments, the vector is a viral vector. The vector may be a recombinant vector. The viral vector of the present disclosure may include a sequence separated or derived from a retrovirus, a lentivirus, an adenovirus, an adeno-associated virus, or any combination thereof. The viral vector may include a sequence separated or derived from an adeno-associated virus (AAV). The viral vector may include a recombinant AAV (rAAV). Exemplary adeno-associated viruses and recombinant adeno-associated viruses of the present disclosure include two or more inverted terminal repeat (ITR) sequences, which are adjacent to the sequence encoding the VHH or VCAR of the present disclosure in cis position. Exemplary adeno-associated viruses and recombinant adeno-associated viruses of the present disclosure include, but are not limited to, all serotypes (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, and AAV9). Exemplary adeno-associated viruses and recombinant adeno-associated viruses of the present disclosure include, but are not limited to, self-complementary AAV (scAAV) and AAV hybrids (e.g., AAV2 / 5, AAV-DJ, and AAV-DJ8) containing a genome of one serotype and a capsid of another serotype. Exemplary adeno-associated viruses and recombinant adeno-associated viruses of the present disclosure include, but are not limited to, rAAV-LK03. The viral vector of the present disclosure may include a selection gene. The selection gene may encode a gene product necessary for cell viability and survival. The selection gene may encode a gene product necessary for cell viability and survival when challenged by selective cell culture conditions. The selective cell culture conditions may include a compound that is harmful to cell viability or survival, and wherein the gene product confers resistance to the compound. Exemplary selection genes of the present disclosure may include, but are not limited to, neo (confers resistance to neomycin), DHFR (encoding dihydrofolate reductase and confers resistance to methotrexate), TYMS (encoding thymidylate synthase), MGMT (encoding O(6)-methylguanine-DNA methyltransferase), multidrug resistance gene (MDR1), ALDH1 (encoding aldehyde dehydrogenase 1 family, member A1), FRANCF, RAD51C (encoding RAD51 paralog C), GCS (encoding glucosylceramide synthase), NKX2.2 (encoding NK2 homeobox 2), or any combination thereof. The viral vector of the present disclosure may include an inducible pro-apoptotic polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a pro-apoptotic polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the non-human sequence includes a restriction site. In certain embodiments, the ligand binding region can be a multimeric ligand binding region. The inducible pro-apoptotic polypeptide of the present disclosure may also be referred to as an "iC9 safety switch". In certain embodiments, the viral vector of the present disclosure may include an inducible caspase polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a caspase polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the viral vector of the present disclosure may include an inducible caspase polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a caspase polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the viral vector of the present disclosure may comprise an inducible caspase polypeptide comprising (a) a ligand binding region, (b) a linker, and (c) a truncated caspase 9 polypeptide, wherein the inducible pro-apoptotic polypeptide does not comprise a non-human sequence. In certain embodiments of the inducible pro-apoptotic polypeptide, inducible caspase polypeptide, or truncated caspase 9 polypeptide of the present disclosure, the ligand binding region may comprise a FK506 binding protein 12 (FKBP12) polypeptide. In certain embodiments, the amino acid sequence of the ligand binding region comprising the FK506 binding protein 12 (FKBP12) polypeptide may comprise a modification at position 36 of the sequence. The modification may be a substitution of valine (V) for phenylalanine (F) at position 36 (F36V). In certain embodiments, the FKBP12 polypeptide is encoded by an amino acid sequence comprising GVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPF KFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPP HATLVFDVELLKLE (SEQ ID NO: 384).In certain embodiments, the FKBP12 polypeptide consists of GGGGTCCAGGTCGAGACTATTTCACCAGGGGATGGGCGAACATTTCCAAAAAGGGGCCAGACTTGCGTCGTGCATTACACCGGGATGCTGGAGGACGGGAAGAAAGTGGACAGCTCCAGGGATCGCAACAAGCCCTTCAA GTTCATGCTGGGAAAGCAGGAAGTGATCCGAGGATGGGAGGAAGGCGTGGCACAGATGTCAGTCGGCCAGCGGGCCAAACTGACCATTAGCCCTGACTACGCTTATGGAGCAACAGGCCACCCAGGGATCATTCCCCCTCATGCCACCCTGGTCTTCGAT. In some embodiments, the inducer specific for the ligand binding region includes AP20187 and / or AP1903, both of which are synthetic drugs, and the ligand binding region may include a FK506 binding protein 12 (FKBP12) polypeptide having a substitution (F36V) of phenylalanine (F) at position 36 with valine (V). In certain embodiments of the inducible pro-apoptotic polypeptide, inducible caspase polypeptide or truncated caspase 9 polypeptide of the present disclosure, the linker region is encoded by an amino acid comprising GGGGS (SEQ ID NO: 386) or a nucleic acid sequence comprising GGAGGAGGAGGATCC (SEQ ID NO: 387). In certain embodiments, the nucleic acid sequence encoding the linker does not comprise a restriction site. In certain embodiments of the truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain arginine (R) at position 87 of the sequence. Alternatively or additionally, in certain embodiments of the inducible pro-apoptotic polypeptides, inducible caspase polypeptides or truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain alanine (A) at position 282 of the sequence. In certain embodiments of the inducible pro-apoptotic polypeptides, inducible caspase polypeptides or truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain alanine (A) at position 282 of the sequence. GFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRT GSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGAL DCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSL GGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGL The amino acid sequence of RTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTS (SEQ ID NO:388) or comprising TTGGGGACGTGGGGGCCCTGGAGTCTCTGCGAGGAAATGCCGATC TGGCTTACATCCTGAGCATGGAACCCTGCGGCCACTGTCTGATCA TTAACAATGTGAACTTCTGCAGAGAAAGCGGACTGCGAACACGG ACTGGCTCCAATATTGACTGTGAGAAGCTGCGGAGAAGGTTCTCT AGTCTGCACTTTATGGTCGAAGTGAAAGGGGATCTGACCGCCAAG AAAATGGTGCTGGCCCTGCTGGAGCTGGCTCAGCAGGACCATGGA GCTCTGGATTGCTGCGTGGTCGTGATCCTGTCCCACGGGTGCCAG GCTTCTCATCTGCAGTTCCCCGGAGCAGTGTACGGAACAGACGGC TGTCCTGTCAGCGTGGAGAAGATCGTCAACATCTTCAACGGCACT TCTTGCCCTAGTCTGGGGGGAAAGCCAAAACTGTTCTTTATCCAG GCCTGTGGCGGGGAACAGAAAGATCACGGCTTCGAGGTGGCCAG CACCAGCCCTGAGGACGAATCACCAGGGAGCAACCCTGAACCAG ATGCAACTCCATTCCAGGAGGGACTGAGGACCTTTGACCAGCTGG ATGCTATCTCAAGCCTGCCCACTCCTAGTGACATTTTCGTGTCTTA CAGTACCTTCCCAGGCTTTGTCTCATGGCGCGATCCCAAGTCAGG GAGCTGGTACGTGGAGACACTGGACGACATCTTTGAACAGTGGGC CCATTCAGAGGACCTGCAGAGCCTGCTGCTGCGAGTGGCAAACGC Encoded by the nucleic acid sequence of TGTCTCTGTGAAGGGCATCTACAAACAGATGCCCGGGTGCTTCAATTTTCTGAGAAAGAAACTGTTCTTTAAGACTTCC (SEQ ID NO: 389). The viral vector of the present disclosure may include at least one self-cleaving peptide. In some embodiments, the vector may include at least one self-cleaving peptide, and wherein the self-cleaving peptide is located between CAR and the selection gene. In some embodiments, the vector may include at least one self-cleaving peptide, and wherein the first self-cleaving peptide is located upstream of CAR and the second self-cleaving peptide is located downstream of CAR. The viral vector of the present disclosure may include at least one self-cleaving peptide, which is located between one or more of the VCAR, VCAR or VCAR of the present disclosure and the inducible pro-apoptotic polypeptide of the present disclosure. The viral vector of the present disclosure may include at least two self-cleaving peptides, that is, a first self-cleaving peptide located upstream or immediately upstream of the inducible pro-apoptotic polypeptide of the present disclosure, and a second first self-cleaving peptide located downstream or immediately upstream of the inducible pro-apoptotic polypeptide of the present disclosure. The self-cleaving peptide may include, for example, a T2A peptide, a GSG-T2A peptide, an E2A peptide, a GSG-E2A peptide, a F2A peptide, a GSG-F2A peptide, a P2A peptide or a GSG-P2A peptide. The T2A peptide may comprise an amino acid sequence comprising EGRGSLLTCGDVEENPGP (SEQ ID NO: 392), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-T2A peptide may comprise an amino acid sequence comprising GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 393), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-T2A peptide may comprise a nucleic acid sequence comprising ggatctggagagggaaggggaagcctgctgacctgtggagacgtggaggaaaacccaggacca (SEQ ID NO: 394). The E2A peptide may comprise an amino acid sequence comprising QCTNYALLKLAGDVESNPGP (SEQ ID NO: 395), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-E2A peptide may comprise an amino acid sequence comprising GSGQCTNYALLKLAGDVESNPGP (SEQ ID NO: 396), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto.The F2A peptide may comprise an amino acid sequence comprising VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 397), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-F2A peptide may comprise an amino acid sequence comprising GSGVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 398), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The P2A peptide may comprise an amino acid sequence comprising ATNFSLLKQAGDVEENPGP (SEQ ID NO: 399), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-P2A peptide may comprise an amino acid sequence comprising GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 400), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The disclosure provides a carrier comprising a VCAR of the disclosure. In certain embodiments, the carrier is a nanoparticle. The exemplary nanoparticle carrier of the disclosure includes, but is not limited to nucleic acid (such as RNA, DNA, synthetic nucleotides, modified nucleotides or any combination thereof), amino acid (L-amino acid, D-amino acid, synthetic amino acid, modified amino acid, or any combination thereof), polymer (such as polymer vesicle (polymersome)), micelle, lipid (such as liposome), organic molecule (such as carbon atom, sheet, fiber, tube), inorganic molecule (such as calcium phosphate or gold) or any combination thereof. The nanoparticle carrier can be transported through the cell membrane passively or actively. The nanoparticle carrier of the present disclosure may include a selection gene. The selection gene may encode a gene product necessary for cell viability and survival. The selection gene may encode a gene product necessary for cell viability and survival when challenged by selective cell culture conditions. The selective cell culture conditions may include a compound that is harmful to cell viability or survival and wherein the gene product confers resistance to the compound. Exemplary selection genes of the present disclosure may include, but are not limited to, neo (confers resistance to neomycin), DHFR (encoding dihydrofolate reductase and confers resistance to methotrexate), TYMS (encoding thymidylate synthase), MGMT (encoding O(6)-methylguanine-DNA methyltransferase), multidrug resistance gene (MDR1), ALDH1 (encoding aldehyde dehydrogenase 1 family, member A1), FRANCF, RAD51C (encoding RAD51 paralog C), GCS (encoding glucosylceramide synthase), NKX2.2 (encoding NK2 homeobox 2) or any combination thereof. The nanoparticle carrier of the present disclosure may include an inducible pro-apoptotic polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a pro-apoptotic polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the non-human sequence includes a restriction site. In certain embodiments, the ligand binding region can be a multimeric ligand binding region. The inducible pro-apoptotic polypeptide of the present disclosure may also be referred to as an "iC9 safety switch". In certain embodiments, the nanoparticle carrier of the present disclosure may include an inducible caspase polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a caspase polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the nanoparticle carrier of the present disclosure may include an inducible caspase polypeptide, which includes (a) a ligand binding region, (b) a linker, and (c) a caspase polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments, the nanoparticle carrier of the present disclosure may include an inducible caspase polypeptide comprising (a) a ligand binding region, (b) a linker, and (c) a truncated caspase 9 polypeptide, wherein the inducible pro-apoptotic polypeptide does not include a non-human sequence. In certain embodiments of the inducible pro-apoptotic polypeptide, inducible caspase polypeptide, or truncated caspase 9 polypeptide of the present disclosure, the ligand binding region may include a FK506 binding protein 12 (FKBP12) polypeptide. In certain embodiments, the amino acid sequence of the ligand binding region comprising the FK506 binding protein 12 (FKBP12) polypeptide may include a modification at position 36 of the sequence. The modification may be a substitution (F36V) of valine (V) to phenylalanine (F) at position 36. In certain embodiments, the FKBP12 polypeptide is encoded by an amino acid sequence comprising GVQVETISPGDGRTFPKRGQTCVVHYTGMLEDGKKVDSSRDRNKPF KFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLE (SEQ ID NO: 384).In certain embodiments, the FKBP12 polypeptide consists of GGGGTCCAGGTCGAGACTATTTCACCAGGGGATGGGCGAACATTTCCAAAAAGGGGCCAGACTTGCGTCGTGCATTACACCGGGATGCTGGAGGACGGGAAGAAAGTGGACAGCTCCAGGGATCGCAACAAGCCCTTCAA GTTCATGCTGGGAAAGCAGGAAGTGATCCGAGGATGGGAGGAAGGCGTGGCACAGATGTCAGTCGGCCAGCGGGCCAAACTGACCATTAGCCCTGACTACGCTTATGGAGCAACAGGCCACCCAGGGATCATTCCCCCTCATGCCACCCTGGTCTTCGAT. In some embodiments, the inducer specific for the ligand binding region includes AP20187 and / or AP1903, both of which are synthetic drugs, and the ligand binding region may include a FK506 binding protein 12 (FKBP12) polypeptide having a substitution (F36V) of phenylalanine (F) at position 36 with valine (V). In certain embodiments of the inducible pro-apoptotic polypeptide, inducible caspase polypeptide or truncated caspase 9 polypeptide of the present disclosure, the linker region is encoded by an amino acid comprising GGGGS (SEQ ID NO: 386) or a nucleic acid sequence comprising GGAGGAGGAGGATCC (SEQ ID NO: 387). In certain embodiments, the nucleic acid sequence encoding the linker does not comprise a restriction site. In certain embodiments of the truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain arginine (R) at position 87 of the sequence. Alternatively or additionally, in certain embodiments of the inducible pro-apoptotic polypeptides, inducible caspase polypeptides or truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain alanine (A) at position 282 of the sequence. In certain embodiments of the inducible pro-apoptotic polypeptides, inducible caspase polypeptides or truncated caspase 9 polypeptides of the present disclosure, the truncated caspase 9 polypeptide is encoded by an amino acid sequence that does not contain alanine (A) at position 282 of the sequence. GFGDVGALESLRGNADLAYILSMEPCGHCLIINNVNFCRESGLRTRT GSNIDCEKLRRRFSSLHFMVEVKGDLTAKKMVLALLELAQQDHGAL DCCVVVILSHGCQASHLQFPGAVYGTDGCPVSVEKIVNIFNGTSCPSL GGKPKLFFIQACGGEQKDHGFEVASTSPEDESPGSNPEPDATPFQEGL The amino acid sequence of RTFDQLDAISSLPTPSDIFVSYSTFPGFVSWRDPKSGSWYVETLDDIFEQWAHSEDLQSLLLRVANAVSVKGIYKQMPGCFNFLRKKLFFKTS (SEQ ID NO:388) or contains TTGGGGACGTGGGGGCCCTGGAGTCTCTGCGAGGAAATGCCGATC TGGCTTACATCCTGAGCATGGAACCCTGCGGCCACTGTCTGATCA TTAACAATGTGAACTTCTGCAGAGAAAGCGGACTGCGAACACGG ACTGGCTCCAATATTGACTGTGAGAAGCTGCGGAGAAGGTTCTCT AGTCTGCACTTTATGGTCGAAGTGAAAGGGGATCTGACCGCCAAG AAAATGGTGCTGGCCCTGCTGGAGCTGGCTCAGCAGGACCATGGA GCTCTGGATTGCTGCGTGGTCGTGATCCTGTCCCACGGGTGCCAG GCTTCTCATCTGCAGTTCCCCGGAGCAGTGTACGGAACAGACGGC TGTCCTGTCAGCGTGGAGAAGATCGTCAACATCTTCAACGGCACT TCTTGCCCTAGTCTGGGGGGAAAGCCAAAACTGTTCTTTATCCAG GCCTGTGGCGGGGAACAGAAAGATCACGGCTTCGAGGTGGCCAG CACCAGCCCTGAGGACGAATCACCAGGGAGCAACCCTGAACCAG ATGCAACTCCATTCCAGGAGGGACTGAGGACCTTTGACCAGCTGG ATGCTATCTCAAGCCTGCCCACTCCTAGTGACATTTTCGTGTCTTA CAGTACCTTCCCAGGCTTTGTCTCATGGCGCGATCCCAAGTCAGG GAGCTGGTACGTGGAGACACTGGACGACATCTTTGAACAGTGGGC CCATTCAGAGGACCTGCAGAGCCTGCTGCTGCGAGTGGCAAACGC Encoded by the nucleic acid sequence of TGTCTCTGTGAAGGGCATCTACAAACAGATGCCCGGGTGCTTCAATTTTCTGAGAAAGAAACTGTTCTTTAAGACTTCC (SEQ ID NO:389). The nanoparticle carrier of the present disclosure may include at least one self-cleaving peptide. In some embodiments, the nanoparticle carrier may include at least one self-cleaving peptide, and wherein the self-cleaving peptide is located between VCAR and the nanoparticle. In some embodiments, the nanoparticle carrier may include at least one self-cleaving peptide, and wherein the first self-cleaving peptide is located upstream of VCAR and the second self-cleaving peptide is located downstream of VCAR. In some embodiments, the nanoparticle carrier may include at least one self-cleaving peptide, and wherein the first self-cleaving peptide is located between VCAR and the nanoparticle and the second self-cleaving peptide is located downstream of VCAR. In some embodiments, the nanoparticle carrier may include at least one self-cleaving peptide, and wherein the first self-cleaving peptide is located between VCAR and the nanoparticle and the second self-cleaving peptide is located downstream of VCAR, for example, between VCAR and a selection gene. The nanoparticle carrier of the present disclosure may include at least one self-cleaving peptide, which is located, for example, between one or more VHHs or VCARs of the present disclosure and the inducible pro-apoptotic polypeptide of the present disclosure. The nanoparticle carrier of the present disclosure may include at least two self-cleaving peptides, i.e., a first self-cleaving peptide located upstream or immediately upstream of the inducible pro-apoptotic polypeptide of the present disclosure, and a second first self-cleaving peptide located downstream or immediately upstream of the inducible pro-apoptotic polypeptide of the present disclosure, for example. The self-cleaving peptide may include, for example, a T2A peptide, a GSG-T2A peptide, an E2A peptide, a GSG-E2A peptide, a F2A peptide, a GSG-F2A peptide, a P2A peptide or a GSG-P2A peptide. The T2A peptide may include an amino acid sequence containing EGRGSLLTCGDVEENPGP (SEQ ID NO: 392) or a sequence having at least 70%, 80%, 90%, 95% or 99% identity to an amino acid sequence containing EGRGSLLTCGDVEENPGP (SEQ ID NO: 392). The GSG-T2A peptide may comprise an amino acid sequence comprising GSGEGRGSLLTCGDVEENPGP (SEQ ID NO: 393), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-T2A peptide may comprise a nucleic acid sequence comprising ggatctggagagggaaggggaagcctgctgacctgtggagacgtggaggaaaacccaggacca (SEQ ID NO: 394). The E2A peptide may comprise an amino acid sequence comprising QCTNYALLKLAGDVESNPGP (SEQ ID NO: 395), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-E2A peptide may comprise an amino acid sequence comprising GSGQCTNYALLKLAGDVESNPGP (SEQ ID NO: 396), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The F2A peptide may comprise an amino acid sequence comprising VKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 397), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto.The GSG-F2A peptide may comprise an amino acid sequence comprising GSGVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 398), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The P2A peptide may comprise an amino acid sequence comprising ATNFSLLKQAGDVEENPGP (SEQ ID NO: 399), or a sequence having at least 70%, 80%, 90%, 95%, or 99% identity thereto. The GSG-P2A peptide can comprise an amino acid sequence comprising GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 400), or a sequence at least 70%, 80%, 90%, 95%, or 99% identical to an amino acid sequence comprising GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 400). The present disclosure provides compositions comprising a vector of the present disclosure. The present disclosure provides cells comprising VCAR of the present disclosure. The present disclosure provides cells comprising transposons of the present disclosure. In certain embodiments, cells comprising VCAR, transposons or vectors of the present disclosure may express VCAR on the cell surface. The cell may be any type of cell. Preferably, the cell is an immune cell. The immune cell may be a T cell, a natural killer (NK) cell, a natural killer (NK)-like cell, a cytokine-induced killer (CIK) cell, a hematopoietic progenitor cell, a peripheral blood (PB)-derived T cell or an umbilical cord blood (UCB)-derived T cell. Preferably, the immune cell is a T cell. The T cell may be an early memory cell, a stem cell-like T cell, a ... SCM T-like cells SCM or T CM . T cells can be T SCM The cell may be an artificial antigen presenting cell, which optionally may be used to stimulate and expand the modified immune cells or T cells of the present disclosure. The cell may be a tumor cell, which optionally may be used as an artificial or modified antigen presenting cell. The modified cells of the present disclosure useful for adoptive therapy may be autologous or allogeneic. The present disclosure provides a method for expressing VCAR on the surface of a cell, comprising: (a) obtaining a cell population, (b) contacting the cell population with a composition comprising a VCAR of the present disclosure or a sequence encoding the VCAR under conditions sufficient to transfer the VCAR across the cell membrane of at least one cell in the cell population, thereby producing a modified cell population; (c) culturing the modified cell population under conditions suitable for transposon integration; and (d) expanding and / or selecting at least one cell expressing VCAR on the cell surface from the modified cell population. In certain embodiments of the method for expressing VCAR, the cell colony may include leukocytes and / or CD4+ and CD8+ leukocytes. The cell colony may include CD4+ and CD8+ leukocytes of an optimized ratio. The optimized ratio of CD4+ and CD8+ leukocytes does not exist naturally in vivo. The cell colony may include tumor cells. In certain embodiments of this method of expressing a VCAR, the transposon or vector comprises the VCAR or a sequence encoding the VCAR. In certain embodiments of this method of expressing a VCAR, conditions sufficient to transfer a sequence encoding the VCAR across the cell membrane of at least one cell in the cell population include nucleofection. In certain embodiments of this method of expressing VCAR, the conditions where the sequence encoding VCAR is transferred across the cell membrane of at least one cell in the cell population include at least one of the following: one or more electric pulses under a specified voltage, a buffer and one or more supplementary factors. In certain embodiments, the buffer may include PBS, HBSS, OptiMEM, BTXpress, Amaxa Nucleofector, human T cell nuclear transfection buffer or any combination thereof. In certain embodiments, one or more supplementary factors may include (a) recombinant human cytokines, chemokines, interleukins or any combination thereof; (b) salts, minerals, metabolites or any combination thereof; (c) cell culture medium; (d) cell DNA sensing, metabolism, differentiation, signal transduction, one or more apoptotic pathways or inhibitors of a combination thereof; and (e) reagents for modifying or stabilizing one or more nucleic acids. Recombinant human cytokines, chemokines, interleukins, or any combination thereof may include IL2, IL7, IL12, IL15, IL21, IL1, IL3, IL4, IL5, IL6, IL8, CXCL8, IL9, IL10, IL11, IL13, IL14, IL16, IL17, IL18, IL19, IL20, IL22, IL23, IL25, IL26, IL27, IL28, IL29, IL30, IL31, IL32, IL33, IL35, IL36, GM-CSF, I FN-γ, IL-1α / IL-1F1, IL-1β / IL-1F2, IL-12p70, IL-12 / IL-35p35, IL-13, IL-17 / IL-17A, IL-17A / F heterodimer, IL-17F, IL-18 / IL-1F4, IL-23, IL-24, IL-32, IL-32β, IL-32γ, IL-33, LAP (TGF-β1), lymphotoxin-α / TNF-β, TGF-β, TNF-α, TRANCE / TNFSF11 / RANK L, or any combination thereof.The salts, minerals, metabolites, or any combination thereof may include HEPES, nicotinamide, heparin, sodium pyruvate, L-glutamine, MEM non-essential amino acid solution, ascorbic acid, nucleosides, FBS / FCS, human serum, serum replacement, antibiotics, pH adjusters, Earle's salts, 2-mercaptoethanol, human transferrin, recombinant human insulin, human serum albumin, Nucleofector PLUS supplement, KCL, MgCl2, Na2HPO4, NAH2PO4, sodium lactobionate, mannitol, sodium succinate, sodium chloride, CINa, glucose, Ca(NO3)2, Tris / HCl, K2HPO4, KH2PO4, polyethyleneimine, polyethylene glycol, poloxamer 188, poloxamer 181, poloxamer 407, polyvinylpyrrolidone, Pop313, Crown-5, or any combination thereof. The cell culture medium may include PBS, HBSS, OptiMEM, DMEM, RPMI 1640, AIM-V, X-VIVO 15, CellGro DC Medium, CTS OpTimizer T Cell Expansion SFM, TexMACS Medium, PRIME-XV T Cell Expansion Medium, ImmunoCult-XF T Cell Expansion Medium, or any combination thereof. Inhibitors of cellular DNA sensing, metabolism, differentiation, signal transduction, one or more apoptotic pathways, or a combination thereof include TLR9, MyD88, IRAK, TRAF6, TRAF3, IRF-7, NF-KB, type 1 interferon, proinflammatory cytokines, cGAS, STING, Sec5, TBK1, IRF-3, RNA pol III, RIG-1, IPS-1, FADD, RIP1, TRAF3, AIM2, ASC, inhibitors of caspase 1, Pro-IL1B, PI3K, Akt, Wnt3A, inhibitors of glycogen synthase kinase-3β (GSK-3β) (such as TWS119), bafilomycin, chloroquine, quinacrine, AC-YVAD-CMK, Z-VAD-FMK, Z-IETD-FMK, or any combination thereof. Agents that modify or stabilize one or more nucleic acids include pH modifiers, DNA binding proteins, lipids, phospholipids, CaPO4, net neutrally charged DNA binding peptides with or without NLS sequences, TREX1 enzymes, or any combination thereof. In certain embodiments of this method of expressing VCAR, conditions suitable for integrating the VCAR of the present disclosure or the sequence encoding VCAR include at least one of the following: buffer and one or more supplementary factors. In certain embodiments, the transposon or vector of the present disclosure comprises the VCAR of the present disclosure or the sequence encoding VCAR. In certain embodiments, the buffer may include PBS, HBSS, OptiMEM, BTXpress, AmaxaNucleofector, human T cell nuclear transfection buffer or any combination thereof. In certain embodiments, one or more supplementary factors may include (a) recombinant human cytokines, chemokines, interleukins or any combination thereof; (b) salts, minerals, metabolites or any combination thereof; (c) cell culture medium; (d) cell DNA sensing, metabolism, differentiation, signal transduction, one or more apoptotic pathways or inhibitors of their combination; and (e) reagents for modifying or stabilizing one or more nucleic acids. Recombinant human cytokines, chemokines, interleukins, or any combination thereof may include IL2, IL7, IL12, IL15, IL21, IL1, IL3, IL4, IL5, IL6, IL8, CXCL8, IL9, IL10, IL11, IL13, IL14, IL16, IL17, IL18, IL19, IL20, IL22, IL23, IL25, IL26, IL27, IL28, IL29, IL30, IL31, IL32, IL33, IL35, IL36, GM-CSF, I FN-γ, IL-1α / IL-1F1, IL-1β / IL-1F2, IL-12p70, IL-12 / IL-35p35, IL-13, IL-17 / IL-17A, IL-17A / F heterodimer, IL-17F, IL-18 / IL-1F4, IL-23, IL-24, IL-32, IL-32β, IL-32γ, IL-33, LAP (TGF-β1), lymphotoxin-α / TNF-β, TGF-β, TNF-α, TRANCE / TNFSF11 / RANK L, or any combination thereof.The salts, minerals, metabolites, or any combination thereof may include HEPES, nicotinamide, heparin, sodium pyruvate, L-glutamine, MEM non-essential amino acid solution, ascorbic acid, nucleosides, FBS / FCS, human serum, serum replacement, antibiotics, pH adjusters, Earle's salts, 2-mercaptoethanol, human transferrin, recombinant human insulin, human serum albumin, Nucleofector PLUS supplement, KCL, MgCl2, Na2HPO4, NAH2PO4, sodium lactobionate, mannitol, sodium succinate, sodium chloride, CINa, glucose, Ca(NO3)2, Tris / HCl, K2HPO4, KH2PO4, polyethyleneimine, polyethylene glycol, poloxamer 188, poloxamer 181, poloxamer 407, polyvinylpyrrolidone, Pop313, Crown-5, or any combination thereof. The cell culture medium may include PBS, HBSS, OptiMEM, DMEM, RPMI 1640, AIM-V, X-VIVO 15, CellGro DC Medium, CTS OpTimizer T Cell Expansion SFM, TexMACS Medium, PRIME-XV T Cell Expansion Medium, ImmunoCult-XF T Cell Expansion Medium, or any combination thereof. Inhibitors of cellular DNA sensing, metabolism, differentiation, signal transduction, one or more apoptotic pathways, or a combination thereof include TLR9, MyD88, IRAK, TRAF6, TRAF3, IRF-7, NF-KB, type 1 interferon, proinflammatory cytokines, cGAS, STING, Sec5, TBK1, IRF-3, RNA pol III, RIG-1, IPS-1, FADD, RIP1, TRAF3, AIM2, ASC, inhibitors of caspase 1, Pro-IL1B, PI3K, Akt, Wnt3A, inhibitors of glycogen synthase kinase-3β (GSK-3β) (such as TWS119), bafilomycin, chloroquine, quinacrine, AC-YVAD-CMK, Z-VAD-FMK, Z-IETD-FMK, or any combination thereof. Agents that modify or stabilize one or more nucleic acids include pH modifiers, DNA binding proteins, lipids, phospholipids, CaPO4, net neutrally charged DNA binding peptides with or without NLS sequences, TREX1 enzymes, or any combination thereof. In certain embodiments of the method for expressing VCAR, amplification and selection steps occur sequentially. Amplification can occur before selection. Amplification can occur after selection, and optionally, further (i.e., second) selection can occur after amplification. In certain embodiments of this method of expressing a VCAR, the amplification and selection steps can occur simultaneously. In certain embodiments of the method of expressing VCAR, amplification may include contacting at least one cell of the modified cell colony with an antigen to stimulate at least one cell by VCAR, thereby producing an amplified cell colony. Antigens may be presented on the surface of a matrix. The matrix may have any form, including, but not limited to, a surface, a hole, a bead or a plurality of beads, and a matrix. The matrix may further comprise a paramagnetic or magnetic component. In certain embodiments of the method of expressing VCAR, antigens may be presented on the surface of a matrix, wherein the matrix is ​​a magnetic bead, and wherein a magnet may be used to remove or separate the magnetic bead from the modified and amplified cell colony. Antigens may be presented on the surface of a cell or an artificial antigen presenting cell. The artificial antigen presenting cells of the present disclosure may include, but are not limited to, tumor cells and stem cells. In certain embodiments of this method of expressing a VCAR, wherein the transposon or vector comprises a selection gene, and wherein the selection step comprises contacting at least one cell of the modified cell population with a compound to which the selection gene confers resistance, thereby identifying cells expressing the selection gene as surviving the selection and identifying cells that failed to express the selection gene as failing to survive the selection step. In certain embodiments of this method of expressing a VCAR, the amplification and / or selection steps may be performed for a period of 10-14 days, inclusive. The present disclosure provides compositions comprising modified, expanded, and selected cell populations of the methods of the present disclosure. The present disclosure provides a method for treating cancer in a subject in need thereof, including administering a composition of the present disclosure to a subject, wherein VCAR specifically binds to an antigen on a tumor cell. In certain embodiments, the tumor cell may be a malignant tumor cell. In certain embodiments, including administering a composition of a cell or cell colony comprising the modification of the present disclosure to a subject, the cell or cell colony may be autologous. In certain embodiments, including administering a composition of a cell or cell colony comprising the modification of the present disclosure to a subject, the cell or cell colony may be allogeneic. The present disclosure provides a method for treating an autoimmune condition in a subject in need thereof, including administering a composition of the present disclosure to a subject, wherein VCAR specifically binds to an antigen on the subject's autoimmune cells. In certain embodiments, the autoimmune cell can be a lymphocyte that specifically binds to the autoantigen on the subject's target cell. In certain embodiments, the autoimmune cell can be a B lymphocyte (i.e., a B cell). In certain embodiments, the autoimmune cell can be a T lymphocyte (i.e., a T cell). In certain embodiments, including administering to a subject a composition comprising a cell or cell colony modified by the present disclosure, the cell or cell colony can be autologous. In certain embodiments, including administering to a subject a composition comprising a cell or cell colony modified by the present disclosure, the cell or cell colony can be allogeneic. The present disclosure provides a method for treating infection in a subject in need, including administering a composition of the present disclosure to a subject, wherein VCAR specifically binds to an antigen on a cell containing an infectious agent, a cell associated with an infectious agent, or a cell exposed to an infectious agent. In some embodiments, the cell associated with an infectious agent can be in air contact (e.g., the infectious agent is airborne or inhaled) or fluid contact (e.g., the infectious agent is carried in an aqueous or biological fluid) with the infectious agent. The infectious agent causing host cell infection can be a bacterium, a virus, a yeast, or a microorganism. The infectious agent can induce exemplary conditions in a cell or a host organism (subject) of the cell, including but not limited to viral infection, immunodeficiency conditions, inflammatory conditions, and proliferative conditions. In certain embodiments, infection causes tuberculosis, microcephaly, neurodegeneration, or malaria. In certain embodiments, infection causes microcephaly in a fetus of a subject. In certain embodiments (including those in which infection causes microcephaly in a fetus of a subject), the infectious agent is a virus, and wherein the virus is Zika virus. In certain embodiments, the immunodeficiency condition is acquired immunodeficiency syndrome (AIDS). In certain embodiments, the proliferative disorder is cancer. In certain embodiments, the cancer is cervical cancer, and wherein the infectious agent is human papillomavirus (HPV). In certain embodiments, comprising administering to a subject a composition comprising a modified cell or cell population of the disclosure, the cell or cell population may be autologous. In certain embodiments, comprising administering to a subject a composition comprising a modified cell or cell population of the disclosure, the cell or cell population may be allogeneic. The present disclosure provides a method for treating mast cell disease in a subject in need, including administering the composition of the present disclosure to a subject, wherein VCAR specifically binds to an antigen on a mast cell. In certain embodiments, VCAR specifically binds to an antigen on a subject's mast cell. In certain embodiments, mast cell disease may include but is not limited to a disorder associated with mast cell hyperplasia, a disorder associated with mast cells with abnormal activity, and a disorder associated with both abnormal mast cell number and abnormal mast cell activity. Exemplary disorders associated with mast cell hyperplasia include but are not limited to mastocytosis, cutaneous mastocytosis (e.g., urticaria pigmentosa or macular cutaneous mastocytosis), systemic mastocytosis (including mast cell leukemia) and localized mast cell hyperplasia. Exemplary disorders associated with mast cells with abnormal activity include but are not limited to mast cell activation syndrome (MCAS) or mast cell activation disorder (MCAD), allergic diseases (including allergic reactions), asthma, inflammatory diseases (including, for example, autoimmune-related inflammation of joint tissue, arthritis, etc.) or any combination thereof. In certain embodiments, including administering to a subject a composition comprising a modified cell or cell colony of the present disclosure, the cell or cell colony may be autologous. In certain embodiments, including administering to a subject a composition comprising a modified cell or cell colony of the present disclosure, the cell or cell colony may be allogeneic. The present disclosure provides a method for treating a degenerative disease in a subject in need thereof, comprising administering to a subject a composition of the present disclosure, wherein VCAR specifically binds to an antigen on harmful cells or senescent cells. In certain embodiments, VCAR specifically binds to an antigen on harmful cells or senescent cells of a subject. In certain embodiments, degenerative diseases may include, but are not limited to, neurodegenerative disorders, metabolic disorders, vascular disorders, and aging. Exemplary neurodegenerative disorders include, but are not limited to, disorders associated with loss of function or efficacy of one or more of neurons, glial cells, or microglial cells. Exemplary neurodegenerative disorders include, but are not limited to, disorders associated with accumulation of one or more signaling molecules, proteins, or prions that interfere with the function of one or more of neurons, glial cells, or microglial cells or reduce their efficacy. Exemplary metabolic disorders include, but are not limited to, disorders associated with mitochondrial disorders, disruption of the electron transport chain, disruption of cellular production of ATP, loss of function or reduced efficiency of one or more mitochondria of one or more of neurons, glial cells, or microglia.Exemplary metabolic disorders include, but are not limited to, disorders associated with loss of circulating blood flow or decreased blood flow to neurons, glial cells, or microglial cells (e.g., stroke); transient or permanent hypoxia of neurons, glial cells, or microglial cells (e.g., sufficient to release free radicals in the cells); loss of circulating CNS or decreased CNS flow to neurons, glial cells, or microglial cells during the sleep state of the subject, which is sufficient to reduce the waste removal efficiency of neurons, glial cells, or microglial cells during the sleep state. Exemplary aging disorders include, but are not limited to, disorders associated with increased shortened or shortened telomeres on one or more chromosomes of neurons, glial cells, or microglial cells; loss of function or decreased efficacy of telomerase in neurons, glial cells, or microglial cells; or loss of function or decreased efficacy of DNA repair mechanisms in neurons, glial cells, or microglial cells. In certain embodiments, harmful cells or senescent cells interfere with the function of another cell or reduce its efficacy in a network comprising the harmful cells or senescent cells, and the targeted removal of harmful cells or senescent cells improves or restores the function of the network or improves its efficacy. In certain embodiments, harmful cells or senescent cells can transform the function or efficacy of a second cell, and the targeted removal of harmful cells or senescent cells prevents the transformation of a second cell. In certain embodiments, the degenerative disease is a neurodegenerative disorder, and the harmful cells or senescent cells are stem cells, immune cells, neurons, glial cells or microglial cells. In certain embodiments, the degenerative disease is a metabolic disorder, and the harmful cells or senescent cells are stem cells, somatic cells, neurons, glial cells or microglial cells. In certain embodiments, the degenerative disease is a vascular disorder, and the harmful cells or senescent cells are stem cells, somatic cells, immune cells, endothelial cells, neurons, glial cells or microglial cells. In certain embodiments, the degenerative disease is aging, and the harmful cells or senescent cells are oocytes, sperm, stem cells, somatic cells, immune cells, endothelial cells, neurons, glial cells or microglial cells. In certain embodiments, including administering to a subject a composition comprising a modified cell or cell colony of the present disclosure, the cell or cell colony may be autologous. In certain embodiments, including administering to a subject a composition comprising a modified cell or cell colony of the present disclosure, the cell or cell colony may be allogeneic. The present disclosure provides a method for adjusting a cell therapy in a subject in need thereof, comprising administering to the subject a composition comprising cells, the cells comprising a transposon or vector of a composition comprising an inducible pro-apoptotic polypeptide, wherein apoptosis can be selectively induced in the cells by contacting the cells with an inducer. In certain embodiments, the cells are autologous. In certain embodiments, the cells are allogeneic. In certain embodiments of the method, the cell therapy is adoptive cell therapy. In certain embodiments of the method, adjusting the cell therapy comprises terminating the cell therapy. In certain embodiments of the method, adjusting the cell therapy comprises depleting a portion of the cells provided in the cell therapy. In certain embodiments, the method further comprises the step of administering an inhibitor of the inducer to inhibit the adjustment of the cell therapy, thereby restoring the function and / or efficacy of the cell therapy. The methods of adjusting cell therapy of the present disclosure can be used to terminate or reduce treatment in response to, for example, signs of recovery or signs of reduced disease severity / progression, signs of disease remission / cessation, and / or the occurrence of adverse events. If signs or symptoms of disease reappear or increase in severity and / or adverse events are resolved, cell therapy of the present disclosure can be resumed by inhibiting the inducing agent. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph showing weight change versus days post-treatment for VCAR of the present disclosure. Figure 2 is a graph showing tumor burden versus days post-treatment for VCAR of the present disclosure. Figure 3 is a graph showing the percent survival versus days post-treatment for VCAR of the present disclosure. Figure 4 is a graph of tumor burden as shown by bioluminescent signal versus days after treatment for VH-A (triangles), irrelevant CAR (squares), or no tumor / no CAR-T (circles). Figure 5 is a graph of tumor burden as shown by bioluminescent signal versus days after treatment for VH-B (triangles), irrelevant CAR (squares), or no tumor / no CAR-T (circles). Figure 6 is a graph of tumor burden as shown by bioluminescent signal versus days after treatment for VH-C (triangles), irrelevant CAR (squares), or no tumor / no CAR-T (circles). Figure 7 is a graph of tumor burden as shown by bioluminescent signal versus days after treatment for VH-D (triangles), irrelevant CAR (squares), or no tumor / no CAR-T (circles). Figure 8is a graph of tumor burden as shown by bioluminescent signal versus days after treatment for VH-E (triangles), irrelevant CAR (squares), or no tumor / no CAR-T (circles). Fig. 9 is a graph of tumor burden as shown by bioluminescent signal versus days after treatment for VH-F (triangles), irrelevant CAR (squares), or no tumor / no CAR-T (circles). Fig. 10A is a table providing consensus sequences of framework and CDR sequences of exemplary VHs of the present disclosure. Fig. 10B : is an alignment of exemplary VHs of the present disclosure. From top to bottom, the sequences correspond to the consensus sequences of frameworks VH-B (SEQ ID NO: 410), VH-D (SEQ ID NO: 411), VH-A (SEQ ID NO: 412), VH-E (SEQ ID NO: 413), VH-F (SEQ ID NO: 414), and VH-C (SEQ ID NO: 415). Fig.11 It is a bar graph depicting the knockout efficiency of restriction point signaling proteins on armored T cells. Primary human T cells are usually in a resting state when isolated from normal healthy donors. Cas-CLOVER was used to knock out restriction point receptors PD-1, TGFBR2, LAG-3, TIM-3, and CTLA-4. The percentage knockout is shown on the y-axis. As measured by flow cytometry, gene editing resulted in a 30-70% loss of protein expression on the cell surface. Fig.12It is a schematic diagram of wild-type, invalid and switch receptors in primary T cells and their effects on intracellular signaling (inhibitory or stimulatory). The binding of wild-type inhibitory receptors endogenously expressed on T cells to their endogenous ligands results in the transmission of inhibitory signals, which partially reduces T cell effector function. However, restriction point receptor proteins, such as mutations (mutated invalid) or deletions (truncated invalid) of the intracellular domain (ICD) of PD1 (upper figure) or TGFBRII (lower figure) reduce or eliminate its signaling ability when one or more associated ligands bind. Therefore, the expression of engineered mutant or truncated invalid receptors on the surface of modified T cells results in competition with endogenously expressed wild-type receptors for binding to one or more free endogenous ligands, effectively reducing or eliminating the delivery of inhibitory signals by endogenously expressed wild-type receptors. Specifically, any binding by mutation or invalid receptors masks one or more endogenous ligands to bind to wild-type receptors, and causes the total level of restriction point signaling effectively delivered to modified T cells to be diluted, thereby reducing or blocking the restriction point inhibition and functional exhaustion of modified T cells. By replacing wild-type ICD with ICD from costimulatory molecules (such as CD3z, CD28, 4-1BB) or different inhibitory molecules (such as CTLA4, PD1, Lag3), conversion receptors are produced. In the former case, the binding of one or more endogenous ligands by the modified conversion receptor causes the delivery of positive signals to T cells, thereby helping to enhance the stimulation of modified T cells and possibly enhancing target tumor cell killing. In the latter case, the binding of one or more endogenous ligands by the modified conversion receptor causes the delivery of negative signals to T cells, thereby eliminating the stimulation of modified T cells, and possibly reducing target tumor cell killing. Signal peptide (purple arrow), extracellular domain (ECD) (bright green), transmembrane domain (yellow), intracellular signaling domain (ICD) (orange) and replacement ICD (green) are shown in the receptor diagram. "*" indicates a mutant ICD. "+" indicates the presence of a restriction point signal. "-" indicates the absence of a restriction point signal. Fig.13It is a schematic diagram showing the design of PD1 and TGFBRII invalid receptors.Showing the signal peptide domain (SP), transmembrane domain (TM) and extracellular domain (ECD) of the truncated invalid receptor of PD1 (upper figure) and TGFBRII (lower figure).The first of the four molecules in the upper part is a wild-type PD-1 receptor, which encodes wild-type PD-1SP and TM.For PD1 invalid receptors, it is depicted that the SP or TM domain (red) of human T cell CD8a receptor replaces PD1 wild-type SP or TM domain (green; light green).The second molecule encodes CD8a SP together with natural PD-1TM, the third encodes wild-type PD-1SP and alternative CD8aTM, and the fourth encodes both CD8a SP and TM alternatives.Similarly, for the invalid receptor of TGFβRII, the SP domain (red) of human T cell CD8a receptor replaces wild-type TGFBRII SP (pink).The name of the construct and the amino acid length (aa) of each construct protein are listed on the left side of the figure. Fig.14 is a series of histograms depicting the expression of PD1 and TGFBRII null receptors on the surface of primary human T cells as determined by flow cytometry. Fig.13 Each of the six truncated null constructs. T cells were stained with anti-PD1 (upper; blue histogram) or anti-TGFβRII (lower; blue histogram) or isotype control or secondary antibody only (gray histogram). Cells that were positive for PD-1 or TGFβRII expression were gated (frequency is shown above the gate), and the mean fluorescence intensity (MFI) value is shown above each positive histogram. The name of the null receptor construct is depicted above each figure. Two null receptor gene strategies, replacing wild-type SP with alternative CD8a, were successfully expressed. 02.8aSP-PD-1 and 02.8aSP-TGFβRII resulted in the highest level of expression on the surface of T cells. The 02.8aSP-PD-1 null receptor exhibited an MFI of 43,680, which is 177 times that of endogenous T cell PD-1 expression and 2.8 times that of wild-type PD-1 null receptor. 02.8aSP-TGFβRII null receptors exhibited an MFI of 13,809, which is 102-fold that of endogenous T cell TGFβRII expression and 1.8-fold that of wild-type TGFβRII null receptors. For both PD1 and TGRBRII, replacement of the wild-type SP with alternative CD8a SPs resulted in enhanced surface expression of null or switched receptors, which helps maximize restriction point inhibition or costimulation, respectively, upon binding of one or more endogenous ligands. Fig.15A-B is a pair of schematic diagrams depicting NF-KB inducible vectors for expression in T cells. Two T cell activation NF-KB inducible vectors were developed; a gene expression system (GES) with a forward orientation (A), and the other is a complementary orientation (B), both of which are before the constitutive EF1a promoter. These vectors also guide the expression of CAR molecules and DHFR selection genes separated by T2A sequences. Both the conditional NF-KB inducible system and the genes guided by EF1a are part of the piggyBac transposon that can be permanently integrated into T cells using electroporation (EP). Once integrated into the genome, T cells will constitutively express CAR on the membrane surface and DHFR in the cell, while the expression of the NF-KB inducible gene GFP will only be expressed to the highest level when T cells are activated. Fig.16 is a pair of graphs depicting NF-KB inducible expression of GFP in activated T cells. T cells were nucleofected with piggyBac vectors expressing anti-BCMACAR and DHFR mutant protein genes under the control of the EF1a promoter and the absence (no GES control) or presence of an NF-KB inducible expression system driving GFP expression in the forward (pNFKB-GFP forward) or reverse orientation (pNFKB-GFP reverse). Cells were cultured with methotrexate selection until the cells were almost completely quiescent (day 19), and GFP expression was assessed on days 5 and 19. On day 5, all T cells proliferated and were highly stimulated, while cells with the NFKB inducible expression cassette produced high levels of GFP due to strong NFκB activity. No GES control cells did not express detectable levels of GFP. By day 19, GES T cells were almost completely quiescent, and GFP expression was significantly lower than on day 5 (~1 / 8 MFI), due to lower NFκB activity. GFP expression was still observed at day 19, which could be due to the long half-life of the GFP protein (~30 hours), or basal levels of NFκB activity through, for example, TCR, CAR, cytokine receptors, or growth factor receptor signaling. Fig.17It is a series of figures depicting the activation of anti-BCMACAR-mediated by NF-KB inducible expression of GFP in the presence of BCMA+ tumor cells.T cells are unmodified (simulated T cells) or piggyBac vectors expressing anti-BCMACAR and DHFR mutant protein genes under the control of EF1a promoter and the absence (no GES control) or the presence of NF-KB inducible expression system driving forward (pNFKB-GFP forward) or reverse orientation (pNFKB-GFP reverse) GFP expression, and nuclear transfection is performed.With or without methotrexate selection (simulated T cells), all cells are cultured for 22 days until cells are almost completely quiescent.Then in the absence of (no stimulation) or the presence of BCMA-(K562), BMCA+(RPMI8226) or positive control anti-CD3 anti-CD28 activating reagents (CD3 / 28 stimulation), cells are stimulated for 3 days.Under all conditions, GFP expression is not detectable with no GES control or simulation T cells. However, while pNFKB-GFP forward and reverse transposed cells showed a small amount of GFP expression relative to the unstimulated control when cultured with BCMA-K562 cells, they both showed a dramatic upregulation of gene expression in the presence of BCMA+ tumor cells or under positive control conditions. Almost no difference in GFP expression was observed between pNFKB-GFP forward and reverse transposed cells co-cultured with BCMA+ tumor cells. Fig.18It is a series of figures that confirm that the expression level of inducible gene can be regulated by the number of response elements before promoter.T cell carries out nuclear transfection with piggyBac vector, and the piggyBac vector encodes anti-BCMA CARTyrin and the selection gene thereafter, both of which are under the control of people EF1a promoter.Further, the conditional NF-KB inducible gene expression system that the CD19 protein (dCD19) of driving truncation is encoded in addition, and includes many NFKB response elements (RE) varying from 0 to 5, without GES (without GES), or accepts electroporation pulse but without piggyBac nucleic acid (simulation).Only the data about the GES of reverse (opposite) direction / orientation are shown.All cells are cultured for 18 days, and include the selection of T cell modified for piggyBac using methotrexate addition.Then anti-CD3 anti-CD28 beads are used to activate cells for 3 days, and dCD19 surface expression is assessed by FACS at the 0th, 3rd and 18th day, and data are displayed as the MFI of FACS histogram and target protein staining. At day 0, low levels of surface dCD19 expression were detected in all T cells transposed with vectors encoding GES. At 3 days after stimulation, a dramatic upregulation of dCD19 expression was observed for all T cells expressing GES, with greater fold increases in surface expression in those with a higher number of REs. Thus, surface dCD19 expression is proportional to the number of REs encoded in the GES. No dCD19 was detected on the surface of T cells without GES: no GES and mock controls. Fig.19 It is a schematic drawing of Csy4-T2A-Clo051-G4S linker-dCas9 construct diagram (embodiment 2). Fig. 20 is a schematic representation of the pRT1-Clo051-dCas9 dual NLS construct (Embodiment 1). Fig.21 is a pair of figures comparing embodiment 1 (pRT1-Clo051-dCas9 dual NLS, such as Fig. 20 ) or embodiment 2 (Csy4-T2A-Clo051-G4S linker-dCas9, as shown in Fig.19 ) knockout B2M in whole T cells (left) or the α-chain of the T cell receptor in Jurkat cells (right). For the right panel, fusion proteins were provided at 10 μg or 20 μg as indicated. Fig. 22 This is an implementation example 1 (pRT1-Clo051-dCas9 dual NLS, such as Fig. 20) and embodiment 2 (Csy4-T2A-Clo051-G4S linker-dCas9, as shown Fig.19 Photographs of gel electrophoresis analysis of mRNA in the presence of each of the 5,6-dihydropyruvate (ADP-γ-L-glucopyranoside) and 5,6-dihydropyruvate (ADP-γ-L-glucopyranoside). As shown, both were effective in knocking down mRNA expression. Fig.23 It's UniRat TM Schematic representation of the human heavy chain antibody production platform. Fig.24 It is used to identify the immunization by UniRat TM Schematic diagram of the immunization, B cell isolation, mRNA purification, next generation sequencing (NGS), bioinformatics analysis, high-throughput vector assembly, and high-throughput expression and screening process of the complete antigen-specific repertoire of the generated heavy chain antibodies. The unique gene assembly method converts the sequence information of the antibody repertoire into a large collection of fully human heavy chain antibodies that can be screened for multiple functions. Fig.25 is a pair of heat maps showing how next generation sequencing (NGS) analysis reveals expanded VH sequence repertoires. The extent of red (high) or blue (low) in the heat map indicates that VH sequence families have expanded due to immunization. Some high-ranking VH sequences are unique to a single animal. Other high-ranking VH sequences appear in more than one animal, indicating convergent selection of these sequence families. Fig.26 is a series of flow cytometry images showing expression of P-PSMA-101 and inclusion of T SCM / T CM The mixed CAR-T population gave rise to CAR+T CM , T EM and Teff attack solid tumors. After solid tumors are eliminated, CAR-T+T SCM Although demonstrated with CARTyrin, the principles shown here apply to VCAR+T of the present disclosure. SCM and VCAR+T CM population. Specifically, a murine xenograft model using a luciferase-expressing LNCaP cell line (LNCaP.luc) injected subcutaneously (SC) into NSG mice was used to evaluate the in vivo anti-tumor efficacy of CARs (P-PSMA5-101 and P-PSMA8-101) at a "stress" dose (4x10^6) of total CAR-T cells. For these in vivo studies, all CAR-T cells were produced using the Poseida production process using PB delivery of P-PSMA5-101 or P-PSMA8-101 plasmids. Mice were injected in the axilla with LNCaP and when tumors were established (100-300mm measured by calipers), the tumors were assessed. 3) for treatment. Mice were treated with a "stress" dose (4x10^6) of P-PSMA-101 by IV injection to clarify any possible differences in efficacy between PSMA5 and PSMA8 CAR. Anti-tumor activity was evaluated by survival, CD8+T cell expansion and detection in the blood, tumor volume assessed by caliper measurement, and bioluminescence of LNCaP tumors. Compared with T cell (no CAR) control mice, "stress" doses of P-PSMA5-101 and P-PSMA8-101 demonstrated significantly enhanced anti-tumor efficacy and survival for SC LNCaP.luc solid tumors established in NSG mice. Specifically, there was no survival in T cell (no CAR) control animals, 25% survival in the P-BCMA-101 treatment group, 75% survival in the P-PSMA5-101 treatment group, and 100% survival in animals treated with a "stress" dose of P-PSMA8-101. In the peripheral blood, P-PSMA5-101 and P-PSMA8-101 expanded and generated differentiated effector CARTyrin+ T cells, which accompanied the reduction of tumor burden to below the detectable limit of caliper and bioluminescent imaging. These cells then shrank but still persisted in the peripheral blood. DETAILED DESCRIPTION The present disclosure provides a chimeric antigen receptor (CAR) comprising at least one VHH (VCAR). The chimeric antigen receptor of the present disclosure may comprise more than one VHH. For example, a bispecific VCAR may comprise two VHHs that specifically bind to two different antigens. The VHH proteins of the present disclosure specifically bind antigens. The chimeric antigen receptors of the present disclosure comprising one or more VHHs that specifically bind an antigen can be used to direct the specificity of cells (eg, cytotoxic immune cells) to a particular antigen. The present disclosure provides a chimeric antigen receptor (CAR) comprising an antigen recognition region (VCAR) containing a single domain antibody. In some embodiments, the single domain antibody is a VHH antibody. In some embodiments, the single domain antibody is a VH antibody. The chimeric antigen receptor of the present disclosure may include a signal peptide of human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR. The hinge / spacer domain of the present disclosure may include a hinge / spacer / stem of human CD8α, IgG4 and / or CD4. The intracellular domain or intracellular domain of the present disclosure may include an intracellular signaling domain of human CD3ζ, and may further include human 4-1BB, CD28, CD40, ICOS, MyD88, OX-40 intracellular segments or any combination thereof. Exemplary transmembrane domains include, but are not limited to, human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR transmembrane domains. The present disclosure provides genetically modified cells, such as T cells, NK cells, hematopoietic progenitor cells, peripheral blood (PB) derived T cells (including T cells from peripheral blood mobilized by G-CSF), umbilical cord blood (UCB) derived T cells, by introducing the VCAR of the present disclosure into these cells so that the cells have specificity for one or more antigens. The cells of the present disclosure can be modified by electrotransfer of a transposon encoding the VCAR of the present disclosure and a plasmid comprising a sequence encoding the transposase of the present disclosure (preferably, the sequence encoding the transposase of the present disclosure is an mRNA sequence). VH of the present disclosure The present disclosure provides a chimeric antigen receptor (CAR) comprising a single domain antibody (VCAR). In some embodiments, a single domain antibody comprises a VH. In some embodiments, VH is separated or derived from a human sequence. In some embodiments, VH comprises a human CDR sequence and / or a human framework sequence and a non-human or humanized sequence (e.g., a rat Fc domain). In some embodiments, VH is a fully humanized VH. In some embodiments, VH is neither a naturally occurring antibody nor a fragment of a naturally occurring antibody. In some embodiments, VH is not a fragment of a monoclonal antibody. In some embodiments, VH is a UniDab TM Antibodies (TeneoBio). In some embodiments, UniRat TM (TeneoBio) system and "NGS-based discovery" to generate VHs. Using this method, the specific VHs are not naturally occurring and are generated using a fully engineered system. The VHs are not derived from naturally occurring monoclonal antibodies (mAbs) directly isolated from a host (e.g., mouse, rat, or human) or directly from a monoclonal isolation of a cell or cell line (hybridoma). These VHs are not subsequently cloned from the cell line. Instead, the VH sequences are generated using UniRatTM The system is fully engineered to contain a transgenic human variable region (VH domain) with a rat Fc domain, and is therefore a human / rat chimera without a light chain and is different from the standard mAb format. The native rat gene is knocked out, and the only antibodies expressed in rats are from transgenics with a VH domain connected to a rat Fc (UniAb). These are the only Abs expressed in UniRat. Next generation sequencing (NGS) and bioinformatics are used to identify the UniRat after immunization. TM The complete antigen-specific repertoire of heavy chain antibodies produced. Then, a unique gene assembly method is used to convert the antibody repertoire sequence information into a large collection of fully human heavy chain antibodies that can be screened for multiple functions in vitro. In some embodiments, fully humanized VHs are produced by fusing human VH domains to human Fcs in vitro (to produce non-naturally occurring recombinant VH antibodies). In some embodiments, VHs are fully humanized, but they are expressed in vivo as human / rat chimeras without light chains (human VH, rat Fc). Fully humanized VHs are expressed in vivo as human / rat chimeras without light chains (human VH, rat Fc), which are about 80 kDa (relative to 150 kDa). The VCAR of the present disclosure may include at least one VH of the present disclosure. In some embodiments, the VH of the present disclosure may be modified to remove the Fc domain or a portion thereof. In some embodiments, the framework sequence of the VH of the present disclosure may be modified to, for example, improve expression, reduce immunogenicity or improve function. Exemplary VCARs of the Disclosure In some embodiments of the VCARs of the present disclosure, the VCAR comprises at least one of an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence: VH-A: malpvtalllplalllhaarpevqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvagiigsggstyyadsvkgrf sisrdnskntldlqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgl dfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqn qlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 362). In some embodiments of the VCAR of the present disclosure, the amino acid sequence of the VCAR is encoded by a nucleotide sequence comprising a sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleotide sequence: VH-A: atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgcctgaagttcagctgcttgaatctggcggagg cctggttcaacctggcggatctctgagactgagctgtgccgccagcggcttcacctttagcagctacgccatgaactgggtccgacaggc ccctggcaaaggactggaatgggtggccggaatcatcggcagcggcggcagcacatattacgccgattctgtgaagggccgcttcagc atcagccgggacaacagcaagaacaccctggacctgcagatgaacagcctgagagccgaggataccgccgtgtactactgcgtgaag gattggaacaccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctccaa caccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagagga ctggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgtaag agaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacaaggaggaggacggctgctcttgta ggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacag aaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgg gaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatc ggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga (SEQ ID NO: 363). In some embodiments of the VCARs of the present disclosure, the VCAR comprises at least one of an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence: VH-B: malpvtalllplalllhaarpevqllesggglvqpggsltlscaasgftfsnyamnwvrqapgkglewvsgiigsgattyyadsvkgrf tisrdnskntlnlqmnslraedtaiyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgld facdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnql ynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 364). In some embodiments of the VCAR of the present disclosure, the amino acid sequence of the VCAR is encoded by a nucleotide sequence comprising a sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleotide sequence: VH-B: atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgcctgaagttcagctgcttgaatctggcggagg cctggttcaacctggcggatctctgacactgagctgtgccgccagcggcttcaccttcagcaactacgccatgaactgggtccgacagg cccctggcaaaggccttgaatgggtgtccggcatcattggctctggcgccaccacctactacgccgattctgtgaagggcagattcacca tcagccgggacaacagcaagaacaccctgaacctgcagatgaacagcctgagagccgaggacaccgccatctactactgcgtgaagg actggaacacccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctccaa caccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagagga ctggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgtaag agaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacaaggaggaggacggctgctcttgta ggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacag aaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgg gaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatc ggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatgac (SEQ ID NO: 365). In some embodiments of the VCARs of the present disclosure, the VCAR comprises at least one of an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence: VH-C: malpvtalllplalllhaarpevqllesggglvqpgeslrlscaasgftfsnyamnwvrqapgkglewvsgivggggtsyyadsvrgr ftisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgl dfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqn qlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 366). In some embodiments of the VCAR of the present disclosure, the amino acid sequence of VCAR is encoded by a nucleotide sequence comprising a sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleotide sequence of VH-C: atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgcctgaagttcagctgcttgaatctggcggagg cctggttcagcctggcgaatctctgagactgagctgtgccgccagcggcttcaccttcagcaactacgccatgaactgggtccgacagg cccctggcaaaggccttgaatgggtgtccggaatcgttggcggcggaggcacaagctactacgccgattctgtgcggggcagattcac catcagccgggacaacagcaagaacaccctgtacctgcagatgaacagcctgagagccgaggacaccgccgtgtactactgcgtgaa ggactggaacaccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctcc aacaccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagag gactggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgta agagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacaaggaggaggacggctgctcttg taggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggac agaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatg ggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagat cggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga (SEQ ID NO: 367). In some embodiments of the VCARs of the present disclosure, the VCAR comprises at least one of an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence: VH-D: malpvtalllplalllhaarpevqllesggglvqpggslrlscaasgftfsnyamtwirqapgkglewvsgitgdggstfyadsvkgrft isrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgldf acdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnql ynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 368). In some embodiments of the VCAR of the present disclosure, the amino acid sequence of the VCAR is encoded by a nucleotide sequence comprising a sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleotide sequence: VH-D atggctctgcctgtgacagctctgctgctgcctctggctctgcttcttcatgcggcgcgcctgaagttcagctgcttgaatctggcggagg cctggttcaacctggcggatctctgagactgagctgtgccgccagcggcttcaccttcagcaattacgccatgacctggatcagacaggc ccctggcaaaggcctggaatgggtgtccggaattacaggcgacggcggcagcaccttttacgccgattctgtgaagggcagattcacca tcagccgggacaacagcaagaacaccctgtacctgcagatgaacagcctgagagccgaggacaccgccgtgtactactgcgtgaagg actggaacacccaccatgatcaccgagagaggccagggcacactggtcaccgtgtcctctacaacaacaccggcgcctcggcctccaa caccagctcctacaatcgcgagtcagcccctgtctctcagacccgaagcctgtagacctgctgctggcggagctgtgcataccagagga ctggatttcgcctgcgacatctacatctgggctcctctggctggcacatgcggagttttgctgctgagcctggtcatcaccctgtactgtaag agaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacaaggaggaggacggctgctcttgta ggttcccagaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagcagggacag aaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggaccccgagatgg gaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattctgagatc ggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga (SEQ ID NO: 369). In some embodiments of the VCARs of the present disclosure, the VCAR comprises at least one of an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence: VH-E: malpvtalllplalllhaarpevqllesggglaqpggslrlscaasgftfssyamnwirqapgkglewvsgisgsggstyyadsvkgrf tisrdnskntvylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgl dfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqn qlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 370). In some embodiments of the VCAR of the present disclosure, the amino acid sequence of the VCAR is encoded by a nucleotide sequence comprising a sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleotide sequence: VH-E atggcactgcctgtgacagccctgctgctgcctctggccctgctgctgcacgcagcacggcccgaggtgcagctgctggagtccggag gaggcctggcccagcctggcggcagcctgaggctgtcctgcgccgcctctggcttcacctttagctcctacgccatgaactggatcaga caggcccctggcaagggcctggagtgggtgtccggcatctccggctctggaggctctacatactatgccgacagcgtgaagggccggt tcaccatcagcagagataactccaagaataccgtgtacctccagatgaactctctgcgggccgaggacaccgccgtgtactattgcgtga aggattggaatacccacaatgatcacagaggggccagggcaccctggtgacagtgtctagcaccacaacccctgcccccagacctc ccacacccgcccctaccatcgcgagtcagccactgtccctgcggcctgaggcctgccggcccgccgccggcggagcagtgcacaca cggggcctggactttgcctgtgacatctacatatgggcaccactggcaggaacctgcggcgtgctgctgctgagcctggtcatcaccctg tactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacacaggaggaggacggct gctcttgtaggttcccaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcatacaagca gggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccgggacccc gagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcctattc tgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaaggacacctatgatgccctgcacatgcaggccctgccccctagatga (SEQ ID NO: 371). In some embodiments of the VCARs of the present disclosure, the VCAR comprises at least one of an amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence: VH-F: malpvtalllplalllhaarpevqllesggglvqpgrslrlscaasgftftnyamnwvrqapgkglewvsgisggggstyyadsvkgrf tisrdnskntlylqmnslraedtavyycvkdwnttmitergqgtlvtvsstttpaprpptpaptiasqplslrpeacrpaaggavhtrgld facdiyiwaplagtcgvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnql ynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 372). In some embodiments of the VCAR of the present disclosure, the amino acid sequence of the VCAR is encoded by a nucleotide sequence comprising a sequence that is at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following nucleotide sequence: VH-F atggcactgcctgtgacagccctgctgctgcctctggccctgctgctgcacgcagcacggcccgaggtgcagctgctggagtctggag gaggcctggtgcagcccggccggtccctgagactgtcttgcgccgccagcggcttcacctttacaaactacgccatgaattgggtgcgg caggcccctggcaagggcctggagtgggtgtctggcatcagcggaggaggaggcagcacctactatgcagactccgtgaagggcag gttcaccatctcccgcgataactctaagaatacactgtacctccagatgaacagcctgagggcagaggacaccgccgtgtactattgcgt gaaggattggaatacccacaatgatcacagaggggacagggcaccctggtgaccgtgagcagcaccacaacccctgcccccagac ctcccacacccgcccctaccatcgcgagtcagccactgtccctgcggcctgaggcctgccggcccgccgccggcggagcagtgcac acacggggcctggactttgcctgtgacatctacatatgggcaccactggcaggaacctgcggcgtgctgctgctgagcctggtcatcac cctgtactgtaagagaggcaggaagaagctgctgtatatcttcaagcagcccttcatgagacccgtgcagaccacaaggaggaggac ggctgctcttgtaggttcccaggaggaggagggaggatgcgagctgcgcgtgaagtttagccggtccgccgatgcacctgcataca agcagggacagaaccagctgtataacgagctgaatctgggccggagagaggagtacgacgtgctggataagaggcggggccggga ccccgagatgggaggcaagcctcggagaaagaacccacaggagggcctgtacaatgagctgcaaaaggacaagatggccgaggcc tattctgagatcggcatgaagggagagaggcgccggggcaagggacacgatggcctgtaccagggcctgagcaccgccacaaagg acacctatgatgccctgcacatgcaggcctgccccctagatga (SEQ ID NO: 373). In some embodiments of VCAR of the present disclosure, VCAR comprises a sequence encoding VH-A, VH-B, VH-C, VH-D, VH-E or VH-F. In some embodiments of VCAR of the present disclosure, VCAR comprises two sequences encoding VH-A, VH-B, VH-C, VH-D, VH-E or VH-F. Immune and immune precursor cells In certain embodiments, the immune cells of the present disclosure include lymphocyte progenitor cells, natural killer (NK) cells, T lymphocytes (T cells), stem memory T cells (T cells), SCM cells), central memory T cells (central memory T cells) (T CM ), stem-like T cells, B lymphocytes (B-cells), myeloid progenitor cells, neutrophils, basophils, eosinophils, monocytes, macrophages, platelets, erythrocytes, red blood cells (RBC), megakaryocytes or osteoclasts. In certain embodiments, immune precursor cells include any cells that can differentiate into one or more types of immune cells. In certain embodiments, immune precursor cells include pluripotent stem cells that can self-renew and develop into immune cells. In certain embodiments, immune precursor cells include hematopoietic stem cells (HSC) or their offspring. In certain embodiments, immune precursor cells include precursor cells that can develop into immune cells. In certain embodiments, immune precursor cells include hematopoietic progenitor cells (HPC). Hematopoietic Stem Cells (HSC) Hematopoietic stem cells (HSCs) are multipotent, self-renewing cells. All differentiated blood cells from the lymphoid and myeloid lineages arise from HSCs. HSCs can be found in adult bone marrow, peripheral blood, mobilized peripheral blood, peritoneal dialysis effluent, and umbilical cord blood. The HSC of the present disclosure may be isolated or derived from primary or cultured stem cells. The HSC of the present disclosure may be isolated or derived from embryonic stem cells, pluripotent stem cells, multipotent stem cells, adult stem cells or induced pluripotent stem cells (iPSC). The immune precursor cells of the present disclosure may include HSC or HSC progeny cells. Exemplary HSC progeny cells of the present disclosure include, but are not limited to, pluripotent stem cells, lymphoid progenitor cells, natural killer (NK) cells, T lymphocytes (T cells), B lymphocytes (B cells), myeloid progenitor cells, neutrophils, basophils, eosinophils, monocytes and macrophages. The HSC produced by the method of the present disclosure can maintain the characteristics of "primitive" stem cells, which, although separated or derived from adult stem cells and although committed to a single line, share the characteristics of embryonic stem cells. For example, the "primitive" HSC produced by the method of the present disclosure maintains its "stemness" after division and does not differentiate. Therefore, as an adoptive cell therapy, the "primitive" HSC produced by the method of the present disclosure not only replenishes its number, but also expands in vivo. When administered as a single dose, the "primitive" HSC produced by the method of the present disclosure can be therapeutically effective. In some embodiments, the original HSC of the present disclosure is CD34+. In some embodiments, the original HSC of the present disclosure is CD34+ and CD38-. In some embodiments, the original HSC of the present disclosure is CD34+, CD38- and CD90+. In some embodiments, the original HSC of the present disclosure is CD34+, CD38-, CD90+ and CD45RA-. In some embodiments, the primitive HSCs of the present disclosure are CD34+, CD38-, CD90+, CD45RA-, and CD49f+. In some embodiments, the most primitive HSCs of the present disclosure are CD34+, CD38-, CD90+, CD45RA-, and CD49f+. In some embodiments of the present disclosure, the original HSC, HSC and / or HSC progeny cells can be modified according to the methods of the present disclosure to express exogenous sequences (e.g., chimeric antigen receptors or therapeutic proteins). In some embodiments of the present disclosure, the modified original HSC, modified HSC and / or modified HSC progeny cells can be forward differentiated to produce modified immune cells, including but not limited to, modified T cells, modified natural killer cells and / or modified B cells of the present disclosure. T cells The modified T cells of the present disclosure may be derived from modified hematopoieticstem and progenitor cells (HSPC) or modified HSC. Unlike traditional biological preparations and chemotherapeutics, the modified T cells of the present disclosure have the ability to rapidly reproduce upon antigen recognition, thereby possibly eliminating the need for repeated treatment. To achieve this, in some embodiments, the modified T cells of the present disclosure not only drive the initial response, but also persist in the patient as a stable population of viable memory T cells to prevent possible recurrence. Alternatively, in some embodiments, when not desired, the modified T cells of the present disclosure do not persist in the patient. Intensified efforts have been focused on developing antigen receptor molecules that do not cause T cell exhaustion through tonic signaling, as well as on containing early memory T cells, especially stem cell memory (T SCM ) or stem cell-like T cells). The stem cell-like modified T cells of the present disclosure exhibit the greatest self-renewal capacity and multipotency to derive central memory (T CM )T cells or T CM Like cells, effector memory (T EM ) and effector T cells (T E ), resulting in better tumor eradication and long-term modified T cell engraftment. Linear differentiation pathways may be responsible for the generation of these cells: naive T cells (T N )>T SCM >T CM >T EM >T E >T TE , where T N It directly generates T SCM The parental precursor cell, T SCM Then directly generate T CM The composition of T cells of the present disclosure may comprise one or more of each parental T cell subset, wherein T SCM or T CM cells are the most abundant (e.g., T SCM >T CM >T EM >T E >T TE ). In some embodiments of the methods of the present disclosure, immune cell precursors differentiate into or are capable of differentiating into early memory T cells, stem cell-like T cells, naive T cells (T N ), T SCM , T CM , T EM , T E or T TE In some embodiments, the immune cell precursor is a primitive HSC, HSC, or HSC progeny cell of the present disclosure. In some embodiments of the methods of the present disclosure, the immune cells are early memory T cells, stem cell-like T cells, naive T cells (T N ), T SCM , T CM , T EM , T E or T TE . In some embodiments of the methods of the present disclosure, the immune cell is an early memory T cell. In some embodiments of the methods of the present disclosure, the immune cell is a stem-like T cell. In some embodiments of the methods of the present disclosure, the immune cell is a T SCM . In some embodiments of the methods of the present disclosure, the immune cell is a T CM . In some embodiments of the methods of the present disclosure, the methods modify and / or the methods produce a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage therebetween of the plurality of modified T cells express one or more cell surface markers of early memory T cells. In certain embodiments, the plurality of modified early memory T cells include at least one modified stem cell-like T cell. In certain embodiments, the plurality of modified early memory T cells include at least one modified T cell. SCM In certain embodiments, the plurality of modified early memory T cells comprises at least one modified T CM . In some embodiments of the methods of the present disclosure, the methods modify and / or the methods produce a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween of the plurality of modified T cells express one or more cell surface markers of stem cell-like T cells. In certain embodiments, the plurality of modified stem cell-like T cells comprises at least one modified T cell. SCM In certain embodiments, the plurality of modified stem-like T cells comprises at least one modified T CM . In some embodiments of the methods of the present disclosure, the methods modify and / or the methods produce a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, express stem memory T cells (T cells). SCM). In certain embodiments, the cell surface markers include CD62L and CD45RA. In certain embodiments, the cell surface markers include one or more of CD62L, CD45RA, CD28, CCR7, CD127, CD45RO, CD95, CD95, and IL-2Rβ. In certain embodiments, the cell surface markers include one or more of CD45RA, CD95, IL-2Rβ, CCR7, and CD62L. In some embodiments of the methods of the present disclosure, the methods modify and / or the methods produce a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, express central memory T cells (T cells). CM ). In certain embodiments, the cell surface markers include one or more of CD45RO, CD95, IL-2Rβ, CCR7 and CD62L. In some embodiments of the methods of the present disclosure, the methods modify and / or the methods produce a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, express naive T cells (T cells). N ). In certain embodiments, the cell surface markers include one or more of CD45RA, CCR7 and CD62L. In some embodiments of the methods of the present disclosure, the methods modify and / or the methods generate a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, express effector T cells (modified T cells). EFF ). In certain embodiments, the cell surface markers include one or more of CD45RA, CD95, and IL-2Rβ. In some embodiments of the methods of the present disclosure, the methods modify and / or the methods produce a plurality of modified T cells, wherein at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, express stem cell-like T cells, stem memory T cells (T cells), or any percentage thereof. SCM ) or central memory T cells (T CM )'s cell surface markers. In some embodiments of the methods of the present disclosure, the buffer comprises an immune cell or a precursor thereof. The buffer maintains or enhances the cell viability level and / or stem cell-like phenotype of an immune cell or a precursor thereof (including a T cell). In certain embodiments, before nuclear transfection, the buffer maintains or enhances the cell viability level and / or stem cell-like phenotype of primary human T cells. In certain embodiments, during nuclear transfection, the buffer maintains or enhances the cell viability level and / or stem cell-like phenotype of primary human T cells. In certain embodiments, after nuclear transfection, the buffer maintains or enhances the cell viability level and / or stem cell-like phenotype of primary human T cells. In certain embodiments, the buffer comprises KCl, MgCl, or any combination thereof in any absolute or relative abundance or concentration. 2 , ClNa, glucose and Ca(NO 3 ) 2 In some embodiments, the buffer comprises 5 mM KCl, 15 mM MgCl 2 , 90 mM ClNa, 10 mM glucose and 0.4 mM Ca(NO 3 ) 2 In certain embodiments, the buffer comprises 5 mM KCl, 15 mM MgCl 2 , 90 mM ClNa, 10 mM glucose and 0.4 mM Ca(NO 3 ) 2 and a supplement containing 20 mM HEPES and 75 mM Tris / HCl. In certain embodiments, the buffer comprises 5 mM KCl, 15 mM MgCl 2 , 90mM ClNa, 10mM glucose and 0.4mM Ca(NO 3 ) 2 and 40 mM Na 2 HPO 4 / NaH 2 PO 4In certain embodiments, the composition comprising primary human T cells comprises 100 μl of buffer and 5×10 6 -25x10 6 In certain embodiments, during the introducing step, the composition comprises 250 x 10 6 Primary human T cells. In some embodiments of the methods of the present disclosure, the methods include contacting immune cells of the present disclosure (including T cells of the present disclosure) with a T cell expansion composition. In some embodiments of the methods of the present disclosure, the step of introducing a transposon and / or a transposase of the present disclosure into immune cells of the present disclosure may further include contacting the immune cells with a T cell expansion composition. In some embodiments, including those in which the introducing step of the method includes an electroporation or nuclear transfection step, an electroporation or nuclear transfection step may be performed with immune cells of the present disclosure contacted with a T cell expansion composition. In some embodiments of the methods of the present disclosure, the T cell expansion composition comprises, consists essentially of, or consists of phosphorus; one or more of octanoic acid, palmitic acid, linoleic acid, and oleic acid; a sterol; and an alkane. In certain embodiments of the method for producing the modified T cell of the present disclosure, the expansion supplement comprises one or more cytokines. One or more cytokines may include any cytokine, including but not limited to, lymphokines. Exemplary lymphokines include, but are not limited to, interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-15 (IL-15), interleukin-21 (IL-21), granulocyte macrophage colony stimulating factor (GM-CSF) and interferon-γ (INFγ). One or more cytokines may include IL-2. In some embodiments of the methods of the present disclosure, the T cell expansion composition comprises human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol and expansion supplement. In certain embodiments of this method, the T cell expansion composition further comprises one or more of octanoic acid, nicotinamide, 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD), diisopropyl adipate (DIPA), n-butylbenzenesulfonamide, 1,2-phthalic acid, bis(2-methylpropyl) ester, palmitic acid, linoleic acid, oleic acid, stearic acid hydrazide, oleamide, sterols and alkanes. In certain embodiments of this method, the T cell expansion composition further comprises one or more of octanoic acid, palmitic acid, linoleic acid, oleic acid and sterols. In certain embodiments of this method, the T cell expansion composition further comprises one or more of the following: octanoic acid at a concentration of 0.9 mg / kg-90 mg / kg (including endpoints); palmitic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); linoleic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); oleic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); and sterols at a concentration of about 0.1 mg / kg-10 mg / kg (including endpoints). In certain embodiments of this method, the T cell expansion composition further comprises one or more of octanoic acid at a concentration of about 9 mg / kg, palmitic acid at a concentration of about 2 mg / kg, linoleic acid at a concentration of about 2 mg / kg, oleic acid at a concentration of about 2 mg / kg, and sterols at a concentration of about 1 mg / kg. In certain embodiments of this method, the T cell expansion composition further comprises one or more of the following: octanoic acid at a concentration of 6.4 μmol / kg-640 μmol / kg (including endpoints); palmitic acid at a concentration of 0.7 μmol / kg-70 μmol / kg (including endpoints); linoleic acid at a concentration of 0.75 μmol / kg-75 μmol / kg (including endpoints); oleic acid at a concentration of 0.75 μmol / kg-75 μmol / kg (including endpoints); and sterols at a concentration of 0.25 μmol / kg-25 μmol / kg (including endpoints). In certain embodiments of this method, the T cell expansion composition further comprises one or more of octanoic acid at a concentration of about 64 μmol / kg, palmitic acid at a concentration of about 7 μmol / kg, linoleic acid at a concentration of about 7.5 μmol / kg, oleic acid at a concentration of about 7.5 μmol / kg, and sterols at a concentration of about 2.5 μmol / kg. In certain embodiments, the T cell expansion composition comprises one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, and an expansion supplement to produce a plurality of expanded modified T cells, wherein at least 2% of the plurality of modified T cells express early memory T cells, stem cell-like T cells, stem memory T cells (T SCM ) and / or central memory T cells (T CM). In certain embodiments, the T cell expansion composition comprises or further comprises one or more cell surface markers of octanoic acid, nicotinamide, 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD), diisopropyl adipate (DIPA), n-butylbenzenesulfonamide, 1,2-phthalic acid, bis(2-methylpropyl) ester, palmitic acid, linoleic acid, oleic acid, stearic acid hydrazide, oleamide, sterols and alkanes. In certain embodiments, the T cell expansion composition comprises one or more of octanoic acid, palmitic acid, linoleic acid, oleic acid and sterols (e.g., cholesterol). In certain embodiments, the T cell expansion composition comprises one or more of the following: octanoic acid at a concentration of 0.9 mg / kg-90 mg / kg (including endpoints); palmitic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); linoleic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); oleic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); and sterols at a concentration of about 0.1 mg / kg-10 mg / kg (including endpoints) (where mg / kg = parts per million). In certain embodiments, the T cell expansion composition comprises one or more of octanoic acid at a concentration of about 9 mg / kg, palmitic acid at a concentration of about 2 mg / kg, linoleic acid at a concentration of about 2 mg / kg, oleic acid at a concentration of about 2 mg / kg, and sterols at a concentration of about 1 mg / kg (where mg / kg = parts per million). In certain embodiments, the T cell expansion composition comprises one or more of octanoic acid at a concentration of 9.19 mg / kg, palmitic acid at a concentration of 1.86 mg / kg, linoleic acid at a concentration of about 2.12 mg / kg, oleic acid at a concentration of about 2.13 mg / kg, and sterols at a concentration of about 1.01 mg / kg (wherein mg / kg = parts per million). In certain embodiments, the T cell expansion composition comprises octanoic acid at a concentration of 9.19 mg / kg, palmitic acid at a concentration of 1.86 mg / kg, linoleic acid at a concentration of 2.12 mg / kg, oleic acid at a concentration of about 2.13 mg / kg, and sterols at a concentration of 1.01 mg / kg (wherein mg / kg = parts per million). In certain embodiments, the T cell expansion composition comprises one or more of the following: octanoic acid at a concentration of 6.4 μmol / kg-640 μmol / kg (including endpoints); palmitic acid at a concentration of 0.7 μmol / kg-70 μmol / kg (including endpoints); linoleic acid at a concentration of 0.75 μmol / kg-75 μmol / kg (including endpoints); oleic acid at a concentration of 0.75 μmol / kg-75 μmol / kg (including endpoints); and sterols at a concentration of 0.25 μmol / kg-25 μmol / kg (including endpoints).In certain embodiments, the T cell expansion composition comprises one or more of octanoic acid at a concentration of about 64 μmol / kg, palmitic acid at a concentration of about 7 μmol / kg, linoleic acid at a concentration of about 7.5 μmol / kg, oleic acid at a concentration of about 7.5 μmol / kg, and sterols at a concentration of about 2.5 μmol / kg. In certain embodiments, the T cell expansion composition comprises one or more of octanoic acid at a concentration of about 63.75 μmol / kg, palmitic acid at a concentration of about 7.27 μmol / kg, linoleic acid at a concentration of about 7.57 μmol / kg, oleic acid at a concentration of about 7.56 μmol / kg, and sterols at a concentration of about 2.61 μmol / kg. In certain embodiments, the T cell expansion composition comprises octanoic acid at a concentration of about 63.75 μmol / kg, palmitic acid at a concentration of about 7.27 μmol / kg, linoleic acid at a concentration of about 7.57 μmol / kg, oleic acid at a concentration of 7.56 μmol / kg, and sterols at a concentration of 2.61 μmol / kg. As used herein, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, and an expansion supplement at 37°C. Alternatively or additionally, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of phosphorus, octyl fatty acid, palmitic fatty acid, linoleic fatty acid, and oleic acid. In certain embodiments, the culture medium contains 10 times the amount of phosphorus that can be present in, for example, Iscove's modified Dulbecco's medium ((IMDM); available at ThermoFisher Scientific as catalog number 12440053). As used herein, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, Iscove's MDM and expansion supplements at 37°C. Alternatively or additionally, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of the following elements: boron, sodium, magnesium, phosphorus, potassium and calcium. In certain embodiments, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of the following elements present at corresponding average concentrations: 3.7 mg / L boron, 3000 mg / L sodium, 18 mg / L magnesium, 29 mg / L phosphorus, 15 mg / L potassium and 4 mg / L calcium. As used herein, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol and an expansion supplement at 37°C. Alternatively or additionally, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of the following components: octanoic acid (CAS No. 124-07-2), nicotinamide (CAS No. 98-92-0), 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD) (CAS No. 126-86-3), diisopropyl adipate (DIPA) (CAS No. 6938-94-9), n-butylbenzenesulfonamide (CAS No. 3622 -84-2), 1,2-phthalic acid, bis(2-methylpropyl) ester (CAS No. 84-69-5), palmitic acid (CAS No. 57-10-3), linoleic acid (CAS No. 60-33-3), oleic acid (CAS No. 112-80-1), stearic acid hydrazide (CAS No. 4130-54-5), oleamide (CAS No. 3322-62-1), sterols (e.g., cholesterol) (CAS No. 57-88-5) and alkanes (e.g., nonadecane) (CAS No. 629-92-5). In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of the following components: octanoic acid (CAS No. 124-07-2), nicotinamide (CAS No. 98-92-0), 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD) (CAS No. 126-86-3), diisopropyl adipate (DIPA) (CAS No. 6938-94-9), n-butylbenzenesulfonamide (CAS No. 3622-84-2), 1 , 2-phthalic acid, bis(2-methylpropyl) ester (CAS No. 84-69-5), palmitic acid (CAS No. 57-10-3), linoleic acid (CAS No. 60-33-3), oleic acid (CAS No. 112-80-1), stearic acid hydrazide (CAS No. 4130-54-5), oleamide (CAS No. 3322-62-1), sterols (e.g., cholesterol) (CAS No. 57-88-5), alkanes (e.g., nonadecane) (CAS No. 629-92-5) and phenol red (CAS No. 143-74-8).In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of the following components: octanoic acid (CAS No. 124-07-2), nicotinamide (CAS No. 98-92-0), 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD) (CAS No. 126-86-3), diisopropyl adipate (DIPA) (CAS No. 6938-94-9), n-butylene glycol (TBE) (CAS No. 126-86-3 ... n-butylene glycol (TBE) (CAS No. 126-86-3), n-butylene glycol (TBE) (CAS No. 126-86-3), n-butylene glycol (TBE) (CAS No. 126-86-3), Benzenesulfonamide (CAS No. 3622-84-2), 1,2-phthalic acid, bis(2-methylpropyl) ester (CAS No. 84-69-5), palmitic acid (CAS No. 57-10-3), linoleic acid (CAS No. 60-33-3), oleic acid (CAS No. 112-80-1), stearic acid hydrazide (CAS No. 4130-54-5), oleamide (CAS No. 3322-62-1), phenol red (CAS No. 143-74-8) and lanolin alcohol. In certain embodiments, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, and an expansion supplement at 37° C. Alternatively or additionally, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of the following ions: sodium, ammonium, potassium, magnesium, calcium, chloride, sulfate, and phosphate. As used herein, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, and an expansion supplement at 37° C. Alternatively or additionally, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of the following free amino acids: histidine, asparagine, serine, glutamic acid, arginine, glycine, aspartic acid, glutamic acid, threonine, alanine, proline, cysteine, lysine, tyrosine, methionine, valine, isoleucine, leucine, phenylalanine, and tryptophan. In certain embodiments, the terms "supplemented T cell expansion composition" or "T cell expansion composition" are used interchangeably with culture media comprising the corresponding average molar percentages of one or more of the following free amino acids: histidine (about 1%), asparagine (about 0.5%), serine (about 1.5%), glutamine (about 67%), arginine (about 1.5%), glycine (about 1.5%), aspartic acid (about 1%), glutamate (about 2%), threonine (about 2%), alanine (about 1%), proline (about 1.5%), cysteine ​​(about 1.5%), lysine (about 3%), tyrosine (about 1.5%), methionine (about 1%), valine (about 3.5%), isoleucine (about 3%), leucine (about 3.5%), phenylalanine (about 1.5%), and tryptophan (about 0.5%). In certain embodiments, the terms "supplemented T cell expansion composition" or "T cell expansion composition" are used interchangeably with culture media comprising the corresponding average molar percentages of one or more of the following free amino acids: histidine (about .78%), asparagine (about 0.4%), serine (about 1.6%), glutamine (about 67.01%), arginine (about 1.67%), glycine (about 1.72%), aspartic acid (about 1.00%), glutamate (about 1.93%), threonine (about 2.38%), alanine (about 1.11%), proline (about 1.49%), cysteine ​​(about 1.65%), lysine (about 2.84%), tyrosine (about 1.62%), methionine (about 0.85%), valine (about 3.45%), isoleucine (about 3.14%), leucine (about 3.3%), phenylalanine (about 1.64%), and tryptophan (about 0.37%). As used herein, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of human serum albumin, recombinant human insulin, human transferrin, 2-mercaptoethanol, Iscove's MDM, and expansion supplements at 37°C. Alternatively or additionally, the term "T cell expansion composition containing supplements" or "T cell expansion composition" can be used interchangeably with a culture medium containing one or more of phosphorus, octyl fatty acid, palmitic fatty acid, linoleic fatty acid, and oleic acid. In certain embodiments, the culture medium contains 10 times the amount of phosphorus that can be present in, for example, Iscove's modified Dulbecco's medium ((IMDM); available at ThermoFisher Scientific as catalog number 12440053). In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid, palmitic acid, linoleic acid, oleic acid, and sterols (e.g., cholesterol). In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of the following: octanoic acid at a concentration of 0.9 mg / kg-90 mg / kg (including endpoints); palmitic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); linoleic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); oleic acid at a concentration of 0.2 mg / kg-20 mg / kg (including endpoints); and sterols at a concentration of about 0.1 mg / kg-10 mg / kg (including endpoints) (where mg / kg = parts per million). In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid at a concentration of about 9 mg / kg, palmitic acid at a concentration of about 2 mg / kg, linoleic acid at a concentration of about 2 mg / kg, oleic acid at a concentration of about 2 mg / kg, and sterols at a concentration of about 1 mg / kg (wherein mg / kg = parts per million). In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid at a concentration of 9.19 mg / kg, palmitic acid at a concentration of 1.86 mg / kg, linoleic acid at a concentration of about 2.12 mg / kg, oleic acid at a concentration of about 2.13 mg / kg, and sterols at a concentration of about 1.01 mg / kg (wherein mg / kg = parts per million). In certain embodiments, the term "supplemented T cell expansion composition" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid at a concentration of 9.19 mg / kg, palmitic acid at a concentration of 1.86 mg / kg, linoleic acid at a concentration of 2.12 mg / kg, oleic acid at a concentration of about 2.13 mg / kg, and sterols at a concentration of 1.01 mg / kg (where mg / kg = parts per million). In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of the following: octanoic acid at a concentration of 6.4 μmol / kg-640 μmol / kg (including the endpoint); palmitic acid at a concentration of 0.7 μmol / kg-70 μmol / kg (including the endpoint); linoleic acid at a concentration of 0.75 μmol / kg-75 μmol / kg (including the endpoint); oleic acid at a concentration of 0.75 μmol / kg-75 μmol / kg (including the endpoint); and sterols at a concentration of 0.25 μmol / kg-25 μmol / kg (including the endpoint).In certain embodiments, the term "supplemented T cell expansion composition" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid at a concentration of about 64 μmol / kg, palmitic acid at a concentration of about 7 μmol / kg, linoleic acid at a concentration of about 7.5 μmol / kg, oleic acid at a concentration of about 7.5 μmol / kg, and sterols at a concentration of about 2.5 μmol / kg. In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid at a concentration of about 63.75 μmol / kg, palmitic acid at a concentration of about 7.27 μmol / kg, linoleic acid at a concentration of about 7.57 μmol / kg, oleic acid at a concentration of about 7.56 μmol / kg, and sterols at a concentration of about 2.61 μmol / kg. In certain embodiments, the term "T cell expansion composition containing a supplement" or "T cell expansion composition" can be used interchangeably with a culture medium comprising one or more of octanoic acid at a concentration of about 63.75 μmol / kg, palmitic acid at a concentration of about 7.27 μmol / kg, linoleic acid at a concentration of about 7.57 μmol / kg, oleic acid at a concentration of 7.56 μmol / kg, and sterols at a concentration of 2.61 μmol / kg. In the production of modified T cells (e.g., stem cell-like T cells, T SCM and / or T CM In certain embodiments of the method of the present invention, the method comprises contacting the modified T cells with an inhibitor of the P13K-Akt-mTOR pathway. The modified T cells of the present disclosure include the modified stem cell-like T cells, T cells of the present disclosure, SCM and / or T CM , may be incubated, cultured, grown, stored or otherwise combined in any step of the method of the procedure with a growth medium containing one or more inhibitors of components of the PI3K pathway. Exemplary inhibitors of components of the PI3K pathway include, but are not limited to, inhibitors of GSK3β, such as TWS119 (also known as GSK 3B inhibitor XII; having a chemical formula C 18 H 14 N 4 O 2 CAS No. 601514-19-6). Exemplary inhibitors of components of the PI3K pathway include, but are not limited to, bb007 (BLUEBIRDBIO TMAdditional exemplary inhibitors of components of the PI3K pathway include, but are not limited to, allosteric Akt inhibitor VIII (also known as Akti-1 / 2 with compound number 10196499), ATP competitive inhibitors (orthosteric inhibitors targeting the ATP-binding pocket of protein kinase B (Akt)), isoquinoline-5-sulfonamides (H-8, H-89, and NL-71-101), azepane derivatives (a series of structures derived from (-)-balanol), aminofurazans (GSK690693), heterocyclic rings (7-azaindole, 6-phenylpurine derivatives, pyrrolo[2,3-d]pyrimidine derivatives, CCT128930, 3-aminopyrrolidine, anilinotriazole derivatives, spiroindoline derivatives, AZD5363, epatath sertib (GDC-0068, RG7440), A-674563 and A-443654), phenylpyrazole derivatives (AT7867 and AT13148), thiophenecarboxamide derivatives (Afuresertib (GSK2110183), 2-pyrimidinyl-5-amidothiophene derivatives (DC120), uprosertib (GSK2141795)), allosteric inhibitors (superior to orthosteric inhibitors, providing higher specificity, reduced side effects and less toxicity), 2,3-diphenylquinoxaline analogs (2,3-diphenylquinoxaline derivatives, triazolo[3,4-f][1,6]naphthyridin-3(2H)-one derivatives (MK-2206)), alkyl phospholipids (Edelfosine (1-O-octadecyl-2-O-methyl-racem-glycero-3-phosphocholine, ET-18-OCH 3) ilmofosine (BM41.440), miltefosine (hexadecylphosphocholine, HePC), perifosine (D-21266), erucylphosphocholine (ErPC), erufosine (ErPC3, erucylphosphohomocholine), indole-3-carbinol analog (indole-3 -methanol, 3-chloroacetylindole, diindolylmethane, 6-methoxy-5,7-dihydroindole [2,3-b] carbazole-2,10-dicarboxylic acid diethyl ester (SR13668), OSU-A9), sulfonamide derivatives (PH-316 and PHT-427), thiourea derivatives (PIT-1, PIT-2, DM-PIT-1, N-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-N'-(3-bromophenyl])-thiourea), purine derivatives (Triciribine (TCN, NSC 154020), triciribine monophosphate active analogs (TCN-P), 4-amino-pyrido [2,3-d] pyrimidine derivatives API-1, 3-phenyl-3H-imidazo [4,5-b] pyridine derivatives, ARQ 092), BAY1125976, 3-methyl-xanthine, quinoline-4-carboxamide and 2-[4-(cyclohexa-1,3-dien-1-yl)-1H-pyrazol-3-yl]phenol, 3-oxo-gansulic acid, 3α- and 3β-acetoxy-gansulic acid, acetoxy-gansulic acid and irreversible inhibitors (antibiotics, lactoquinomycin, frenolicin B, kalamycin, medromycin, Boc-Phe-vinyl ketone, 4-hydroxynonenal (4-HNE), 1,6-naphthyridone derivatives and imidazo-1,2-pyridine derivatives). In the production of modified T cells (e.g., stem cell-like T cells, T SCM and / or T CM In certain embodiments of the method of claim 1, the method comprises contacting the modified T cell with an inhibitor of T cell effector differentiation. Exemplary inhibitors of T cell effector differentiation include, but are not limited to, BET inhibitors (e.g., JQ1, a hienotriazolodiazepine) and / or inhibitors of the BET protein family (e.g., BRD2, BRD3, BRD4, and BRDT). In the production of modified T cells (e.g., stem cell-like T cells, T SCM and / or T CMIn certain embodiments of the method of claim 1 , the method comprises contacting the modified T cell with an agent that reduces nucleoplasmic acetyl-CoA. Exemplary agents that reduce nucleoplasmic acetyl-CoA include, but are not limited to, 2-hydroxycitrate (2-HC) and agents that increase Acss1 expression. In certain embodiments of the method for producing modified T cells (e.g., stem cell-like T cells, TSCMs, and / or TCMs) of the present disclosure, the method includes contacting the modified T cells with a composition comprising a histone deacetylase (HDAC) inhibitor. In some embodiments, the composition comprising the HDAC inhibitor comprises valproic acid, sodium phenylbutyrate (NaPB), or a combination thereof or is composed thereof. In some embodiments, the composition comprising the HDAC inhibitor comprises valproic acid or is composed thereof. In some embodiments, the composition comprising the HDAC inhibitor comprises sodium phenylbutyrate (NaPB) or is composed thereof. In the present disclosure, the modified T cells (e.g., stem cell-like T cells, T SCM and / or T CM ), the activation supplement may include one or more cytokines. The one or more cytokines may include any cytokine, including, but not limited to, lymphokines. Exemplary lymphokines include, but are not limited to, interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-15 (IL-15), interleukin-21 (IL-21), granulocyte macrophage colony stimulating factor (GM-CSF) and interferon-γ (INFγ). The one or more cytokines may include IL-2. In the present disclosure, the modified T cells (e.g., stem cell-like T cells, T SCM and / or T CM ), the activation supplement may comprise one or more activator protein complexes. Exemplary and non-limiting activator protein complexes may include monomeric, dimeric, trimeric, or tetrameric antibody complexes that bind one or more of CD3, CD28, and CD2. In some embodiments, the activation supplement comprises or consists of an activator protein complex that comprises a human antibody, a humanized antibody, a recombinant antibody, or a chimeric antibody. In some embodiments, the activation supplement comprises or consists of an activator protein complex that binds CD3 and CD28. In some embodiments, the activation supplement comprises or consists of an activator protein complex that binds CD3, CD28, and CD2. Natural Killer (NK) Cells In certain embodiments, the modified immune or immune precursor cells of the present disclosure are natural killer (NK) cells. In certain embodiments, NK cells are cytotoxic lymphocytes differentiated from lymphoid progenitor cells. The modified NK cells of the present disclosure may be derived from modified hematopoietic stem progenitor cells (HSPC) or modified HSC. In certain embodiments, non-activated NK cells are derived from CD3-depleted leukopheresis (containing CD14 / CD19 / CD56+ cells). In certain embodiments, NK cells are electroporated using a Lonza 4D nucleofector or a BTX ECM 830 (500 V, 700 usec pulse duration, 0.2 mm electrode gap, one pulse). All Lonza 4D nucleofector procedures are contemplated to be within the scope of the methods of the present disclosure. In certain embodiments, 5x10E6 cells are electroporated per electroporation in 100 μL P3 buffer in a cuvette. However, this ratio of cells per volume is scalable for commercial manufacturing processes. In certain embodiments, NK cells are stimulated by co-culturing with other cell lines. In certain embodiments, other cell lines include artificial antigen presenting cells (aAPC). In certain embodiments, stimulation occurs on the 1st, 2nd, 3rd, 4th, 5th, 6th or 7th day after electroporation. In certain embodiments, stimulation occurs on the 2nd day after electroporation. In certain embodiments, NK cells express CD56. B cells In certain embodiments, the modified immune or immune precursor cells of the present disclosure are B cells. B cells are a type of lymphocyte that expresses a B cell receptor on the cell surface. The B cell receptor binds to a specific antigen. The modified B cells of the present disclosure may be derived from modified hematopoietic stem progenitor cells (HSPCs) or modified HSCs. In certain embodiments, HSPCs are modified using the methods of the disclosure and then primed for B cell differentiation in the presence of human IL-3, Flt3L, TPO, SCF, and G-CSF for at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days. In certain embodiments, HSPCs are modified using the methods of the disclosure and then primed for B cell differentiation in the presence of human IL-3, Flt3L, TPO, SCF, and G-CSF for 5 days. In certain embodiments, after initiation, the modified HSPC cells are transferred to a feeder cell layer and fed once every two weeks, and transferred to a fresh feeder layer once a week. In certain embodiments, the feeder cells are MS-5 feeder cells. In certain embodiments, the modified HSPC cells are cultured with MS-5 feeder cells for at least 7, 14, 21, 28, 30, 33, 35, 42, or 48 days. In certain embodiments, the modified HSPC cells are cultured with MS-5 feeder cells for 33 days. Transposition system Exemplary transposon / transposase systems of the present disclosure include, but are not limited to, piggyBac transposon and transposase, piggyBac-like transposon and transposase, SleepingBeauty transposon and transposase, Helaizer transposon and transposase, and Tol2 transposon and transposase. The piggyBac transposase recognizes the transposon-specific inverted terminal repeats (ITRs) on the ends of the transposon and moves the contents between the ITRs into the TTAA chromosomal locus. For genes of concern that may be included between the ITRs, the piggyBac transposon system has no payload limitations. In certain embodiments, and, in particular, in those embodiments in which the transposon is a piggyBac transposon, the transposase is a piggyBac or super piggyBac (SPB) transposase. In certain embodiments, and, in particular, in those embodiments in which the transposase is a super piggyBac (SPB) transposase, the sequence encoding the transposase is an mRNA sequence. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac (PB) transposase. The piggyBac (PB) transposase may comprise or consist of an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween to the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at one or more of positions 30, 165, 282, or 538 of the following sequence: In certain embodiments, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at two or more of positions 30, 165, 282, or 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at three or more of positions 30, 165, 282, or 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the transposase is a piggyBac (PB) transposase comprising or consisting of an amino acid sequence having an amino acid substitution at each of the following positions 30, 165, 282, and 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the amino acid substitution at position 30 of the sequence of SEQ ID NO: 4 is a substitution of valine (V) for isoleucine (I). In certain embodiments, the amino acid substitution at position 165 of the sequence of SEQ ID NO: 4 is a substitution of serine (S) for glycine (G). In certain embodiments, the amino acid substitution at position 282 of the sequence of SEQ ID NO: 4 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 538 of the sequence of SEQ ID NO: 4 is a substitution of lysine (K) for asparagine (N). In certain embodiments of the methods of the present disclosure, the transposase is a super piggyBac (SPB) transposase. In certain embodiments, the super piggyBac (SPB) transposase of the present disclosure may comprise or consist of an amino acid sequence of the sequence of SEQ ID NO: 4, wherein the amino acid substitution at position 30 is a substitution of valine (V) for isoleucine (I), the amino acid substitution at position 165 is a substitution of serine (S) for glycine (G), the amino acid substitution at position 282 is a substitution of valine (V) for methionine (M), and the amino acid substitution at position 538 is a substitution of lysine (K) for asparagine (N). In certain embodiments, the super piggyBac (SPB) transposase may comprise or consist of an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween with the following sequence: In certain embodiments of the methods of the present disclosure, including those wherein the transposase comprises the above-described mutations at positions 30, 165, 282, and / or 538, the piggyBac or super piggyBac transposase may further comprise an amino acid substitution at one or more of positions 3, 46, 82, 103, 119, 125, 177, 180, 185, 187, 200, 207, 209, 226, 235, 240, 241, 243, 258, 296, 298, 311, 315, 319, 327, 328, 340, 421, 436, 456, 470, 486, 503, 552, 570, and 591 of the sequence of SEQ ID NO:4 or SEQ ID NO:1. In certain embodiments, including those wherein the transposase comprises the above mutations at positions 30, 165, 282, and / or 538, the piggyBac or super piggyBac transposase can further comprise an amino acid substitution at one or more of positions 46, 119, 125, 177, 180, 185, 187, 200, 207, 209, 226, 235, 240, 241, 243, 296, 298, 311, 315, 319, 327, 328, 340, 421, 436, 456, 470, 485, 503, 552, and 570. In certain embodiments, the amino acid substitution at position 3 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of asparagine (N) for serine (S). In certain embodiments, the amino acid substitution at position 46 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for alanine (A). In certain embodiments, the amino acid substitution at position 46 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of threonine (T) for alanine (A). In certain embodiments, the amino acid substitution at position 82 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for tryptophan (W). In certain embodiments, the amino acid substitution at position 103 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for proline (P). In certain embodiments, the amino acid substitution at position 119 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for arginine (R). In certain embodiments, the amino acid substitution at position 125 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of cysteine ​​(C) for alanine (A). In certain embodiments, the amino acid substitution at position 125 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of cysteine ​​(C) with leucine (L).In certain embodiments, the amino acid substitution at position 177 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 177 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of histidine (H) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 180 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 180 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 180 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 185 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for methionine (M). In certain embodiments, the amino acid substitution at position 187 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for alanine (A). In certain embodiments, the amino acid substitution at position 200 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tryptophan (W) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 207 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for valine (V). In certain embodiments, the amino acid substitution at position 209 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for valine (V). In certain embodiments, the amino acid substitution at position 226 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for methionine (M). In certain embodiments, the amino acid substitution at position 235 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of arginine (R) for leucine (L). In certain embodiments, the amino acid substitution at position 240 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for valine (V). In certain embodiments, the amino acid substitution at position 241 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 243 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for proline (P).In certain embodiments, the amino acid substitution at position 258 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for asparagine (N). In certain embodiments, the amino acid substitution at position 296 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tryptophan (W) for leucine (L). In certain embodiments, the amino acid substitution at position 296 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tyrosine (Y) for leucine (L). In certain embodiments, the amino acid substitution at position 296 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for leucine (L). In certain embodiments, the amino acid substitution at position 298 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for methionine (M). In certain embodiments, the amino acid substitution at position 298 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of alanine (A) for methionine (M). In certain embodiments, the amino acid substitution at position 298 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 311 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for proline (P). In certain embodiments, the amino acid substitution at position 311 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine for proline (P). In certain embodiments, the amino acid substitution at position 315 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for arginine (R). In certain embodiments, the amino acid substitution at position 319 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for threonine (T). In certain embodiments, the amino acid substitution at position 327 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of arginine (R) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 328 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 340 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for cysteine ​​(C). In certain embodiments, the amino acid substitution at position 340 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for cysteine ​​(C).In certain embodiments, the amino acid substitution at position 421 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of aspartic acid (D) by histidine (H). In certain embodiments, the amino acid substitution at position 436 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) by isoleucine (I). In certain embodiments, the amino acid substitution at position 456 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of methionine (M) by tyrosine (Y). In certain embodiments, the amino acid substitution at position 470 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) by phenylalanine (F). In certain embodiments, the amino acid substitution at position 485 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for serine (S). In certain embodiments, the amino acid substitution at position 503 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of methionine (M) by leucine (L). In certain embodiments, the amino acid substitution at position 503 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for (M) methionine. In certain embodiments, the amino acid substitution at position 552 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for valine (V). In certain embodiments, the amino acid substitution at position 570 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of threonine (T) for alanine (A). In certain embodiments, the amino acid substitution at position 591 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for glutamine (Q). In certain embodiments, the amino acid substitution at position 591 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of arginine (R) for glutamine (Q). In certain embodiments of the methods of the present disclosure, including those in which the transposase comprises the above-mentioned mutations at positions 30, 165, 282 and / or 538, the piggyBac transposase may comprise or the super piggyBac transposase may further comprise an amino acid substitution at one or more of positions 103, 194, 372, 375, 450, 509 and 570 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments of the methods of the present disclosure, including those in which the transposase comprises the above-mentioned mutations at positions 30, 165, 282 and / or 538, the piggyBac transposase may comprise or the super piggyBac transposase may further comprise an amino acid substitution at two, three, four, five, six or more of positions 103, 194, 372, 375, 450, 509 and 570 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments, including those in which the transposase comprises the above mutations at positions 30, 165, 282, and / or 538, the piggyBac transposase may comprise or the super piggyBac transposase may further comprise amino acid substitutions at positions 103, 194, 372, 375, 450, 509, and 570 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments, the amino acid substitution at position 103 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for serine (S). In certain embodiments, the amino acid substitution at position 194 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 372 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of alanine (A) for arginine (R). In certain embodiments, the amino acid substitution at position 375 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of alanine (A) for lysine (K). In certain embodiments, the amino acid substitution at position 450 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of asparagine (N) for aspartic acid (D). In certain embodiments, the amino acid substitution at position 509 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for serine (S). In certain embodiments, the amino acid substitution at position 570 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for asparagine (N).In certain embodiments, the piggyBac transposase may comprise a substitution of valine (V) for methionine (M) at position 194 of SEQ ID NO: 4. In certain embodiments, including those embodiments in which the piggyBac transposase may comprise a substitution of valine (V) for methionine (M) at position 194 of SEQ ID NO: 4, the piggyBac transposase may further comprise amino acid substitutions at positions 372, 375, and 450 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments, the piggyBac transposase may comprise a substitution of valine (V) for methionine (M) at position 194 of SEQ ID NO: 4, a substitution of alanine (A) for arginine (R) at position 372 of SEQ ID NO: 4, and a substitution of alanine (A) for lysine (K) at position 375 of SEQ ID NO: 4. In certain embodiments, the piggyBac transposase may comprise a substitution of methionine (M) with valine (V) at position 194 of SEQ ID NO:4, a substitution of arginine (R) with alanine (A) at position 372 of SEQ ID NO:4, a substitution of lysine (K) with alanine (A) at position 375 of SEQ ID NO:4, and a substitution of asparagine (N) with aspartic acid (D) at position 450 of SEQ ID NO:4. The sleeping beauty transposon transposes into the target genome by recognizing the ITRs and moving the contents between the ITRs to the Sleeping Beauty transposase in the TA chromosomal locus. In various embodiments, SB transposon-mediated gene transfer or gene transfer using any of a number of similar transposons can be used in the compositions and methods of the present disclosure. In certain embodiments, and, in particular, those embodiments in which the transposon is a Sleeping Beauty transposon, the transposase is a Sleeping Beauty transposase or a hyperactive Sleeping Beauty transposase (SB100X). In certain embodiments of the methods of the present disclosure, the Sleeping Beauty transposase comprises an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, identical to: In certain embodiments of the methods of the present disclosure, the highly active Sleeping Beauty (SB100X) transposase comprises an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, identical to the following sequence: The Helraiser transposon is transposed by the Helitron transposase. The Helitron transposase transfers the Helraiser transposon, an ancient element from the bat genome that was active about 30 to 36 million years ago. Exemplary Helraiser transposons of the present disclosure include Helibat1, which comprises a nucleic acid sequence comprising the following sequence: Unlike other transposases, Helitron transposase does not contain an RNase-H-like catalytic domain, but rather contains a RepHel motif consisting of a replication initiator domain (Rep) and a DNA helicase domain. The Rep domain is a nuclease domain of the HUH nuclease superfamily. Exemplary Helitron transposases of the present disclosure comprise an amino acid sequence comprising the sequence: In Helitron transposition, a hairpin near the 3' end of the transposon acts as a terminator. However, this hairpin can be bypassed by the transposase, resulting in transduction of the flanking sequences. In addition, Helaiser transposition generates a covalently closed circular intermediate. In addition, Helitron transposition can lack target site repeats. In the Helaiser sequence, the transposase is flanked by left and right terminal sequences called LTS (5' terminal sequence) and RTS (3' terminal sequence). These sequences terminate with a conserved 5'-TC / CTAG-3' motif. A 19 bp palindromic sequence with the potential to form a hairpin termination structure is located 11 nucleotides upstream of the RTS and consists of the sequence GTGCACGAATTTCGTGCACCGGGCCACTAG (SEQ ID NO: 5). The Tol2 transposon can be isolated or derived from the genome of the medaka fish and can be similar to the transposons of the hAT family. An exemplary Tol2 transposon of the present disclosure is encoded by a sequence comprising approximately 4.7 kilobases and contains a gene encoding a Tol2 transposase, which contains four exons. An exemplary Tol2 transposase of the present disclosure comprises an amino acid sequence comprising the following sequence: An exemplary Tol2 transposon of the present disclosure, including an inverted repeat sequence, a subterminal sequence, and a Tol2 transposase, is encoded by a nucleic acid sequence comprising the following sequence: Exemplary transposon / transposase systems of the present disclosure include, but are not limited to, piggyBac and piggyBac-like transposons and transposases. PiggyBac and piggyBac-like transposases recognize transposon-specific inverted terminal repeats (ITRs) on the ends of transposons and move the contents between the ITRs into TTAA or TTAT chromosomal sites. The piggyBac or piggyBac-like transposon system has no payload limitations for genes of interest that can be contained between the ITRs. In certain embodiments, and, in particular, in those embodiments in which the transposon is a piggyBac transposon, the transposase is a piggyBac, super piggyBac (SPB) transposase. In certain embodiments, and, in particular, in those embodiments in which the transposase is piggyBac, super piggyBac (SPB), the sequence encoding the transposase is an mRNA sequence. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase comprising or consisting of an amino acid sequence having an amino acid substitution at one or more of positions 30, 165, 282, or 538 of the following sequence: In certain embodiments, the transposase is a piggyBac or piggyBac-like transposase comprising or consisting of an amino acid sequence having an amino acid substitution at two or more of positions 30, 165, 282, or 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the transposase is a piggyBac or piggyBac-like transposase comprising or consisting of an amino acid sequence having an amino acid substitution at three or more of positions 30, 165, 282, or 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the transposase is a piggyBac or piggyBac-like transposase comprising or consisting of an amino acid sequence having an amino acid substitution at each of the following positions 30, 165, 282, and 538 of the sequence of SEQ ID NO: 4. In certain embodiments, the amino acid substitution at position 30 of the sequence of SEQ ID NO: 4 is a substitution of valine (V) for isoleucine (I). In certain embodiments, the amino acid substitution at position 165 of the sequence of SEQ ID NO: 4 is a substitution of serine (S) for glycine (G). In certain embodiments, the amino acid substitution at position 282 of the sequence of SEQ ID NO: 4 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 538 of the sequence of SEQ ID NO: 4 is a substitution of lysine (K) for asparagine (N). In certain embodiments of the methods of the present disclosure, the transposase is a super piggyBac (SPB) or piggyBac-like transposase. In certain embodiments, the super piggyBac (SPB) or piggyBac-like transposase of the present disclosure may comprise or consist of an amino acid sequence of the sequence of SEQ ID NO: 4, wherein the amino acid substitution at position 30 is a substitution of valine (V) for isoleucine (I), the amino acid substitution at position 165 is a substitution of serine (S) for glycine (G), the amino acid substitution at position 282 is a substitution of valine (V) for methionine (M), and the amino acid substitution at position 538 is a substitution of lysine (K) for asparagine (N). In certain embodiments, a super piggyBac (SPB) or piggyBac-like transposase may comprise or consist of an amino acid sequence that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage in between, identical to: In certain embodiments of the methods of the present disclosure, including those wherein the transposase comprises the above-mentioned mutations at positions 30, 165, 282 and / or 538, the piggyBac, super piggyBac or piggyBac-like transposase may further comprise an amino acid substitution at one or more of positions 3, 46, 82, 103, 119, 125, 177, 180, 185, 187, 200, 207, 209, 226, 235, 240, 241, 243, 258, 296, 298, 311, 315, 319, 327, 328, 340, 421, 436, 456, 470, 486, 503, 552, 570 and 591 of the sequence of SEQ ID NO:4 or SEQ ID NO:1. In certain embodiments, including those wherein the transposase comprises the above mutations at positions 30, 165, 282, and / or 538, the piggyBac, super piggyBac, or piggyBac-like transposase may further comprise an amino acid substitution at one or more of positions 46, 119, 125, 177, 180, 185, 187, 200, 207, 209, 226, 235, 240, 241, 243, 296, 298, 311, 315, 319, 327, 328, 340, 421, 436, 456, 470, 485, 503, 552, and 570. In certain embodiments, the amino acid substitution at position 3 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of asparagine (N) for serine (S). In certain embodiments, the amino acid substitution at position 46 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for alanine (A). In certain embodiments, the amino acid substitution at position 46 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of threonine (T) for alanine (A). In certain embodiments, the amino acid substitution at position 82 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for tryptophan (W). In certain embodiments, the amino acid substitution at position 103 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for proline (P). In certain embodiments, the amino acid substitution at position 119 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for arginine (R). In certain embodiments, the amino acid substitution at position 125 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of cysteine ​​(C) for alanine (A).In certain embodiments, the amino acid substitution at position 125 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for cysteine ​​(C). In certain embodiments, the amino acid substitution at position 177 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 177 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of histidine (H) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 180 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 180 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 180 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 185 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for methionine (M). In certain embodiments, the amino acid substitution at position 187 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for alanine (A). In certain embodiments, the amino acid substitution at position 200 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tryptophan (W) for phenylalanine (F). In certain embodiments, the amino acid substitution at position 207 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for valine (V). In certain embodiments, the amino acid substitution at position 209 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for valine (V). In certain embodiments, the amino acid substitution at position 226 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for methionine (M). In certain embodiments, the amino acid substitution at position 235 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of arginine (R) for leucine (L). In certain embodiments, the amino acid substitution at position 240 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for valine (V). In certain embodiments, the amino acid substitution at position 241 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for phenylalanine (F).In certain embodiments, the amino acid substitution at position 243 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for proline (P). In certain embodiments, the amino acid substitution at position 258 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for asparagine (N). In certain embodiments, the amino acid substitution at position 296 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tryptophan (W) for leucine (L). In certain embodiments, the amino acid substitution at position 296 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tyrosine (Y) for leucine (L). In certain embodiments, the amino acid substitution at position 296 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for leucine (L). In certain embodiments, the amino acid substitution at position 298 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for methionine (M). In certain embodiments, the amino acid substitution at position 298 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of alanine (A) for methionine (M). In certain embodiments, the amino acid substitution at position 298 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 311 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for proline (P). In certain embodiments, the amino acid substitution at position 311 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine for proline (P). In certain embodiments, the amino acid substitution at position 315 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for arginine (R). In certain embodiments, the amino acid substitution at position 319 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for threonine (T). In certain embodiments, the amino acid substitution at position 327 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of arginine (R) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 328 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for tyrosine (Y). In certain embodiments, the amino acid substitution at position 340 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for cysteine ​​(C).In certain embodiments, the amino acid substitution at position 340 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for cysteine ​​(C). In certain embodiments, the amino acid substitution at position 421 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of histidine (H) for aspartic acid (D). In certain embodiments, the amino acid substitution at position 436 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for valine (V). In certain embodiments, the amino acid substitution at position 456 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of tyrosine (Y) for methionine (M). In certain embodiments, the amino acid substitution at position 470 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of phenylalanine (F) for leucine (L). In certain embodiments, the amino acid substitution at position 485 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for serine (S). In certain embodiments, the amino acid substitution at position 503 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of leucine (L) for methionine (M). In certain embodiments, the amino acid substitution at position 503 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of isoleucine (I) for (M) methionine. In certain embodiments, the amino acid substitution at position 552 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) for valine (V). In certain embodiments, the amino acid substitution at position 570 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of threonine (T) for alanine (A). In certain embodiments, the amino acid substitution at position 591 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for glutamine (Q). In certain embodiments, the amino acid substitution at position 591 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of arginine (R) for glutamine (Q). In certain embodiments of the methods of the present disclosure, including those in which the transposase comprises the above mutations at positions 30, 165, 282, and / or 538, the piggyBac or piggyBac-like transposase may comprise or the super piggyBac transposase may further comprise an amino acid substitution at one or more of positions 103, 194, 372, 375, 450, 509, and 570 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments of the methods of the present disclosure, including those in which the transposase comprises the above mutations at positions 30, 165, 282, and / or 538, the piggyBac or piggyBac-like transposase may comprise or the super piggyBac transposase may further comprise an amino acid substitution at two, three, four, five, six, or more of positions 103, 194, 372, 375, 450, 509, and 570 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments, including those in which the transposase comprises the above mutations at positions 30, 165, 282, and / or 538, the piggyBac or piggyBac-like transposase may comprise or the super piggyBac transposase may further comprise amino acid substitutions at positions 103, 194, 372, 375, 450, 509, and 570 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments, the amino acid substitution at position 103 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of proline (P) for serine (S). In certain embodiments, the amino acid substitution at position 194 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of valine (V) for methionine (M). In certain embodiments, the amino acid substitution at position 372 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of alanine (A) for arginine (R). In certain embodiments, the amino acid substitution at position 375 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of lysine (K) by alanine (A). In certain embodiments, the amino acid substitution at position 450 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of asparagine (N) for aspartic acid (D). In certain embodiments, the amino acid substitution at position 509 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of glycine (G) for serine (S). In certain embodiments, the amino acid substitution at position 570 of SEQ ID NO: 4 or SEQ ID NO: 1 is a substitution of serine (S) for asparagine (N).In certain embodiments, the piggyBac or piggyBac-like transposase may comprise a substitution of valine (V) for methionine (M) at position 194 of SEQ ID NO: 4. In certain embodiments, including those embodiments in which the piggyBac or piggyBac-like transposase may comprise a substitution of valine (V) for methionine (M) at position 194 of SEQ ID NO: 4, the piggyBac or piggyBac-like transposase may further comprise amino acid substitutions at positions 372, 375, and 450 of the sequence of SEQ ID NO: 4 or SEQ ID NO: 1. In certain embodiments, the piggyBac or piggyBac-like transposase may comprise a substitution of valine (V) for methionine (M) at position 194 of SEQ ID NO: 4, a substitution of alanine (A) for arginine (R) at position 372 of SEQ ID NO: 4, and a substitution of alanine (A) for lysine (K) at position 375 of SEQ ID NO: 4. In certain embodiments, the piggyBac or piggyBac-like transposase may comprise a substitution of methionine (M) by valine (V) at position 194 of SEQ ID NO:4, a substitution of arginine (R) by alanine (A) at position 372 of SEQ ID NO:4, a substitution of lysine (K) by alanine (A) at position 375 of SEQ ID NO:4, and a substitution of asparagine (N) for aspartic acid (D) at position 450 of SEQ ID NO:4. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from an insect. In certain embodiments, the insect is Trichoplusia ni (GenBank Accession No. AAA87375; SEQ ID NO: 442), Argyrogramma agnata (GenBank Accession No. GU477713; SEQ ID NO: 37, SEQ ID NO: 437), Anopheles gambiae (GenBank Accession No. XP_312615 (SEQ ID NO: 146); GenBank Accession No. XP_320414 (SEQ ID NO: 148); GenBank Accession No. XP_310729 (SEQ ID NO: 149)), Aphis gossypii (GenBank Accession No. GU329918; SEQ ID NO: 150, SEQ ID NO: 151), Acyrthosiphon pisum (GenBank Accession No. XP_001948139; SEQ ID NO: 152), NO:152), Agrotis ipsilon (GenBank Accession No. GU477714; SEQ ID NO:40, SEQ ID NO:153), Bombyx mori (GenBank Accession No. BAD11135; SEQ ID NO:441), Chilo suppressalis (GenBank Accession No. JX294476; SEQ ID NO:154, SEQ ID NO:155), Drosophila melanogaster (GenBank Accession No. AAL39784; SEQ ID NO:156), Helicoverpa armigera (GenBank Accession No. ABS18391; SEQ ID NO:28), Heliothis virescens (GenBank Accession No. ABD76335; SEQ ID NO:157), NO:157), Macdunnoughia crassisigna (GenBank Accession No. EU287451; SEQ ID NO:158, SEQ ID NO:159), Pectinophora agouti (GenBank Accession No. GU270322;SEQ ID NO:33, SEQ ID NO:160), Tribolium castaneum (GenBank Accession No. XP_001814566; SEQ ID NO:161), Ctenoplusia agnata (also known as Spodoptera exigua), Messour bouvieri, Megachile rotundata, Bombus impatiens, Mamestrabrassicae, Mayetiola destructor, or Apis mellifera. ; In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from an insect. In certain embodiments, the insect is Trichoplusia ni (AAA87375). In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from an insect. In certain embodiments, the insect is Bombyx mori (BAD11135). In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from a crustacean. In certain embodiments, the crustacean is Daphnia pulicaria (AAM76342, SEQ ID NO: 162). In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from a vertebrate. In certain embodiments, the vertebrate is Xenopus tropicalis (GenBank Accession No. BAF82026; SEQ ID NO: 21), Homo sapiens (GenBank Accession No. NP_689808; SEQ ID NO: 163), Mus musculus (GenBank Accession No. NP_741958; SEQ ID NO: 164), Macaca fascicularis (GenBank Accession No. AB179012; SEQ ID NO: 165, SEQ ID NO: 166), Rattus norvegicus (GenBank Accession No. XP_220453; SEQ ID NO: 167), or Myotis lucifugus. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from a tunicate. In certain embodiments, the tunicate is Ciona intestinalis (GenBank Accession No. XP_002123602; SEQ ID NO: 168). In certain embodiments, the piggyBac or piggyBac-like transposase inserts the transposon at the sequence 5'-TTAT-3' (TTAT target sequence) within the chromosomal site. In certain embodiments, the piggyBac or piggyBac-like transposase inserts the transposon at the sequence 5'-TTAA-3' (TTAA target sequence) within the chromosomal site. In certain embodiments, the target sequence of a piggyBac or piggyBac-like transposon comprises 5'-CTAA-3', 5'-TTAG-3', 5'-ATAA-3', 5'-TCAA-3', 5'AGTT-3', 5'-ATTA-3', 5'-GTTA-3', 5'-TTGA-3', 5'-TTTA-3', 5'-TTAC-3', 5'-ACTA-3', 5'-AGGG-3', 5'-CTAG-3', 5'-TGAA-3', 5'-AGGT-3', 5'-ATCA-3', 5'-CTCC-3', 5'-TAAA-3', 5'-TCTC-3', 5'-TGAA-3', 5'-AAAT-3', 5'-AATC-3', 5'-ACAA-3', 5'-ACAT-3', 5'-ACTC-3', 5'-AGTG-3', 5'-ATAG-3', 5'-CAAA-3', 5'-CACA-3', 5'-CATA-3', 5'-CCAG-3', 5'-CCCA-3', 5'-CGTA-3', 5'-GTCC-3', 5'-TAAG-3', 5'-TCTA-3', 5'-TGAG-3', 5'-TGTT-3', 5'-TTCA-3' 5'-TTCT-3' and 5'-TTTT-3'. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Bombyx mori. The piggyBac or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween: The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence that is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween, identical to: In certain embodiments, the piggyBac or piggyBac-like transposase is fused to a nuclear localization signal. In certain embodiments, the amino acid sequence of the piggyBac or piggyBac-like transposase fused to a nuclear localization signal is encoded by a polynucleotide sequence comprising the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposase is hyperactive. A hyperactive piggyBac or piggyBac-like transposase is a transposase that is more active than the naturally occurring variant from which it is derived. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase is isolated or derived from Bombyx mori. In certain embodiments, the piggyBac or piggyBac-like transposase is a hyperactive variant of SEQ ID NO: 441. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises a sequence that is at least 90% identical to: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises SEQ ID NO: 79. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase has higher activity than the transposase of SEQ ID NO: 441. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase has at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to SEQ ID NO: 441, or any percentage in between. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises an amino acid substitution at a position selected from 92, 93, 96, 97, 165, 178, 189, 196, 200, 201, 211, 215, 235, 238, 246, 253, 258, 261, 263, 271, 303, 321, 324, 330, 373, 389, 399, 402, 403, 404, 448, 473, 484, 507, 523, 527, 528, 543, 549, 550, 557, 601, 605, 607, 609, 610, or a combination thereof (relative to SEQ ID NO: 441). In certain embodiments, the highly active piggyBac or piggyBac-like transposase comprises Q92A, V93L, V93M, P96G, F97H, F97C, H165E, H165W, E178S, E178H, C189P, A196G, L200I, A201Q, L211A, W215Y, G219S, Q235Y, Q235G, Q238L, K246I , K253V, M258V, F261L, S263K, C271S, N303R, F321W, F321D, V324K, V324H, A330V, L373C, L373V , V389L, S399N, R402K, T403L, D404Q, D404S, D404M, N441R, G448W, E449A, V469T, C473Q, R484K amino acid substitutions of T507C, G523A, I527M, Y528K Y543I, E549A, K550M, P557S, E601V, E605H, E605W, D607H, S609H, L610I, or any combination thereof.In certain embodiments, the highly active piggyBac or piggyBac-like transposase comprises Q92A, V93L, V93M, P96G, F97H, F97C, H165E, H165W, E178S, E178H, C189P, A196G, L200I, A201Q, L211A, W215Y, G219S, Q235Y, Q235G, Q238L, K246I , K253V, M258V, F261L, S263K, C271S, N303R, F321W, F321D, V324K, V324H, A330V, L373C, L373V, V389L, S399N, R402K, T403L, D404Q, D404S, D404M, N441R, G448W, E449A, V469T, C473Q, R484K T507C, G523A, I527M, Y528K Y543I, E549A, K557S, E601V, E605H, E605W, D607H, S609H and L610I. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises one or more substitutions of non-wild-type amino acids, wherein the one or more substitutions of wild-type amino acids comprise E4X, A12X, M13X, L14X, E15X, D20X, E24X, S25X, S26X, S27X, D32X, H33X, E36X, E44X, E45X, E46X, I48X, D49X, R58X, A62X, N63X, A64X, I65X, I66X, N68X, E69X, D71X, S72X, D76X, P79X, R84X, Q85X, A87X, S88X, Q92X, V93X , S94X, G95X, P96X, F97X, Y98X, T99X, I145X, S149X, D150X, L152X, E154X, T 157X, N160X, S161X, S162X, H165X, R166X, T168X, K169X, T170X, A171X, E173 X, S175X, S176X, E178X, T179X, M183X, Q184X, T186X, T187X, L188X, C189X, L194X, I195X, A196X, L198X, L200X, A201X, L203X, I204X, K205X, A206X, N20 7X, Q209X, S210X, L211X, K212X, D213X, L214X, W215X, R216X, T217X, G219X , V222X, D223X, I224X, T227X, M229X, Q235X, L237X, Q238X, N239X, N240X, P3 02X, N303X, P305X, A306X, K307X, Y308X, I310X, K311X, I312X, L313X, A314 X, L315X, V316X, D317X, A318X, K319X, N320X, F321X, Y322X, V323X, V324X, L 326X, E327X, V328X, A330X, Q333X, P334X, S335X, G336X, P337X, A339X, V34 0X, S341X, N342X, R343X, P344X, F345X, E346X, V347X, E349X, I352X, Q353X, V355X, A356X, R357X, N361X, D365X, W367X, T369X, G370X, L373X, M374X, L37 5X, H376X, N379X, E380X, R382X, V386X, V389X, N392X, R394X, Q395X, S399X,F400X, I401X, R402XT403X, D404X, R405X, Q406X, P407X, N408X, S409X, S410X, V411X, F412X, F414X, Q415X, I 418X, T419X, L420X, N428XV432X, M434X, D440X, N441X, S442X, I443X, D444X, E445X, G448X, E449X, Q451X, K45 2X, M455X, I456X, T457X, F458X, S461X, A464X, V466X, Q468X, V469X, E471X, L472X, C473X, A474X, K483X, W485 X, T488X, L489X, Y491X, G492X, V493X, M496X, I499X, C502X, I503X, T507X, K509X, N510X, V511X, T512X, I513X , R515X, E517X, S521X, G523X, L524X, S525X, I527X, Y528X, E529X, H532X, S533X, N535X, K536X, K537X, N539X, I540X, T542X, Y543X, Q546X, E549X, K550X, Q551X, G553X, E554X, P555X, S556X, P557X, R558X, H559X, V560X, N 561X, V562X, P563X, G564X, R565X, Y566X, V567X, Q570X, D571X, P573X, Y574X, K576X, K581X, S583X, A586X, A588X, E594X, F598X, L599X, E601X, N602X, C603X, A604X, E605X, L606X, D607X, S608X, S609X or L610X substitutions (relative to SEQ ID NO: 441). A list of highly active amino acid substitutions can be found in U.S. Pat. No. 10,041,077, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, the piggyBac or piggyBac-like transposase is integration-defective. In certain embodiments, an integration-defective piggyBac or piggyBac-like transposase is a transposase that can excise its corresponding transposon, but integrates the excised transposon at a lower frequency than the corresponding wild-type transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is an integration-defective variant of SEQ ID NO: 441. In certain embodiments, the excision-competent, integration-defective piggyBac or piggyBac-like transposase comprises one or more substitutions of non-wild-type amino acids, wherein the one or more substitutions of wild-type amino acids comprise R9X, A12X, M13X, D20X, Y21K, D23X, E24X, S25X, S26X, S27X, E28X, E30X, D32X, H33X, E36X, H37X, A39X, Y41X, D42X, T43X, E44X, E45X, E46X, R47X, D49X, S50X, S55X, A62X, N63X, A64X, I66X, A67X, N68X, E69X, D70X, D71X, S72X, D73X, P74X, D75X, D76X, D77X, I78X, S81X, V83X, R84X, Q8 5X, A87X, S88X, A89X, S90X, R91X, Q92X, V93X, S94X, G95X, P96X, F97X, Y98X , T99X, W012X, G103X, Y107X, K108X, L117X, I122X, Q128X, I312X, D135X, S1 37X, E139X, Y140X, I145X, S149X, D150X, Q153X, E154X, T157X, S161X, S162X , R164X, H165X, R166X, Q167X, T168X, K169X, T170X, A171X, A172X, E173X, R 174X, S175X, S176X, A177X, E178X, T179X, S180X, Y182X, Q184X, E185X, T18 7X, L188X, C189X, L194X, I195X, A196X, L198X, L200X, A201X, L203X, I204X , K205X, N207X, Q209X, L211X, D213X, L214X, W215X, R216X, T217X, G219X, T2 20X, V222X, D223X, I224X, T227X, T228X, F234X, Q235X, L237X, Q238X, N239 X, N240X, N303X, K304X, I310X, I312X, L313X, A314X, L315X, V316X, D317X, A 318X, K319X, N320X, F321X, Y322X, V323X, V324X, N325X, L326X, E327X, V32 8X, A330X, G331X, K332X, Q333X, S335X, P337X, P344X, F345X, E349X, H359X,N361X, V362X, D365X, F368X, Y371X, E372X, L373X, H376X, E380X, R382X, R382X, V386X, G387X, T388X, V389X, K391X, N392X, R 394X, Q395X, E398X, S399X, F400X, I401X, R402XT403X, D404X, R405X, Q406X, P407X, N408X, S409X, S410X, Q415X, K416X, A42 4X, K426X, N428X, V430X, V432X, V433X, M434X, D436X, D440X, N441X, S442X, I443X, D444X, E445X, S446X, T447X, G448X, E449 X, K450X, Q451X, E454X, M455X, I456X, T457X, F458X, S461X, A464X, V466X, Q468X, V469X, C473X, A474X, N475X, N477X, K483X , R484X, P486X, T488X, L489X, G492X, V493X, M496X, I499X, I503X, Y505X, T507X, N510X, V511X, T512X, I513X, K514X, T516X, E517X, S521X, G523X, L524X, S525X, I527X, Y528X, L531X, H532X, S533X, N535X, I540X, T542X, Y543X, R545X, Q546X, E549X, L 552X, G553X, E554X, P555X, S556X, P557X, R558X, H559X, V560X, N561X, V562X, P563X, G564X, V567X, Q570X, D571X, P573X, Y574X, K575X, K576X, N585X, A586X, M593X, K596X, E601X, N602X, A604X, E605X, L606X, D607X, S608X, S609X or L610X substitutions (relative to SEQ ID NO: 441). A list of integration-defective amino acid substitutions can be found in U.S. Pat. No. 10,041,077, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the integration-defective transposase comprises a sequence that is at least 90% identical to SEQ ID NO:111. In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Bombyx mori. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises a 5' sequence corresponding to SEQ ID NO: 9 and a 3' sequence corresponding to SEQ ID NO: 10. In certain embodiments, one piggyBac or piggyBac-like transposon end has at least 85%, at least 90%, at least 95%, at least 98%, at least 99% identity, or any percentage therebetween, to SEQ ID NO: 9 and the other piggyBac or piggyBac-like transposon end has at least 85%, at least 90%, at least 95%, at least 98%, at least 99% identity, or any percentage therebetween, to SEQ ID NO: 10. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 9 and SEQ ID NO: 10 or SEQ ID NO: 12. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 11 and SEQ ID NO: 10 or SEQ ID NO: 12. In certain embodiments, the 5' and 3' transposon ends share at their ends a 16 bp repeat of CCCGGCGAGCATGAGG (SEQ ID NO: 13) immediately adjacent to the 5'-TTAT-3 target insertion site, the repeats being oriented in opposite directions at the two ends. In certain embodiments, the 5' transposon end begins with a sequence comprising 5'-TTATCCCGGCGAGCATGAGG-3 (SEQ ID NO: 14), and the 3' transposon ends with a sequence comprising the reverse complement of this sequence: 5'-CCTCATGCTCGCCGGGTTAT-3' (SEQ ID NO: 15). In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end comprising at least 14, 16, 18, 20, 30, or 40 consecutive nucleotides of SEQ ID NO: 9 or SEQ ID NO: 11. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end comprising at least 14, 16, 18, 20, 30, or 40 consecutive nucleotides of SEQ ID NO: 10 or SEQ ID NO: 12. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end that is at least 90% identical to SEQ ID NO: 9 or SEQ ID NO: 11. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end that is at least 90% identical to SEQ ID NO: 10 or SEQ ID NO: 12. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of CCCGGCGAGCATGAGG (SEQ ID NO: 13). In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of SEQ ID NO: 13. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TTATCCCGGCGAGCATGAGG (SEQ ID NO: 14). In certain embodiments, the piggyBac or piggyBac-like transposon comprises at least 16 consecutive nucleotides from SEQ ID NO: 14. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of CCTCATGCTCGCCGGGTTAT (SEQ ID NO: 15). In certain embodiments, the piggyBac or piggyBac-like transposon comprises at least 16 consecutive nucleotides from SEQ ID NO: 15. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end comprising at least 16 consecutive nucleotides from SEQ ID NO: 14 and one end comprising at least 16 consecutive nucleotides from SEQ ID NO: 15. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 14 and SEQ ID NO: 15. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the sequence of TTAACCCGGCGAGCATGAGG (SEQ ID NO: 16). In certain embodiments, the piggyBac or piggyBac-like transposon comprises the sequence of CCTCATGCTCGCCGGGTTAA (SEQ ID NO: 17). In certain embodiments, the piggyBac or piggyBac-like transposon can have ends comprising SEQ ID NO:9 and SEQ ID NO:10, or a variant of either or both of these that has at least 90% sequence identity to SEQ ID NO:9 or SEQ ID NO:10, and the piggyBac or piggyBac-like transposase has the sequence of SEQ ID NO:48 or SEQ ID NO:441, or a sequence that has at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween. In certain embodiments, a piggyBac or piggyBac-like transposon comprises a heterologous polynucleotide inserted between a pair of inverted repeat sequences, wherein the transposon is capable of transposition by a piggyBac or piggyBac-like transposase having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween identity to SEQ ID NO: 48 or SEQ ID NO: 441. In certain embodiments, the transposon comprises two transposon ends, each of which comprises SEQ ID NO: 13 in opposite orientations at the two transposon ends. In certain embodiments, each inverted terminal repeat (ITR) has at least 90% identity to SEQ ID NO: 13. In certain embodiments, the piggyBac or piggyBac-like transposon is capable of inserting at the sequence 5'-TTAT-3 within a target nucleic acid by a piggyBac or piggyBac-like transposase. In certain embodiments, one end of the piggyBac or piggyBac-like transposon comprises at least 16 consecutive nucleotides from SEQ ID NO: 9, and the other end of the transposon comprises at least 16 consecutive nucleotides from SEQ ID NO: 10. In certain embodiments, one end of the piggyBac or piggyBac-like transposon comprises at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 consecutive nucleotides from SEQ ID NO: 9, and the other end of the transposon comprises at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 consecutive nucleotides from SEQ ID NO: 10. In certain embodiments, a piggyBac or piggyBac-like transposon comprises transposon ends corresponding to SEQ ID NO: 9 and SEQ ID NO: 10 (each end comprising an ITR) and has a target sequence corresponding to 5'-TTAT 3'. In certain embodiments, a piggyBac or piggyBac-like transposon also comprises a sequence encoding a transposase (e.g., SEQ ID NO: 441). In certain embodiments, a piggyBac or piggyBac-like transposon comprises one transposon end corresponding to SEQ ID NO: 9 and a second transposon end corresponding to SEQ ID NO: 19. SEQ ID NO: 19 is very similar to SEQ ID NO: 10, but has a large insertion just before the ITR. Although the ITR sequences of the two transposon ends are identical (they are both identical to SEQ ID NO: 13), they have different target sequences: the second transposon has a target sequence corresponding to 5'-TTAA-3', providing evidence that changing the ITR sequence is not necessary to modify target sequence specificity. The piggyBac or piggyBac-like transposase associated with a 5'-TTAA-3' target site (SEQ ID NO: 48) differs from the 5'-TTAT-3' associated transposase (SEQ ID NO: 441) by only four amino acid changes (D322Y, S473C, A507T, H582R). In certain embodiments, the piggyBac or piggyBac-like transposase associated with a 5'-TTAA-3' target site (SEQ ID NO: 48) is less active than the 5'-TTAT-3' associated piggyBac or piggyBac-like transposase (SEQ ID NO: 441) towards transposons having a 5'-TTAT-3' end. In certain embodiments, a piggyBac or piggyBac-like transposon with a 5'-TTAA-3' target site can be converted to a piggyBac or piggyBac-like transposase with a 5'-TTAT-3 target site by replacing the 5'-TTAA-3' target site with 5'-TTAT-3'. Such a transposon can be used with a piggyBac or piggyBac-like transposase that recognizes a 5'-TTAT-3' target sequence, such as SEQ ID NO: 48, or with a variant of a transposase originally associated with a 5'-TTAA-3' transposon. In certain embodiments, the high similarity between 5'-TTAA-3' and 5'-TTAT-3' piggyBac or piggyBac-like transposases demonstrates that minimal changes in the amino acid sequence of a piggyBac or piggyBac-like transposase can alter target sequence specificity.In certain embodiments, a modification of any piggyBac or piggyBac-like transposon-transposase gene transfer system, wherein the 5'-TTAA-3' target sequence is replaced by a 5'-TTAT-3' target sequence, the ITRs remain the same, and the transposase is the original piggyBac or piggyBac-like transposase or a variant thereof generated by using low-level mutagenesis to introduce mutations into the transposase. In certain embodiments, a piggyBac or piggyBac-like transposon-transposase transfer system can be formed by modifying a 5'-TTAT-3'-active piggyBac or piggyBac-like transposon-transposase gene transfer system, wherein the 5'-TTAT-3' target sequence is replaced by a 5'-TTAA-3'-target sequence, the ITRs remain the same, and the piggyBac or piggyBac-like transposase is the original transposase or a variant thereof. In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Bombyx mori. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the transposon comprises at least 16 consecutive bases from SEQ ID NO: 80 and at least 16 consecutive bases from SEQ ID NO: 81, and an inverted terminal repeat sequence that is at least 87% identical to CCCGGCGAGCATGAGG (SEQ ID NO: 13). In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 98 and SEQ ID NO: 99 and is transposed by the piggyBac or piggyBac-like transposase of SEQ ID NO: 441. In certain embodiments, the ITRs of SEQ ID NO: 98 and SEQ ID: 99 are not flanked by 5'-TTAA-3' sequences. In certain embodiments, the ITRs of SEQ ID NO: 98 and SEQ ID: 99 are flanked by 5'-TTAT-3' sequences. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the 5' end of the piggyBac or piggyBac-like transposon comprises the sequence of SEQ ID NO: 80, SEQ ID NO: 98, or SEQ ID NO: 100-012. In certain embodiments, the 5' end of the piggyBac or piggyBac-like transposon is preceded by a 5' target sequence. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the 3' end of the piggyBac or piggyBac-like transposon comprises the sequence of SEQ ID NO:81, SEQ ID NO:99, or SEQ ID NOs:103-104. In certain embodiments, the 3' end of the piggyBac or piggyBac-like transposon is followed by a 3' target sequence. In certain embodiments, the transposon is transposed by a transposase of SEQ ID NO:441. In certain embodiments, the 5' and 3' ends of the piggyBac or piggyBac-like transposon share a 16 bp repeat sequence of SEQ ID NO:13 in opposite orientations and immediately adjacent to the target sequence. In certain embodiments, the 5' transposon end begins with SEQ ID NO:13 and the 3' transposon end ends with the reverse complement of SEQ ID NO:13, 5'-CCTCATGCTCGCCGGG-3' (SEQ ID NO:106). In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR that is at least 93%, at least 87%, or at least 81%, or any percentage therebetween, identical to SEQ ID NO: 13 or SEQ ID NO: 106. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a target sequence followed by a 5' transposon end comprising a sequence selected from SEQ ID NO: 88, 105, or 107 and a 3' transposon end comprising SEQ ID NO: 81 or 106 followed by the target sequence. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end comprising a sequence that is at least 90%, at least 95%, or at least 99%, or any percentage therebetween, identical to SEQ ID NO: 80, and one end comprising a sequence that is at least 90%, at least 95%, or at least 99%, or any percentage therebetween, identical to SEQ ID NO: 81. In certain embodiments, one transposon end comprises at least 14, at least 16, at least 18, or at least 20 consecutive bases from SEQ ID NO:80 and one transposon end comprises at least 14, at least 16, at least 18, or at least 20 consecutive bases from SEQ ID NO:81. In certain embodiments, the piggyBac or piggyBac-like transposon comprises two transposon ends, wherein each transposon end comprises a sequence having at least 81% identity, at least 87% identity, or at least 93% identity, or any percentage identity therebetween, to SEQ ID NO: 13 in opposite orientations at the two transposon ends. One end may further comprise at least 14, at least 16, at least 18, or at least 20 consecutive bases from SEQ ID NO: 102, and the other end may further comprise at least 14, at least 16, at least 18, or at least 20 consecutive bases from SEQ ID NO: 104. The piggyBac or piggyBac-like transposon may be transposed by the transposase of SEQ ID NO: 441, and the transposase may optionally be fused to a nuclear localization signal. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 98 and SEQ ID NO: 99, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO: 48 or SEQ ID NO: 441. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 14597 and SEQ ID NO: 99, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO: 48 or SEQ ID NO: 441. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 98 and SEQ ID NO: 81, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO: 48 or SEQ ID NO: 441. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO:14602 and SEQ ID NO:14600, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO:48 or SEQ ID NO:441. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a 5' end comprising 1, 2, 3, 4, 5, 6, or 7 sequences selected from ATGAGGCAGGGTAT (SEQ ID NO: 117), ATACCCTGCCTCAT (SEQ ID NO: 118), GGCAGGGTAT (SEQ ID NO: 119), ATACCCTGCC (SEQ ID NO: 120), TAAAATTTTA (SEQ ID NO: 121), ATTTTATAAAAT (SEQ ID NO: 122), TCATACCCTG (SEQ ID NO: 123), and TAAATAATAATAA (SEQ ID NO: 124). In certain embodiments, the piggyBac or piggyBac-like transposon comprises a 3' end comprising 1, 2, or 3 sequences selected from SEQ ID NO: 120, SEQ ID NO: 123, and SEQ ID NO: 124. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Xenopus tropicalis. The piggyBac or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In some embodiments, the piggyBac or piggyBac-like transposase is a hyperactive variant of SEQ ID NO: 20. In certain embodiments, the piggyBac or piggyBac-like transposase is an integration-defective variant of SEQ ID NO: 20. The piggyBac or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween identity to: In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Xenopus tropicalis. In certain embodiments, the piggyBac or piggyBac-like transposase is a highly active piggyBac or piggyBac-like transposase. In certain embodiments, the highly active piggyBac or piggyBac-like transposase comprises a sequence having at least 90% identity to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposase is a hyperactive piggyBac or piggyBac-like transposase. A hyperactive piggyBac or piggyBac-like transposase is a transposase that is more active than the naturally occurring variant from which it is derived. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase is more active than the transposase of SEQ ID NO: 20. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises the following sequence: In certain embodiments, the highly active piggyBac or piggyBac-like transposase comprises a member selected from the group consisting of amino acids 6, 7, 16, 19, 20, 21, 22, 23, 24, 26, 28, 31, 34, 67, 73, 76, 77, 88, 91, 141, 145, 146, 148, 150, 157, 162, 179, 182, 189, 192, 193, 196, 198, 200, 210, 2 576, 577, 582, 583, or 587 (relative to SEQ ID NO: 20). In certain embodiments, the highly active piggyBac or piggyBac-like transposase comprises Y6C, S7G, M16S, S19G, S20Q, S20G, S20D, E21D, E22Q, F23T, F23P, S24Y, S26V, S28Q, V31K, A34E, L67A, G73H, A76V, D77N, P88A, N91D, Y141Q, Y 141A, N145E, N145V, P146T, P146V, P146K, P148T, P148H, Y150G, Y150S, Y150C, H157Y, A162C , A179K, L182I, L182V, T189G, L192H, S193N, S193K, V196I, S198G, T200W, L210H, F212N, N21 8E, A248N, L263M, Q270L, S294T, T297M, S308R, L310R, L333M, Q336M, A354H, C357V, L358F, D 359N, L377I, V423H, P426K, K428R, S438A, T447G, T447A, L450V, A462H, A462Q, I469V, I472L , Q498M, L502V, E517I, P520D, P520G, N523S, I533E, D534A, F576R, F576E, K577I, I582R, Y583F, L587Y or L587W, or any combination thereof (relative to SEQ ID NO: 20) comprising at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all of these mutations. In certain embodiments, the hyperactive piggyBac or piggyBac-like transposase comprises one or more substitutions of non-wild-type amino acids, wherein the one or more substitutions of wild-type amino acids comprise A2X, K3X, R4X, F5X, Y6X, S7X, A11X, A13X, C15X, M16X, A17X, S18X, S19X, S20X, E21X, E22X, F23X, S24X, G25X, 26X, D27X, S28X, E29X, E42X, E43X, S44X, C46X, S47X, S48X, S49X, T50X, V51X, S52X, A53X, L54X, E55X, E56X , P57X, M58X, E59X, E62X, D63X, V64X, D65X, D66X, L67X, E68X, D69X, Q70X, E 71X, A72X, G73X, D74X, R75X, A76X, D77X, A78X, A79X, A80X, G81X, G82X, E83 X, P84X, A85X, W86X, G87X, P88X, P89X, C90X, N91X, F92X, P93X, E95X, I96X, P97X, P98X, F99X, T100X, T101X, P103X, G104X, V105X, K106X, V107X, D108X, T109X, N111X, P114X, I115X, N116X, F117X, F118X, Q119X, M122X, T123X, E1 24X, A125X, I126X, L127X, Q128X, D129X, M130X, L132X, Y133X, V126X, Y127 X, A138X, E139X, Q140X, Y141X, L142X, Q144X, N145X, P146X, L147X, P148X, Y150X, A151X, A155X, H157X, P158X, I161X, A162X, V168X, T171X, L172X, A17 3X, M174X, I177X, A179X, L182X, D187X, T188X, T189X, T190X, L192X, S193X , I194X, P195X, V196X, S198X, A199X, T200X, S202X, L208X, L209X, L210X, R 211X, F212X, F215X, N217X, N218X, A219X, T220X, A221X, V222X, P224X, D22 5X, Q226X, P227X, H229X, R231X, H233X, L235X, P237X, I239X, D240X, L242X,S243X、E244X、R244X、F246X、A247X、A248X、V249X、Y250X、T251X、P252X、C253X、Q254X、I256X、C257X、I258X、D259X、E260X、S261X、L262X、L263X、L264X、F265X、K266X、G267X、R268X、L269X、Q270X、F271X、R272X、Q273X、Y274X、I275X、P276X、S277X、K278X、R279X、A280X、R281X、Y282X、G283X、I284X、K285X、F286X、Y287X、K288X、L289X、C290X、E291X、S292X、S293XS294X、G295X、Y296X、T297X、S298X、Y299X、F300X、E304X、L310X、P313X、G314X、P316X、P317X、D318X、L319X、T320X、V321X、K324X、E328X、I330X、S331X、P332X、L333X、L334X、G335X、Q336X、F338X、L340X、D343X、N344X、F345X、Y346X、S347X、L351X、F352X、A354X、L355X、Y356X、C357X、L358X、D359X、T360X、R422X、Y423X、G424X、P426X、K428X、N429X、K430X、P431X、L432X、S434X、K435X、E436X、S438X、K439X、Y440X、G443X、R446X、T447X、L450X、Q451X、N455X、T460X、R461X、A462X、K465X、V467X、G468X、I469X、Y470X、L471X、I472X、M474X、A475X、L476X、R477X、S479X、Y480X、V482XY483X、K484X、A485X、A486X、V487X、P488X、P490X、K491X、S493X、Y494X、Y495X、K496X、Y497T、Q498X、L499X、Q500X、I501X、L502X、P503X、A504X、L505X、L506X、F507X、G508X、G509X、V510X、E511X、E512X、Q513X、T514X、V515X、E517X、M518X、P519X、P520X、S521X、D522X、N523X, V524X, A525X, L527X, I528X, K530X, H531X, F532X, I533X, D534X, T535X, L53 6X, T539X, P540X, Q546X, K550X, R553X, K554X, R555X, G556X, I557X, R558X, R559X, D 560X, T561X, Y564X, P566X, K567X, P569X, R570X, N571X, L574X, C575X, F576X, K577X, P578X, F580X, E581X, I582X, Y583X, T585X, Q586X, L587X, H588X or Y589X substitutions (relative to SEQ ID NO: 20). A list of highly active amino acid substitutions can be found in U.S. Pat. No. 10,041,077, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, the piggyBac or piggyBac-like transposase is integration-defective. In certain embodiments, an integration-defective piggyBac or piggyBac-like transposase is a transposase that can excise its corresponding transposon but integrates the excised transposon at a lower frequency than the corresponding naturally occurring transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is an integration-defective variant of SEQ ID NO: 20. In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase is defective with respect to SEQ ID NO: 20. In certain embodiments, the piggyBac or piggyBac-like transposase is active for excision but defective in integration. In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises a sequence that is at least 90% identical to: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises a sequence that is at least 90% identical to: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises a sequence that is at least 90% identical to: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises SEQ ID NO: 114. In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises a sequence that is at least 90% identical to: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises SEQ ID NO: 115. In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises a sequence that is at least 90% identical to: In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises SEQ ID NO: 116. In certain embodiments, the integration-defective piggyBac or piggyBac-like transposase comprises an amino acid substitution wherein Asn at position 218 is replaced with Glu or Asp (N218D or N218E) (relative to SEQ ID NO: 20). In certain embodiments, the excision-competent, integration-defective piggyBac or piggyBac-like transposase comprises one or more substitutions of non-wild-type amino acids, wherein the one or more substitutions of wild-type amino acids comprise A2X, K3X, R4X, F5X, Y6X, S7X, A8X, E9X, E10X, A11X, A12X, A13X, H14X, C15X, M16X, A17X, S18X, S19X, S20X, E21X, E22X, F23X, S24X, G25X, 26X, D27X, S28X, E29X, V31X, P32X, P33X, A34X, S35X, E36X, S37X, D38 X, S39X, S40X, T41X, E42X, E43X, S44X, W45X, C46X, S47X, S48X, S49X, T50X, V51X, S52X, A53X, L54X, E55X, E56X, P57X, M58X, E59X, V60X, M122X, T123X, E124X, A125X, L127X, Q128X, D129X, L132X, Y133X, V126X, Y127X, E139X, Q1 40X, Y141X, L142X, T143X, Q144X, N145X, P146X, L147X, P148X, R149X, Y150X , A151X, H154X, H157X, P158X, T159X, D160X, I161X, A162X, E163X, M164X, K 165X, R166X, F167X, V168X, G169X, L170X, T171X, L172X, A173X, M174X, G17 5X, L176X, I177X, K178X, A179X, N180X, S181X, L182X, S184X, Y185X, D187X , T188X, T189X, T190X, V191X, L192X, S193X, I194X, P195X, V196X, F197X, S1 98X, A199X, T200X, M201X, S202X, R203X, N204X, R205X, Y206X, Q207X, L208 X, L209X, L210X, R211X, F212X, L213X, H241X, F215X, N216X, N217X, N218X, A 219X, T220X, A221X, V222X, P223X, P224X, D225X, Q226X, P227X, G228X, H22 9X, D230X, R231X, H233X, K234X, L235X, R236X, L238X, I239X, D240X, L242X,S243X、E244X、R244X、F246X、A247X、A248X、V249X、Y250X、T251X、P252X、C253X、Q254X、N255X、I256X、C257X、I258X、D259X、E260X、S261X、L262X、L263X、L264X、F265X、K266X、G267X、R268X、L269X、Q270X、F271X、R272X、Q273X、Y274X、I275X、P276X、S277X、K278X、R279X、A280X、R281X、Y282X、G283X、I284X、K285X、F286X、Y287X、K288X、L289X、C290X、E291X、S292X、S293X、S294X、G295X、Y296X、T297X、S298X、Y299X、F300X、I302X、E304X、G305X、K306X、D307X、S308X、K309X、L310X、D311X、P312X、P313X、G314X、C315X、P316X、P317X、D318X、L319X、T320X、V321X、S322X、G323X、K324X、I325X、V326X、W327X、E328X、L329X、I330X、S331X、P332X、L333X、L334X、G335X、Q336X、F338X、H339X、L340X、V342X、N344X、F345X、Y346X、S347X、S348X、I349X、L351X、T353X、A354X、Y356X、C357X、L358X、D359X、T360X、P361X、A362X、C363X、G364X、I366X、N367X、R368X、D369X、K371X、G372X、L373X、R375X、A376X、L377X、L378X、D379X、K380X、K381X、L382X、N383X、R384XG385X、T387X、Y388X、A389X、L390X、K392X、N393X、E394X、A397X、K399X、F400X、F401X、D402X、N405X、L406X、L409X、R422X、Y423X、G424X、E425X、P426X、K428X、N429X、K430X、P431X、L432X、S434X、K435X、E436X、S438X、K439X、Y440X、G442X、G443X、V444X、R446X、T447X, L450X, Q451X, H452X, N455X, T457X, R458X, T460X, R461X, A462X, Y464X, K465X, V467X, G468X, I469X, L471X, I 472X, Q473X, M474X, L476X, R477X, N478X, S479X, Y480X, V482XY483X, K484X, A485X, A486X, V487X, P488X, G489X, P49 0X, K491X, L492X, S493X, Y494X, Y495X, K496X, Q498X, L499X, Q500X, I501X, L502X, P503X, A504X, L505X, L506X, F507 X, G508X, G509X, V510X, E511X, E512X, Q513X, T514X, V515X, E517X, M518X, P519X, P520X, S521X, D522X, N523X, V524X , A525X, L527X, I528X, G529X, K530X, F532X, I533X, D534X, T535X, L536X, P537X, P538X, T539X, P540X, G541X, F542X, Q543X, R544X, P545X, Q546X, K547X, G548X, C549X, K550X, V551X, C552X, R553X, K554X, R555X, G556X, I557X, R558X, R 559X, D560X, T561X, R562X, Y563X, Y564X, C565X, P566X, K567X, C568X, P569X, R570X, N571X, P572X, G573X, L574X, C575X, F576X, K577X, P578X, C579X, F580X, E581X, I582X, Y583X, H584X, T585X, Q586X, L587X, H588X, or Y589X substitutions (relative to SEQ ID NO: 20). A list of excision-competent, integration-defective amino acid substitutions can be found in U.S. Pat. No. 10,041,077, the contents of which are incorporated herein by reference in their entirety. In certain embodiments, the piggyBac or piggyBac-like transposase is fused to a nuclear localization signal. In certain embodiments, SEQ ID NO: 20 or SEQ ID NO: 21 is fused to a nuclear localization signal. In certain embodiments, the amino acid sequence of the piggyBac or piggyBac-like transposase fused to a nuclear localization signal is encoded by a polynucleotide sequence comprising the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Xenopus tropicalis. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 22 and SEQ ID NO: 23. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence:

[0001] In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 23 and SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 25 and SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end comprising at least 14, 16, 18, 20, 30, or 40 consecutive nucleotides from SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end comprising at least 14, 16, 18, 20, 30, or 40 consecutive nucleotides from SEQ ID NO: 23 or SEQ ID NO: 25. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end that is at least 90% identical to SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26. In certain embodiments, the piggyBac or piggyBac-like transposon comprises one end that is at least 90% identical to SEQ ID NO: 23 or SEQ ID NO: 25. In one embodiment, one transposon end is at least 90% identical to SEQ ID NO: 22 and the other transposon end is at least 90% identical to SEQ ID NO: 23. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TTAACCTTTTTACTGCCA (SEQ ID NO: 27). In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TTAACCCTTTGCCTGCCA (SEQ ID NO: 29). In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TTAACCYTTTTACTGCCA (SEQ ID NO: 30). In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TGGCAGTAAAAGGGTTAA (SEQ ID NO: 32). In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TGGCAGTGAAAGGGTTAA (SEQ ID NO: 34). In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence of TTAACCYTTTKMCTGCCA (SEQ ID NO: 36). In certain embodiments, one end of a piggyBac or piggyBac-like transposon comprises a sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 29, and SEQ ID NO: 30. In certain embodiments, one end of a piggyBac (PB) or piggyBac-like transposon comprises a sequence selected from the group consisting of SEQ ID NO: 32 and SEQ ID NO: 34. In certain embodiments, each inverted terminal repeat sequence of a piggyBac or piggyBac-like transposon comprises a sequence of an ITR sequence of CCYTTTKMCTGCCA (SEQ ID NO: 66). In certain embodiments, each end of a piggyBac (PB) or piggyBac-like transposon comprises SEQ ID NO: 66 in reverse orientation. In certain embodiments, one ITR of a piggyBac or piggyBac-like transposon comprises a sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 29, and SEQ ID NO: 30. In certain embodiments, one ITR of a piggyBac or piggyBac-like transposon comprises a sequence selected from the group consisting of SEQ ID NO: 32 and SEQ ID NO: 34. In certain embodiments, a piggyBac or piggyBac-like transposon comprises SEQ ID NO: 36 in opposite orientations at both transposon ends. In certain embodiments, the piggyBac or piggyBac-like transposon can have ends comprising SEQ ID NO:22 and SEQ ID NO:23, or variants of either or both of these that have at least 90% sequence identity to SEQ ID NO:22 or SEQ ID NO:23, and the piggyBac or piggyBac-like transposase has the sequence of SEQ ID NO:20, or a variant that exhibits at least %, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage therebetween. In certain embodiments, one piggyBac or piggyBac-like transposon end comprises at least 14 consecutive nucleotides from SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26, and the other transposon end comprises at least 14 consecutive nucleotides from SEQ ID NO: 23 or SEQ ID NO: 25. In certain embodiments, one transposon end comprises at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 consecutive nucleotides from SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26, and the other transposon end comprises at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, or at least 30 consecutive nucleotides from SEQ ID NO: 23 or SEQ ID NO: 25. In certain embodiments, a piggyBac or piggyBac-like transposase recognizes a transposon end having a 5' sequence corresponding to SEQ ID NO:22 and a 3' sequence corresponding to SEQ ID NO:23. It will excise the transposon from one DNA molecule by cleaving the DNA (including any heterologous DNA interposed therebetween) from the 5'-TTAA-3' sequence at the 5' end of one transposon end to the 5'-TTAA-3' sequence at the 3' end of the second transposon end, and insert the excised sequence into the second DNA molecule. In certain embodiments, truncated and modified forms of the 5' and 3' transposon ends will also function as part of a transposon that can be transposed by a piggyBac or piggyBac-like transposase. For example, the 5' transposon end can be replaced with a sequence corresponding to SEQ ID NO:24 or SEQ ID NO:26, and the 3' transposon end can be replaced with a shorter sequence corresponding to SEQ ID NO:25. In certain embodiments, the 5' and 3' transposon ends share an 18 bp nearly perfect repeat sequence (5'-TTAACCYTTTKMCTGCCA: SEQ ID NO: 36) at their ends that includes a 5'-TTAA-3' insertion site, with the sequence in opposite orientations at the two ends. That is, in (SEQ ID NO:22) and SEQ ID NO:26, the 5' transposon end begins with the sequence 5'-TTAACCTTTTTACTGCCA-3' (SEQ ID NO:27), or in (SEQ ID NO:24), the 5' transposon end begins with the sequence 5'-TTAACCCTTTGCCTGCCA-3' (SEQ ID NO:29); the 3' transposon ends with approximately the reverse complement of this sequence: in SEQ ID NO:23, it ends with 5'TGGCAGTAAAAGGGTTAA-3' (SEQ ID NO:32), and in (SEQ ID NO:25), it ends with 5'-TGGCAGTGAAAGGGTTAA-3' (SEQ ID NO:34). One embodiment of the present invention is a transposon comprising a heterologous polynucleotide inserted between two transposon ends, each of which comprises SEQ ID NO:36 in opposite orientations at the two transposon ends. In certain embodiments, one transposon end comprises a sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 29, and SEQ ID NO: 30. In some embodiments, one transposon end comprises a sequence selected from the group consisting of SEQ ID NO: 32 and SEQ ID NO: 34. In certain embodiments, piggyBac (PB) or piggyBac-like transposon is isolated or derived from Xenopus tropicalis. In certain embodiments, piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises at least 16 consecutive bases from SEQ ID NO: 76 or SEQ ID NO: 77 and an inverted terminal repeat of CCYTTTBMCTGCCA (SEQ ID NO: 78). In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises a 5' transposon end sequence selected from SEQ ID NO: 76 and SEQ ID NO: 82-88. In certain embodiments, the 5' transposon end sequence is preceded by a 5' target sequence. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises a 3' transposon end sequence selected from the group consisting of SEQ ID NO: 77 and SEQ ID NO: 90-93. In certain embodiments, the 3' transposon end sequence is followed by a 3' target sequence. In certain embodiments, the 5' and 3' transposon ends share a 14-repeat sequence (SEQ ID NO: 78) adjacent to the target sequence in opposite orientations at both ends. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a 5' transposon end comprising a target sequence and a sequence selected from the group consisting of SEQ ID NO: 85-87 and 76, and a 3' transposon end comprising a sequence selected from the group consisting of SEQ ID NO: 91-93 and 77 followed by a 3' target sequence. In certain embodiments, the 5' transposon end of a piggyBac or piggyBac-like transposon comprises (SEQ ID NO: 94) and ITR. In certain embodiments, the 5' transposon end comprises (SEQ ID NO: 95) and ITRs. In certain embodiments, the 3' transposon end of the piggyBac or piggyBac-like transposon comprises (SEQ ID NO: 96) and ITR. In certain embodiments, the 3' transposon end comprises (SEQ ID NO:97) and ITRs. In certain embodiments, one transposon end comprises a sequence that is at least 90%, at least 95%, at least 99%, or any percentage therebetween, identical to SEQ ID NO: 76, and the other transposon end comprises a sequence that is at least 90%, at least 95%, at least 99%, or any percentage therebetween, identical to SEQ ID NO: 77. In certain embodiments, one transposon end comprises at least 14, at least 16, at least 18, at least 20, or at least 25 consecutive nucleotides from SEQ ID NO: 76, and one transposon end comprises at least 14, at least 16, at least 18, at least 20, or at least 25 consecutive nucleotides from SEQ ID NO: 77. In certain embodiments, one transposon end comprises at least 14, at least 16, at least 18, at least 20, or at least 25 consecutive nucleotides from SEQ ID NO: 94, and the other end comprises at least 14, at least 16, at least 18, at least 20, from SEQ ID NO: 96. In certain embodiments, each transposon end comprises SEQ ID NO: 78 in opposite orientations. In certain embodiments, the piggyBac or piggyBac-like transposon comprises a sequence selected from the group consisting of SEQ ID NO:76, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:91, and a sequence selected from the group consisting of SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, and SEQ ID NO:89, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO:20 or SEQ ID NO:21. In certain embodiments, the piggyBac or piggyBac-like transposon comprises ITRs of CCCTTTGCCTGCCA (SEQ ID NO: 125) (5' ITR) and TGGCAGTGAAAGGG (SEQ ID NO: 126) (3' ITR) adjacent to the target sequence. In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from cotton bollworm. The piggyBac or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from cotton bollworm. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from pink bollworm. The piggyBac or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage identity therebetween: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from pink bollworm. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Spodoptera ni. The piggyBac or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Spodoptera ni. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of CCCTAGAAGCCCAATC (SEQ ID NO: 67). In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Agrotis miniata. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween with the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Agrotis miniata. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from alfalfa leafcutter bee. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from alfalfa leafcutter bee. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from an eastern American bumble bee. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween with the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Bombus americanus. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Spodoptera brassicae. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Spodoptera brassicae. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from wheat gall midge. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from wheat gall midge. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Apis mellifera. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Apis mellifera. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Messor bouvieri. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Messorbouvieri. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments of the methods of the present disclosure, the transposase is a piggyBac or piggyBac-like transposase. In certain embodiments, the piggyBac or piggyBac-like transposase is isolated or derived from Trichoplusia ni. The piggyBac (PB) or piggyBac-like transposase may comprise or consist of an amino acid sequence having at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or any percentage identity therebetween to the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Trichoplusia ni. In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises the following sequence: In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 64 and SEQ ID NO: 65, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO: 61. In certain embodiments, the piggyBac or piggyBac-like transposon comprises SEQ ID NO: 112 and SEQ ID NO: 113, and the piggyBac or piggyBac-like transposase comprises SEQ ID NO: 61. In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from cotton aphid.In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of CCTTCCAGCGGGCGCGC (SEQ ID NO: 68). In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Chilo suppressalis.In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of CCCAGATTAGCCT (SEQ ID NO: 69). In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Heliothis virescens.In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of CCCTTAATTACTCGCG (SEQ ID NO: 70). In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Pink bollworm.In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of CCCTAGATAACTAAAC (SEQ ID NO: 71). In certain embodiments, the piggyBac or piggyBac-like transposon is isolated or derived from Anopheles stephensi.In certain embodiments, the piggyBac or piggyBac-like transposon comprises an ITR sequence of CCCTAGAAAGATA (SEQ ID NO: 72). Non-transposition-based gene modification methods In some embodiments of the methods of the present disclosure, modified HSCs or modified HSC progeny cells of the present disclosure can be generated by introducing a transgene into an HSC or HSC progeny cell of the present disclosure. The introducing step can include delivering the nucleic acid sequence and / or genome editing construct via a non-transposition delivery system. In some embodiments of the methods of the present disclosure, the nucleic acid sequence and / or genome editing construct is introduced into HSC or HSC progeny cells in vitro, in vivo, in vitro or in situ, including one or more of local delivery, adsorption, absorption, electroporation, spin infection (spin-fection), co-culture, transfection, mechanical delivery, acoustic wave delivery, vibration delivery, magnetofection (magnetofection) or nanoparticle-mediated delivery. In some embodiments of the methods of the present disclosure, the nucleic acid sequence and / or genome editing construct is introduced into HSC or HSC progeny cells in vitro, in vivo, in vitro or in situ, including one or more of liposome transfection, calcium phosphate transfection, fugene transfection and dendrimer-mediated transfection. In some embodiments of the methods of the present disclosure, the nucleic acid sequence and / or genome editing construct is introduced into HSC or HSC progeny cells in vitro, in vivo, in vitro or in situ, including cell squeezing, cell bombardment or gene gun technology. In some embodiments of the methods of the present disclosure, introduction of nucleic acid sequences and / or genome editing constructs into HSC or HSC progeny cells ex vivo, in vivo, in vitro, or in situ by nanoparticle-mediated transfection includes liposome delivery, delivery by micelles, and delivery by polymerosomes. In some embodiments of the methods of the present disclosure, introducing the nucleic acid sequence and / or genome editing construct into HSC or HSC progeny cells ex vivo, in vivo, in vitro or in situ comprises a non-viral vector. In some embodiments, the non-viral vector comprises a nucleic acid. In some embodiments, the non-viral vector comprises plasmid DNA, linear double-stranded DNA (dsDNA), linear single-stranded DNA (ssDNA), DoggyBone TM DNA, nanoplasmids, minicircle DNA, single-stranded oligodeoxynucleotides (ssODN), DDNA oligonucleotides, single-stranded mRNA (ssRNA) and double-stranded mRNA (dsRNA). In some embodiments, the non-viral vector comprises a transposon of the disclosure. In some embodiments of the methods of the present disclosure, nucleic acid sequences and / or genome editing constructs are introduced into HSC or HSC progeny cells in vitro, in vivo, in vitro or in situ, including viral vectors. In some embodiments, the viral vector is a non-integrating non-chromosomal vector. Exemplary non-integrating non-chromosomal vectors include, but are not limited to, adeno-associated virus (AAV), adenovirus and herpes virus. In some embodiments, the viral vector is an integrative chromosomal vector. Integrative chromosomal vectors include, but are not limited to, adeno-associated vectors (AAV), lentivirus and γ-retrovirus. In some embodiments of the methods of the present disclosure, the introduction of nucleic acid sequences and / or genome editing constructs into HSC or HSC progeny cells ex vivo, in vivo, in vitro or in situ comprises a combination of vectors. Exemplary non-limiting vector combinations include: viral and non-viral vectors, multiple non-viral vectors, or multiple viral vectors. Exemplary but non-limiting vector combinations include: a combination of DNA-derived and RNA-derived vectors, a combination of RNA and reverse transcriptase, a combination of transposons and transposases, a combination of non-viral vectors and endonucleases, and a combination of viral vectors and endonucleases. In some embodiments of the methods of the present disclosure, the genetic modification (including introducing a nucleic acid sequence and / or a genome editing construct into HSC or HSC progeny cells ex vivo, in vivo, in vitro, or in situ) stably integrates the nucleic acid sequence, transiently integrates the nucleic acid sequence, produces site-specific integration of the nucleic acid sequence, or produces biased integration of the nucleic acid sequence. In some embodiments, the nucleic acid sequence is a transgene. In some embodiments of the method of the present disclosure, genetic modification (including introducing nucleic acid sequence and / or genome editing construct into HSC or HSC offspring cells in vitro, in vivo, in vitro or in situ) stably integrates nucleic acid sequence. In some embodiments, stable chromosomal integration can be random integration, site-specific integration or biased integration. In some embodiments, site-specific integration can be non-auxiliary or auxiliary. In some embodiments, auxiliary site-specific integration is co-delivered with site-directed nuclease. In some embodiments, site-directed nuclease includes transgenic, and the transgenic has 5' and 3' nucleotide sequence extensions, which contain the percentage homology with the upstream and downstream regions of the genome integration site. In some embodiments, transgenic with homologous nucleotide extension enables genome integration by homologous recombination, microhomology (microhomology) mediated end connection or non-homologous end connection. In some embodiments, site-specific integration occurs in safe harbor sites (safe harbor site). Genome safe harbor sites can adapt to the integration of new genetic material in a way that ensures that newly inserted genetic elements work reliably (for example, expressed at a therapeutically effective expression level) and do not bring harmful changes that cause host organisms to be dangerous to the host genome. Possible genomic safe harbors include, but are not limited to, intronic sequences of the human albumin gene, adeno-associated virus site 1 (AAVS1), the naturally occurring integration site of the AAV virus on chromosome 19, the site of the chemokine (CC motif) receptor 5 (CCR5) gene, and the site of the human ortholog of the mouse Rosa26 locus. In some embodiments, site-specific transgenic integration occurs at sites that disrupt target gene expression. In some embodiments, disruption of target gene expression occurs by site-specific integration at introns, exons, promoters, genetic elements, enhancers, repressor genes, start codons, stop codons, and response elements. In some embodiments, exemplary target genes targeted by site-specific integration include, but are not limited to, TRAC, TRAB, PDI, any immunosuppressive genes, and genes associated with allogeneic rejection (allo-rejection). In some embodiments, site-specific transgenic integration occurs at a site resulting in enhanced target gene expression. In some embodiments, enhancement of target gene expression occurs by site-specific integration at introns, exons, promoters, genetic elements, enhancers, repressor genes, start codons, stop codons, and response elements. In some embodiments of the methods of the present disclosure, enzymes can be used to generate strand breaks in the host genome to facilitate delivery or integration of transgenes. In some embodiments, the enzyme generates single-strand breaks. In some embodiments, the enzyme generates double-strand breaks. In some embodiments, examples of enzymes that induce breaks include, but are not limited to, transposases, integrases, endonucleases, CRISPR-Cas9, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), Cas-CLOVER TM In some embodiments, the enzyme that induces the breakage can be encoded in DNA, encoded in mRNA, delivered to the cell as a protein, or as a nucleoprotein complex with a guide RNA (gRNA). In some embodiments of the methods of the present disclosure, site-specific transgene integration is controlled by vector-mediated integration site bias. In some embodiments, vector-mediated integration site bias is controlled by a selected lentiviral vector. In some embodiments, vector-mediated integration site bias is controlled by a selected γ-retroviral vector. In some embodiments of the methods of the present disclosure, the site-specific transgene integration is an unstable chromosomal insertion. In some embodiments, the integrated transgene can be silenced, removed, excised, or further modified. In some embodiments of the methods of the present disclosure, the genomic modification is an unstable transgenic integration. In some embodiments, the unstable integration can be a transient non-chromosomal integration, a semi-stable non-chromosomal integration, a semi-persistent non-chromosomal insertion, or an unstable chromosomal insertion. In some embodiments, the transient non-chromosomal insertion can be extrachromosomal (epi-chromosomal) or cytoplasmic. In some embodiments, the transient non-chromosomal insertion of the transgene is not integrated into the chromosome and the modified genetic material is not replicated during cell division. In some embodiments of the methods of the present disclosure, the genomic modification is a semi-stable or persistent non-chromosomal integration of a transgene. In some embodiments, the DNA vector encodes a scaffold / matrix attachment region (S-MAR) component that binds to a nuclear matrix protein for episomal maintenance of the non-viral vector, thereby allowing autonomous replication in the nucleus of a dividing cell. In some embodiments of the methods of the present disclosure, the genomic modification is an unstable chromosomal integration of a transgene. In some embodiments, the integrated transgene can become silenced, removed, excised, or further modified. In some embodiments of the methods of the present disclosure, modification of the genome by transgenic insertion can occur via host cell directed double strand break repair (homology-directed repair) by homologous recombination (HR), microhomology-mediated end joining (MMEJ), non-homologous end joining (NHEJ), transposase-mediated modification, integrase-mediated modification, endonuclease-mediated modification, or recombinase-mediated modification. In some embodiments, modification of the genome by transgenic insertion can occur via CRISPR-Cas9, TALEN, ZFNs, Cas-CLOVER, and Cpf1. In gene editing systems involving the insertion of new or existing nucleotides / nucleic acids, in addition to a cutting enzyme (e.g., a nuclease, a recombinase, an integrase, or a transposase), an insertion tool (e.g., a DNA template vector, a transposable element (transposon or retroposon) must be delivered to the cell. Examples of such insertion tools for recombinases may include DNA vectors. Other gene editing systems require the delivery of an integrase along with an insertion vector, a transposase along with a transposon / retroposon, and the like. In some embodiments, an exemplary recombinase that can be used as a cutting enzyme is a CRE recombinase. In various embodiments, exemplary integrases that can be used in the insertion tool include viral-based enzymes taken from any of a number of viruses, including but not limited to AAV, gamma retroviruses, and lentiviruses. Exemplary transposons / retroposps that can be used in the insertion tool include but are not limited to piggyBac transposons, Sleeping Beauty transposons, and L1 retroposons. In some embodiments of the method of the present disclosure, transgenic delivery in vivo. In some embodiments of the method of the present disclosure, transgenic delivery in vivo can be delivered by local delivery, adsorption, absorption, electroporation, spin infection (spin-fection), co-cultivation, transfection, mechanical delivery, acoustic wave delivery, vibration delivery, magnetofection (magnetofection) or by nanoparticle-mediated delivery. In some embodiments of the method of the present disclosure, transgenic delivery in vivo by transfection can occur by liposome transfection, calcium phosphate transfection, fugene transfection and dendrimer-mediated transfection. In some embodiments of the method of the present disclosure, mechanical transgenic delivery in vivo can occur by cell extrusion, bombardment and gene gun. In some embodiments of the method of the present disclosure, transgenic delivery mediated by nanoparticles in vivo can occur by liposome delivery, by micelle delivery and by polymer delivery. In various embodiments, nucleases that can be used as cleavage enzymes include but are not limited to Cas9, transcription activator-like effector nucleases (TALEN) and zinc finger nucleases. In certain embodiments of the methods of the present disclosure, a non-viral vector is used for transgene delivery. In certain embodiments, the non-viral vector is a nucleic acid. In certain embodiments, the nucleic acid non-viral vector is a plasmid DNA, a linear double-stranded DNA (dsDNA), a linear single-stranded DNA (ssDNA), a DoggyBone TM In some embodiments, the non-viral vector is a transposon. In some embodiments, the transposon is piggyBac. In certain embodiments of the present disclosure methods, transgene delivery can occur by viral vectors. In certain embodiments, the viral vector is a non-integrating non-chromosomal vector. The non-integrating non-chromosomal vector can include adeno-associated virus (AAV), adenovirus and herpes virus. In certain embodiments, the viral vector is an integrating chromosomal vector. The integrating chromosomal vector can include adeno-associated vector (AAV), lentivirus and gamma-retrovirus. In certain embodiments of the methods of the present disclosure, transgene delivery can occur via a combination of vectors. Exemplary but non-limiting vector combinations may include: viral plus non-viral vectors, more than one non-viral vector, or more than one viral vector. Exemplary but non-limiting vector combinations may include: DNA-derived plus RNA-derived vectors, RNA plus reverse transcriptase, transposon and transposase, non-viral vector plus endonuclease, and viral vector plus endonuclease. In certain embodiments of the methods of the present disclosure, the genomic modification can be stable integration of a transgene, transient integration of a transgene, site-specific integration of a transgene, or biased integration of a transgene. In some embodiments of the present disclosure method, genome modification can be the stable chromosomal integration of transgenic. In some embodiments, stable chromosomal integration can be random integration, site-specific integration or biased integration. In some embodiments, site-specific integration can be non-auxiliary or auxiliary. In some embodiments, auxiliary site-specific integration is co-delivered with site-directed nuclease. In some embodiments, site-directed nuclease comprises transgenic, and the transgenic has 5' and 3' nucleotide sequence extensions, which contain the percentage homology with the upstream and downstream regions of the genome integration site. In some embodiments, transgenic with homologous nucleotide extensions enables genome integration by homologous recombination, microhomology-mediated end connection or non-homologous end connection. In some embodiments, site-specific integration occurs at safe harbor sites. Genome safe harbor sites can adapt to the integration of new genetic material in a way that ensures that the newly inserted genetic elements work reliably (for example, expressed at a therapeutically effective expression level) and do not bring harmful changes that cause danger to the host organism to the host genome. Possible genomic safe harbors include, but are not limited to, intronic sequences of the human albumin gene, adeno-associated virus site 1 (AAVS1), the naturally occurring integration site of the AAV virus on chromosome 19, the site of the chemokine (CC motif) receptor 5 (CCR5) gene, and the site of the human ortholog of the mouse Rosa26 locus. In certain embodiments, site-specific transgenic integration occurs at sites that disrupt target gene expression. In certain embodiments, disruption of target gene expression occurs by site-specific integration at introns, exons, promoters, genetic elements, enhancers, repressor genes, start codons, stop codons, and response elements. In certain embodiments, exemplary target genes targeted by site-specific integration include, but are not limited to, TRAC, TRAB, PDI, any immunosuppressive genes, and genes associated with allogeneic rejection. In certain embodiments, site-specific transgenic integration occurs at a site resulting in enhanced expression of the target gene. In certain embodiments, enhancement of target gene expression occurs by site-specific integration at introns, exons, promoters, genetic elements, enhancers, repressor genes, start codons, stop codons, and response elements. In certain embodiments of the methods of the present disclosure, enzymes can be used to generate strand breaks in the host genome to facilitate delivery or integration of transgenes. In certain embodiments, the enzyme generates single-strand breaks. In certain embodiments, the enzyme generates double-strand breaks. In certain embodiments, examples of enzymes that induce breaks include, but are not limited to, transposases, integrases, endonucleases, CRISPR-Cas9, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), Cas-CLOVER TM In certain embodiments, the enzyme that induces the breakage can be encoded in DNA, encoded in mRNA, delivered to the cell as a protein, or as a nucleoprotein complex with a guide RNA (gRNA). In certain embodiments of the methods of the present disclosure, site-specific transgene integration is controlled by vector-mediated integration site bias. In certain embodiments, vector-mediated integration site bias is controlled by a selected lentiviral vector. In certain embodiments, vector-mediated integration site bias is controlled by a selected γ-retroviral vector. In some embodiments of the method of the present disclosure, the site-specific transgenic integration site is an unstable chromosome insertion. In some embodiments, the integrated transgenic can become silent, removed, excised or further modified. In some embodiments of the method of the present disclosure, the genomic modification is an unstable transgenic integration. In some embodiments, the unstable integration can be transient non-chromosomal integration, semi-stable non-chromosomal integration, semi-persistent non-chromosomal insertion or unstable chromosome insertion. In some embodiments, the transient non-chromosomal insertion can be extrachromosomal or cytoplasmic. In some embodiments, the transient non-chromosomal insertion of transgene is not integrated into the chromosome, and the genetic material modified is not replicated during cell division. In certain embodiments of the methods of the present disclosure, the genomic modification is a semi-stable or persistent non-chromosomal integration of a transgene. In certain embodiments, the DNA vector encodes a scaffold / matrix attachment region (S-MAR) component that binds to a nuclear matrix protein for episomal maintenance of the non-viral vector, thereby allowing autonomous replication in the nucleus of a dividing cell. In certain embodiments of the methods of the present disclosure, the genomic modification is an unstable chromosomal integration of a transgene. In certain embodiments, the integrated transgene can become silenced, removed, excised, or further modified. In certain embodiments of the methods of the present disclosure, modification of the genome by transgenic insertion can occur via host cell directed double strand break repair (homology-directed repair) by homologous recombination (HR), microhomology-mediated end joining (MMEJ), non-homologous end joining (NHEJ), transposase-mediated modification, integrase-mediated modification, endonuclease-mediated modification, or recombinase-mediated modification. In certain embodiments, modification of the genome by transgenic insertion can occur via CRISPR-Cas9, TALEN, ZFNs, Cas-CLOVER, and Cpf1. In certain embodiments of the methods of the present disclosure, the cells with in vivo or ex vivo genome modification can be germ cells or somatic cells. In certain embodiments, the modified cells can be human, non-human, mammal, rat, mouse or dog cells. In certain embodiments, the modified cells can be differentiated, undifferentiated or immortalized. In certain embodiments, the modified undifferentiated cells can be stem cells. In certain embodiments, the modified cells can be differentiated, undifferentiated or immortalized. In certain embodiments, the modified undifferentiated cells can be induced pluripotent stem cells. In certain embodiments, the modified cells can be T cells, hematopoietic stem cells, natural killer cells, macrophages, dendritic cells, monocytes, megakaryocytes or osteoclasts. In certain embodiments, the modified cells can be modified when the cells are static, in an activated state, resting, in interphase, in prophase, in metaphase, in anaphase or in separation telophase. In certain embodiments, the modified cells can be fresh, cryopreserved, bulked, classified as subpopulations, from whole blood, from leukocyte removal or from immortalized cell lines. Production and generation of VCAR As is well known in the art, at least one VHH protein or VCAR of the present disclosure can be optionally produced by a cell line, a mixed cell line, an immortalized cell, or a clonal population of immortalized cells. See, e.g., Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, NY (1987-2001); Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor, NY (1989); Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor, NY (1989); Colligan et al., ed., Current Protocols in Immunology, John Wiley & Sons, Inc., NY (1994-2001); Colligan et al., Current Protocols in Protein Science, John Wiley & Sons, NY, NY, (1997-2001). Amino acids of the VHH protein may be altered, added and / or removed to reduce immunogenicity or to reduce, enhance or alter binding, affinity, on-rate, off-rate, avidity, specificity, half-life, stability, solubility or any other suitable characteristic, as known in the art. Optionally, VHH proteins can be engineered while retaining high affinity for antigens and other favorable biological properties. To achieve this goal, VHH proteins can be optionally prepared by using three-dimensional models of parental and engineered sequences to analyze parental sequences and various conceptually engineered products. Three-dimensional models are generally available and are familiar to those skilled in the art. Computer programs that illustrate and display possible three-dimensional conformational structures of selected candidate sequences, and that can measure possible immunogenicity are available (e.g., Monrovia, Immunofilter program of Xencor, Inc. of Calif.). Inspection of these displays allows analysis of the possible role of residues in the functioning of candidate sequences, i.e., analysis of residues that affect the ability of candidate VHH proteins to bind to their antigens. In this way, residues can be selected from parental and reference sequences and combined to obtain desired features, such as affinity for one or more target antigens. Alternatively, or in addition to the above-mentioned procedures, other suitable engineering methods can be used. Screening of VHH proteins Screening for specific binding of VHH to similar proteins or fragments can be conveniently achieved using nucleotide (DNA or RNA display) or peptide display libraries, for example, in vitro display. This method involves screening a large collection of peptides for individual members with the desired function or structure. The length of the displayed nucleotide or peptide sequence can be 3 to 5000 or more nucleotides or amino acids, often 5-100 amino acids in length, and often about 8-25 amino acids in length. In addition to direct chemical synthesis methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves displaying peptide sequences on the surface of phages or cells. Each phage or cell contains a nucleotide sequence encoding a specific displayed peptide sequence. The VHH proteins of the present disclosure can bind to human or other mammalian proteins with a wide range of affinities (KD). In a preferred embodiment, at least one VHH of the present invention can optionally bind to a target protein with high affinity, for example, its KD is equal to or less than about 10 -7 M, for example but not limited to 0.1-9.9 (or any range or value therein) x 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 , 10 -14 , 10 -15 or any range or value therein, as determined by surface plasmon resonance or the Kinexa method, as practiced by one skilled in the art. The affinity or avidity of a VHH or VACR for an antigen can be determined experimentally using any suitable method. (See, e.g., Berzofsky et al., "Antibody-Antigen Interactions," In Fundamental Immunology, Paul, WE, ed., Raven Press: New York, NY (1984); Kuby, Janis Immunology, WH Freeman and Company: New York, NY (1992); and methods described herein). The measured affinity of a particular VHH-antigen or VCAR-antigen interaction may vary if the measurement is performed under different conditions (e.g., salt concentration, pH). Thus, affinity and other antigen binding parameters (e.g., KD, K on , K off ) is preferably performed with standardized solutions of VHH or VCAR and antigen and a standardized buffer such as the buffer described herein. Competitive assays can be performed with the VHH or VCAR of the present disclosure to determine what proteins, antibodies and other antagonists compete with the VHH or VCAR of the present invention for binding to the target protein and / or sharing epitope regions. As is readily known to those of ordinary skill in the art, these assays evaluate competition between antagonists or ligands for a limited number of binding sites on the protein. Before or after the competition, the protein and / or antibody is fixed or insoluble, and the sample bound to the target protein is separated from the unbound sample, for example, by decantation (in the case of pre-insoluble protein / antibody) or by centrifugation (in the case of protein / antibody precipitation after competitive reaction). Similarly, competitive binding can be determined by the following: whether the change in function is through the binding or non-binding of VHH or VCAR to the target protein, for example, whether the VCAR molecule inhibits or enhances the enzymatic activity of, for example, a marker. As is well known in the art, ELISA and other functional assays can be used. Nucleic acid molecules The nucleic acid molecules of the present disclosure encoding VHH proteins or VCARs can be in the form of RNA, such as mRNA, hnRNA, tRNA or any other form, or can be in the form of DNA, including, but not limited to, cDNA and genomic DNA obtained by cloning or produced synthetically, or any combination thereof. The DNA can be triple-stranded, double-stranded or single-stranded or any combination thereof. Any portion of at least one strand of the DNA or RNA can be a coding strand, also referred to as a sense strand, or it can be a non-coding strand, also referred to as an antisense strand. Isolated nucleic acid molecules of the present disclosure may include nucleic acid molecules comprising an open reading frame (ORF), optionally with one or more introns, such as, but not limited to, at least a specified portion of at least one VCAR; nucleic acid molecules comprising a coding sequence for a VACR; and nucleic acid molecules comprising a nucleotide sequence that differs significantly from the above nucleotide sequence, but due to the degeneracy of the genetic code, still encodes a VACR as described herein and / or as known in the art. Of course, the genetic code is well known in the art. Thus, it will be routine for one skilled in the art to generate such degenerate nucleic acid variants encoding a particular VACR of the present invention. See, e.g., Ausubel et al., supra, and such nucleic acid variants are included in the present invention. As indicated herein, nucleic acid molecules of the present disclosure comprising nucleic acids encoding VACRs may include, but are not limited to, those that themselves encode the amino acid sequence of a VHH fragment; the coding sequence of the entire VACR or a portion thereof; the coding sequence of a VHH, fragment or portion and additional sequences, such as the coding sequence of at least one signal leader sequence or fusion peptide, with or without the aforementioned additional coding sequences, such as at least one intron, together with additional non-coding sequences, including but not limited to non-coding 5' and 3' sequences, such as transcribed non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals (e.g., ribosome binding and stability of mRNA); additional coding sequences encoding additional amino acids, such as those that provide additional functionality. Thus, the sequence encoding a VACR may be fused to a marker sequence, such as a sequence encoding a peptide that facilitates purification of the fused VACR comprising the VHH fragment or portion. Polynucleotides that selectively hybridize to a polynucleotide as described herein The disclosure provides isolated nucleic acids that hybridize to polynucleotides disclosed herein under selective hybridization conditions. Therefore, the polynucleotides of this embodiment can be used to separate, detect and / or quantitatively comprise nucleic acids of such polynucleotides. For example, the polynucleotides of the present invention can be used to identify, separate or amplify partial or full-length clones in a library preserved. In some embodiments, the polynucleotides are separated from cDNA from a human or mammalian nucleic acid library or otherwise complementary to a genome or cDNA sequence. Preferably, the cDNA library comprises at least 80% of the full-length sequence, preferably, at least 85% or 90% of the full-length sequence, and, more preferably, at least 95% of the full-length sequence. The cDNA library can be standardized to increase the representation of rare sequences. Low or medium stringency hybridization conditions are generally but not exclusively used with sequences having reduced sequence identity relative to the complementary sequence. For sequences of higher identity, medium and high stringency conditions can be optionally used. Low stringency conditions allow for the selective hybridization of sequences with about 70% sequence identity, and can be used to identify orthologous or paralogous sequences. Optionally, the polynucleotides of the invention will encode at least a portion of a VCAR encoded by a polynucleotide described herein. The polynucleotides of the invention include nucleic acid sequences that can be used to selectively hybridize with a polynucleotide encoding a VCAR of the invention. See, e.g., Ausubel, supra; Colligan, supra, each of which is incorporated herein by reference in its entirety. Construction of nucleic acids The isolated nucleic acids of the present disclosure can be prepared using (a) recombinant methods, (b) synthetic techniques, (c) purification techniques, and / or (d) combinations thereof as are well known in the art. The nucleic acid may conveniently comprise sequences other than the polynucleotides of the present invention. For example, a multiple cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in the isolation of the polynucleotides. Similarly, a translatable sequence may be inserted to aid in the isolation of the translated polynucleotides of the present disclosure. For example, a hexa-histidine tag sequence provides a convenient means for purifying the proteins of the present disclosure. Excluding the coding sequence, the nucleic acid of the present disclosure is optionally a vector, adapter or joint for cloning and / or expressing the polynucleotides of the present disclosure. Additional sequences may be added to such cloning and / or expression sequences to optimize their function in cloning and / or expression, to aid in the isolation of polynucleotides, or to improve the introduction of polynucleotides into cells. The use of cloning vectors, expression vectors, adapters, and linkers is well known in the art. (See, e.g., Ausubel, supra; or Sambrook, supra). Recombinant methods for constructing nucleic acids Nucleic acid compositions of the separation of the present disclosure, such as RNA, cDNA, genomic DNA or any combination thereof, can be obtained from biological sources using many cloning methods known to those skilled in the art. In some embodiments, oligonucleotide probes selectively hybridized with the polynucleotides of the present invention under stringent conditions are used to identify the desired sequence in a cDNA or genomic DNA library. The separation of RNA and the construction of cDNA and genomic libraries are well known to those of ordinary skill in the art. (See, e.g., Ausubel, above; or Sambrook, above). Nucleic Acid Screening and Isolation Methods Probes can be used to screen cDNA or genomic libraries based on the sequences of the polynucleotides of the present disclosure. Probes can be used to hybridize with genomic DNA or cDNA sequences to separate homologous genes in the same or different organisms. It will be understood by those skilled in the art that various degrees of hybridization stringency can be used in the assay; and the hybridization or washing medium can be stringent. As the hybridization conditions become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by one or more of temperature, ionic strength, pH, and the presence of partially denaturing solvents such as formamide. For example, the stringency of hybridization can be conveniently changed by, for example, changing the polarity of the reactant solution by manipulating the concentration of formamide in the range of 0% to 50%. The degree of complementarity (sequence identity) required for detectable binding will vary depending on the stringency of the hybridization medium and / or the washing medium. The degree of complementarity will be optimally 100% or 70-100%, or any range or value therein. However, it should be understood that smaller sequence changes in probes and primers can be compensated by reducing the stringency of the hybridization and / or washing medium. Methods for amplification of RNA or DNA are well known in the art and can be used in accordance with the present disclosure without undue experimentation based on the teachings and guidance presented herein. Known methods for amplifying DNA or RNA include, but are not limited to, polymerase chain reaction (PCR) and related amplification methods (see, e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188 to Mullis et al.; 4,795,699 and 4,921,794 to Tabor et al.; 5,142,033 to Innis; 5,122,464 to Wilson et al.; 5,091,310 to Innis; 5,06 6,584 to Gyllensten et al.; 4,889,818 to Gelfand et al.; 4,994,370 to Silver et al.; 4,766,067 to Biswas; 4,656,134 to Ringold) and RNA-mediated amplification using antisense RNA to a target sequence as a template for double-stranded DNA synthesis (U.S. Pat. No. 5,130,238 to Malek et al., tradename NASBA), the entire contents of which are incorporated herein by reference. (See, e.g., Ausubel, supra; or Sambrook, supra.) For example, polymerase chain reaction (PCR) techniques can be used to amplify sequences of polynucleotides and related genes of the present disclosure directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, for cloning nucleic acid sequences encoding proteins to be expressed, so that the nucleic acids are used as probes for detecting the presence of desired mRNA in a sample, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to guide technicians in completing in vitro amplification methods are found in Berger, supra, Sambrook, supra, and Ausubel, supra, and Mullis et al., U.S. Pat. No. 4,683,202 (1987); and Innis et al., PCR Protocols A Guide to Methods and Applications, Eds., Academic Press Inc., San Diego, Calif. (1990). Commercially available kits for genomic PCR amplification are known in the art. See, for example, Advantage-GC Genomic PCR Kit (Clontech). In addition, for example, T4 gene 32 protein (Boehringer Mannheim) can be used to increase the yield of long PCR products. Synthetic methods for constructing nucleic acids The isolated nucleic acids of the present disclosure can also be prepared by direct chemical synthesis by known methods (see, e.g., Ausubel et al., supra). Chemical synthesis generally produces single-stranded oligonucleotides, which can be converted to double-stranded DNA by hybridization with complementary sequences or by polymerization with a DNA polymerase using a single strand as a template. Those skilled in the art will recognize that although chemical synthesis of DNA can be limited to sequences of about 100 or more bases, longer sequences can be obtained by connecting shorter sequences. Recombinant expression cassette The disclosure further provides a recombinant expression cassette comprising the nucleic acid of the disclosure. The nucleotide sequence of the disclosure, such as cDNA or genomic sequence encoding the VCAR of the disclosure, can be used to construct a recombinant expression cassette, which can be introduced into at least one desired host cell. The recombinant expression cassette will generally comprise a polynucleotide of the disclosure that is operably connected to a transcription initiation regulatory sequence, and the transcription initiation regulatory sequence will instruct the transcription of the polynucleotide in the expected host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters can be used to instruct the expression of the nucleic acid of the disclosure. In some embodiments, an isolated nucleic acid used as a promoter, enhancer or other element can be introduced into an ap...

Claims

1. A chimeric antigen receptor (CAR), comprising: (a) an extracellular domain comprising a human CD8α signal peptide and an antigen recognition region, wherein the antigen recognition region comprises at least one VH that specifically binds to BCMA; (b) a hinge domain comprising a human CD8α hinge domain; (c) a transmembrane domain comprising a human CD8α transmembrane domain; and (d) an intracellular domain comprising a human 4-1BB co-stimulatory domain and a human CD3ζ intracellular domain; wherein the VH comprises: a complementarity determining region 1 (CDR1), consisting of the amino acid sequence of SEQ ID NO: 416; a complementarity determining region 2 (CDR2) consisting of the amino acid sequence of SEQ ID NO: 420; and Complementarity determining region 3 (CDR3), which consists of the amino acid sequence of SEQ ID NO:

424.

2. The CAR of claim 1, wherein the VH consists of the amino acid sequence of SEQ ID NO: 411, wherein the human CD8α signal peptide consists of the amino acid sequence of SEQ ID NO: 374, wherein the human CD8α hinge domain consists of the amino acid sequence of SEQ ID NO: 382, ​​wherein the human CD8α transmembrane domain consists of the amino acid sequence of SEQ ID NO: 376, wherein the human 4-1BB co-stimulatory domain consists of the amino acid sequence of SEQ ID NO: 380, and wherein the human CD3ζ intracellular domain consists of the amino acid sequence of SEQ ID NO:

378.

3. A cell comprising the CAR of claim 1 or 2.

4. The cell of claim 3, wherein the cell is an immune cell.

5. The cell of claim 4, wherein the immune cell is a T cell, a natural killer (NK) cell, a natural killer (NK)-like cell, a cytokine-induced killer (CIK) cell, a hematopoietic progenitor cell, a peripheral blood (PB)-derived T cell, or an umbilical cord blood (UCB)-derived T cell.

6. The cell of claim 4, wherein the cell is a T cell.

7. The cell of claim 6, wherein the cell is autologous.

8. A composition comprising the cell of claim 3 and at least one pharmaceutically acceptable carrier.

9. A composition comprising a population of cells, wherein a plurality of cells of the population comprise the cells of claim 3.